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O cancro do colo do útero é uma das principais causas de morte entre as mulheres, 
especialmente em países com acesso limitado a cuidados de saúde e higiene. Ao contrário da 
maioria dos cancros, que geralmente têm origem em mutações relacionadas com a ação de 
mutagénicos ou carcinogénicos, o desenvolvimento deste cancro em particular está fortemente 
associado à infeção pelo vírus do papiloma humano (HPV). Este vírus é responsável pela 
expressão de oncoproteínas que irão interferir com a regulação do ciclo celular, afetando os 
mecanismos de reparação e proliferação das células infetadas. As proteínas virais com maior 
ação oncogénica são as proteínas E6 e E7 do HPV, que por sua vez interferem com a 
expressão/ação das proteínas supressoras de tumor p53 e pRB, respetivamente. A alteração dos 
níveis de expressão/ação das proteínas supressoras de tumor pode levar à acumulação de erros 
irreparáveis nas células que se encontram em constante divisão, resultando na formação de 
massas celulares cancerígenas altamente proliferativas. Deste modo, identificando a expressão 
das proteínas E6 e E7 como as principais causas para o desenvolvimento do cancro do colo do 
útero, várias estratégias têm vindo a ser desenvolvidas no sentido de reverter ou controlar os 
efeitos associados a esta infeção, perspetivando o desenvolvimento de uma terapêutica efetiva.  
Nas últimas décadas, estratégias inovadoras como vacinação por DNA ou terapia génica têm 
sido alvo de grande foco por parte dos investigadores na procura de uma cura para o cancro do 
colo do útero. Enquanto as vacinas de DNA permitem exercer uma ação tanto terapêutica como 
preventiva contra a infeção por HPV através da estimulação/mobilização do sistema imunitário, 
a terapia génica permite aumentar ou silenciar a expressão de proteínas envolvidas no 
desenvolvimento da patologia. No caso das vacinas de DNA, têm surgido vários estudos com o 
intuito de direcionar a expressão das proteínas E6 e/ou E7 em células apresentadoras de 
antigénios, de forma a criar uma resposta imunológica humoral e celular contra estas proteínas. 
Esta estratégia, para além de ativar o sistema imunitário para o reconhecimento das células 
que apresentam estes antigénios (ação terapêutica), permite também a produção de linfócitos 
de memória que poderão ser ativados aquando de uma posterior infeção por HPV (ação 
preventiva). Por outro lado, a terapia génica tem como intuito atuar diretamente na massa 
cancerígena, induzindo a expressão de proteínas supressoras de tumor (como o caso das 
proteínas p53 e pRB) ou silenciando a expressão de proteínas malignas (como o caso das 
proteínas E6 e E7). No segundo caso existem diversas metodologias pelas quais o mecanismo de 
silenciamento pode ocorrer, desde a utilização de moléculas sintetizadas quimicamente até à 
utilização de moléculas naturalmente expressas pelo organismo capazes de regular a expressão 
de diversas proteínas, como por exemplo os microRNAs (miRs). Estes pequenos RNAs são 
responsáveis por regular a expressão de diversas proteínas através do seu silenciamento. A 
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expressão de microRNAs tem sido recentemente associada ao cancro, dado que a sua 
desregulação pode levar a que haja uma maior apetência para desencadear os mecanismos 
responsáveis pelo desenvolvimento de cancro. Por exemplo, alguns trabalhos descrevem que os 
níveis de miR-375 estão significativamente diminuídos em amostras de cancro do colo do útero. 
Diferentes estudos identificaram que o aumento da expressão do miR-375 leva à diminuição dos 
níveis de expressão das proteínas E6 e E7, aliados ao aumento dos níveis de expressão das 
proteínas supressoras de tumor p53 e pRB. Em suma, tanto a estratégia de vacinas de DNA como 
terapia génica apresentam resultados promissores que poderão contribuir para o 
estabelecimento de uma abordagem terapêutica sólida e eficaz. No entanto existe uma 
problemática que afeta transversalmente estas estratégias e que se prende com o tipo de vetor 
utilizado para entregar e expressar a informação genética pretendida.  
Atualmente, os vetores virais têm vindo a ser amplamente utilizados em detrimento de vetores 
não-virais, como o DNA plasmídeo (pDNA), devido à eficácia terapêutica diminuída demonstrada 
pelos últimos, apesar de serem mais seguros e biocompatíveis para o paciente. Esta realidade 
levou a que vários investigadores se focassem no desenvolvimento de vetores não-virais 
inovadores que apresentam maior efeito terapêutico. O DNA minicircular (mcDNA) consiste num 
vetor de DNA não-viral cuja popularidade tem vindo a aumentar incrivelmente nos últimos anos. 
Este vetor advém da recombinação de uma molécula semelhante ao pDNA convencional, 
denominada plasmídeo parental (PP). Contudo, o PP apresenta dois locais de recombinação 
que, após indução, dão origem à recombinação desta molécula em duas moléculas filhas: uma 
contendo toda a informação procariota necessária para a amplificação do PP em hospedeiros 
procariotas (miniplasmídeo – mP) e outra contendo toda a informação necessária para a 
expressão do gene terapêutico em células eucariotas (mcDNA). A eliminação do conteúdo 
procariota leva a que o vetor de mcDNA apresente um tamanho reduzido, permitindo maior 
facilidade na internalização das células alvo, uma maior biocompatibilidade, eficácia 
terapêutica e segurança. Isto porque, as sequências procariotas presentes nos plasmídeos são 
responsáveis por desencadear respostas imunológicas adversas e consequentemente o 
silenciamento da expressão do gene alvo, o que fica controlado com a utilização de mcDNA. 
Tendo em conta a sua tecnologia de produção inovadora, existe a necessidade de desenvolver 
estratégias adequadas para a obtenção de mcDNA cuja pureza se enquadre nos valores 
estabelecidos pelas agências reguladoras como a European Medicines Agency (EMA) ou a Food 
and Drug Administration (FDA). 
Descrição do trabalho realizado 
Este trabalho baseou-se, numa primeira fase, no desenvolvimento de uma vacina de pDNA para 
a produção simultânea das proteínas antigénicas E6 e E7 do HPV, e numa segunda fase, no 
desenvolvimento de uma estratégia de terapia génica para o silenciamento das proteínas 
referidas através da obtenção de um vetor de mcDNA capaz de codificar o miR-375.  
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Na abordagem sobre vacinas de pDNA, foram realizados estudos in vitro para perceber a 
importância que o método de purificação poderá ter na expressão das proteínas antigénicas 
codificadas na molécula de pDNA, seguindo-se o desenvolvimento de estratégias adequadas 
para a entrega da vacina em estudo. Para tal, a vacina de pDNA foi purificada por cromatografia 
de afinidade aplicando suportes monolíticos modificados com ligandos de arginina e 
posteriormente também foram explorados sistemas de carbonato de cálcio para avaliar a 
capacidade na entrega da vacina de pDNA às células apresentadoras de antigénio (células 
dendríticas).  
Na abordagem de terapia génica, o estudo do silenciamento das oncoproteínas E6 e E7 foi 
realizado através da construção de um vetor mcDNA codificante para o pri-miR-375. Tendo em 
conta o carácter inovador do mcDNA, foram desenvolvidos vários estudos no sentido de 
implementar metodologias adequadas para a sua purificação e caracterização. Para tal, foi 
explorado pela primeira vez um suporte monolítico modificado com ligandos de cadaverina, no 
sentido de isolar mcDNA na isoforma superenrolada (sc) de outras isoformas e constituintes 
bacterianos, bem como de resquícios do seu precursor PP presentes na amostra. Por outro lado, 
também foi explorada a cromatografia de filtração em gel para a purificação desta molécula 
através da utilização da matriz Sephacryl SF-1000. Além disso, foi implementada pela primeira 
vez uma metodologia analítica, baseada em cromatografia com o monolito modificado com 
cadaverina, para a avaliação do conteúdo de mcDNA presente em amostras simples e 
complexas. Por último, a avaliação da potencial ação terapêutica deste vetor foi iniciada tendo 
por base a transfeção de células CaSki, uma linha celular modelo para o cancro do colo do 
útero. 
Principais resultados alcançados 
Este trabalho foi realizado com duas perspetivas diferentes para o tratamento do cancro do 
colo do útero, considerando nomeadamente as vacinas de DNA e terapia génica. 
Primeiramente, no que concerne às vacinas de DNA, o estudo de purificação da vacina de pDNA 
por cromatografia de afinidade permitiu perceber que a estratégia utilizada contribui 
significativamente para a eficiente transfeção e expressão do gene codificado na respetiva 
molécula de pDNA. A utilização de um monolito modificado com ligandos de arginina, 
comparativamente à utilização de estratégias comercialmente disponíveis, permitiu obter um 
maior conteúdo da isoforma sc presente na amostra final da vacina de DNA, contribuindo para 
uma maior expressão das proteínas alvo. Posteriormente, um monólito com ligandos de arginina 
acoplados a um braço espaçador foi desenvolvido com o intuito de melhorar a acessibilidade 
dos ligandos, em comparação ao método de purificação previamente estabelecido, e assim 
melhorar a estratégia de purificação usada para a vacina de pDNA. Verificou-se que a 
capacidade de ligação da estratégia com braço espaçador é menor do que sem braço espaçador, 
provavelmente devido à ocupação de uma área maior pelo braço espaçador. Contudo, observou-
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se um aumento da pureza em condições de carregamento devido à eluição de isoformas não 
funcionais durante este passo, um fenómeno conhecido como sample displacement. Também 
se verificou que o desenvolvimento de nanossistemas compostos por carbonato de cálcio 
permitiu a encapsulação do pDNA e a transfeção de células dendríticas, não se revelando 
citotoxicidade para este tipo de sistemas.  
No que diz respeito ao estudo para potencial aplicação em terapia génica, foi inicialmente 
realizada a construção e produção do vector mcDNA contendo o gene de interesse, pri-miR-
375, sendo posteriormente avaliadas duas estratégias diferentes para a purificação do mcDNA. 
Inicialmente, foi preparado um suporte cromatográfico monolítico modificado com ligandos de 
cadaverina em colaboração com a empresa BIA Separations, Eslovénia. Este suporte foi 
explorado pela primeira vez em cromatografia e a sua utilização na purificação da isoforma sc 
de mcDNA permitiu uma recuperação de 78,6% desta molécula, acoplada a uma pureza de 
98,4%. Estes resultados foram alcançados através da estudo da influência do pH nas condições 
de ligação e eluição e explorando gradientes por passos com aumento da concentração de NaCl. 
Estes valores revelaram-se bastante promissores considerando as estratégias implementadas 
até à data na purificação de mcDNA. Adicionalmente, também foi explorada a cromatografia 
de filtração em gel através da utilização da matriz Sephacryl SF-1000, no sentido de se poder 
aumentar a quantidade de amostra de lisado injetada, e consequentemente a quantidade de 
mcDNA purificada por ensaio. Esta estratégia baseou-se na utilização de uma coluna 
cromatográfica com 60 cm de altura e 121 mL de matriz aliada a um gradiente isocrático com 
uma concentração mínima de NaCl, de forma a impedir ligações inespecíficas à matriz. Após a 
injeção de 2 mL de uma amostra de lisado de mcDNA, foi possível obter-se uma recuperação 
de 66% de mcDNA sc, com uma pureza de 98,35%. Apesar de esta estratégia ter permitido 
aumentar cerca de 12 vezes a quantidade de mcDNA puro obtido por ensaio em relação à 
metodologia anteriormente estudada, o tempo de cada ensaio foi 8 vezes superior ao tempo 
gasto com o monolito modificado com cadaverina, sugerindo que a seleção do método de 
purificação deverá ser de acordo com o objetivo final. Desta forma, foram desenvolvidas e 
caracterizadas duas estratégias de purificação de mcDNA sc, aplicando uma simples estratégia 
cromatográfica, sem implicar modificações genéticas específicas na molécula de PP. Estes 
resultados reforçam a versatilidade destas estratégias de purificação e potencial aplicação a 
qualquer tipo de mcDNA, independentemente do seu tamanho e constituição nucleotídica. 
Contudo, a necessidade de implementar uma metodologia analítica que permita quantificar o 
conteúdo de mcDNA sc de forma rápida, economicamente vantajosa e eficaz levou ao 
desenvolvimento e validação de um método cromatográfico analítico com o monolito 
modificado com cadaverina. Assim, foi estabelecida uma estratégia por passos com o aumento 
da concentração de NaCl durante cerca de 40 minutos para permitir a eluição de todas as 
espécies da coluna, capaz de quantificar a concentração de mcDNA sc presente numa amostra 
complexa ou pura, num intervalo de 1-25 μg/mL. A validação deste método passou pela 
avaliação da sua linearidade, precisão, exatidão e reprodutibilidade de acordo com as normas 
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estabelecidas para o efeito. Para além disso, a utilização de diferentes pares de mcDNA-PP, de 
composição variada, permitiu observar a robustez deste método, dado que apenas pequenas 
alterações deverão ser feitas ao gradiente de forma a permitir a quantificação de diferentes 
moléculas de mcDNA. 
Por último, de forma a estudar o potencial do miR-375 como possível tratamento do cancro do 
colo do útero, estudos in vitro foram realizados para avaliar o efeito do vetor mcDNA-miR-375 
na expressão das oncoproteínas E6 e E7. Para tal, foi utilizado o modelo de células CaSki, que 
consiste em células metásticas do cancro do colo do útero infetadas com HPV-16. Por outro 
lado, uma linha celular de fibroblastos foi utilizada como controlo não cancerígeno. 
Inicialmente foi verificada a expressão correta de miR-375, acompanhada de uma diminuição 
da expressão de E6 e E7, tanto a nível de transcritos como de proteína, comparando as células 
cancerígenas transfetadas com mcDNA com as mesmas células não transfetadas. Além disso, 
verificou-se que este vetor não afetou a viabilidade celular dos fibroblastos, apesar de nas 
células CaSki se ter verificado uma diminuição da proliferação celular ao longo do tempo assim 
como da viabilidade celular das mesmas. Estes resultados são indicativos que a utilização de 
vetor de mcDNA-miR-375 pode ser proposta como uma possível estratégia terapêutica que 
deverá ser mais explorada no futuro. Assim, esta tese pretende contribuir junto da comunidade 
científica com informação útil para o potencial desenvolvimento de novas abordagens para o 
tratamento do cancro do colo do útero, através da implementação de duas plataformas 
biotecnológicas. Uma das estratégias baseia-se no desenvolvimento de uma vacina de pDNA que 
codifica para os antigénios E6 e E7 do HPV com objetivo de ativar as duas vias do sistema imune, 
a via preventiva/humoral e principalmente a via terapêutica/celular, possibilitando 
consequentemente a eliminação das células do organismo que expressarem estes antigénios. A 
segunda estratégia tem como foco a obtenção de um vetor inovador de terapia génica, o mcDNA 
que codifica para o pri-miR-375 no sentido de silenciar as oncoproteínas E6 e E7 do HPV, 
permitindo uma ação direta sobre as células cancerígenas do colo do útero, por reposição da 
expressão ou função de proteínas supressoras de tumor.  
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Cervical cancer is one of the leading causes of death amongst women, especially in countries 
lacking suitable access to health and hygiene care. Contrarily to most cancers, which usually 
take origin in mutations related with the action of mutagenic or carcinogenic agents, the 
development of cervical cancer is strongly associated with infection by Human Papillomavirus 
(HPV). This virus is responsible for the expression of E6 and E7 oncoproteins, which interfere 
with the cell cycle regulation, affecting the cellular mechanisms of repair and proliferation of 
infected cells. In the last decades, DNA-based therapies, such as DNA vaccines or gene therapy, 
have been highly explored by researchers in the search of an efficient non-viral vector for the 
cervical cancer treatment. Plasmid DNA (pDNA) is a popular non-viral vector, which has been 
widely studied in the past decades for the development of a variety of DNA vaccines and gene 
therapy strategies. However, the presence of CpG motifs necessary to its amplification in 
prokaryotic hosts may lead to the activation of the immune system and to the degradation of 
this molecule before it can reach the target cells, in a gene therapy perspective. However, 
these same motifs may contribute to the recognition of this bioproduct by antigen presenting 
cells, facilitating the processing of pDNA as a DNA vaccine. Minicircle DNA (mcDNA) consists in 
a non-viral vector whose popularity has been largely increasing in the last years. This vector 
results from the recombination of a molecule, which is similar to conventional pDNA, named 
parental plasmid (PP). However, PP presents two recombination sites which, upon induction, 
give origin to the recombination of this molecule into two different molecules: one containing 
all the prokaryotic information necessary for PP amplification in prokaryotic hosts (miniplasmid 
– mP) and another containing all the information necessary for the therapeutic gene expression 
in eukaryotic cells (mcDNA). Considering its innovative character, it is crucial to develop 
suitable strategies for mcDNA preparation, with a purity that fits the requirements established 
by regulatory agencies such as European Medicines Agency (EMA) or Food and Drug 
Administration (FDA). 
Thus, this work was performed with two different perspectives regarding cervical cancer 
treatment, namely DNA vaccines and gene therapy. Firstly, concerning DNA vaccines, the 
application of an adequate purification strategy allowed to understand that the purity degree 
of the pDNA sample can significantly contribute for the increased expression of the target 
antigen. The application of a monolith modified with arginine ligands, comparatively to the use 
of commercially available techniques, allowed to retrieve a final DNA vaccine sample with 
higher supercoiled (sc) content, leading to a higher expression of the target proteins. 
Concomitantly, the development of nanocarriers composed by calcium carbonate and gelatin 
allowed the delivery of pDNA vaccine to dendritic cells, also known as antigen presenting cells, 
without detecting cytotoxicity. On the other hand, two different strategies for mcDNA 
purification were explored. Firstly, the preparation of a monolith modified with cadaverine 
 xxii 
ligands and its use in the purification of sc mcDNA allowed a recovery yield of 78.6% coupled 
with 98.4% purity. These results turned out to be very interesting considering the current 
mcDNA purification scenario in the literature. On the other side, size exclusion chromatography 
was also explored through the use of Sephacryl SF-1000 matrix. This strategy allowed to obtain 
a sc mcDNA yield of 66% alongside a purity of 98.35%. Despite 12 times more mass of pure sc 
mcDNA was obtained in one assay, the assay turned out to be approximately 8 times longer 
than the assays performed with the cadaverine modified monolith. In the end, two strategies 
were developed for sc mcDNA purification, each presenting its advantages and disadvantages. 
Nonetheless, both allowed the purification of mcDNA without resorting to PP specific genetic 
modifications, which implies that these strategies can be universally used for mcDNA 
purification. However, the need to implement an analytical methodology that allows to 
quantify sc mcDNA content in a fast, low cost and effective way led to the study of cadaverine-
modified monolith with this purpose. Thus, a chromatographic method was implemented and 
validated to quantify sc mcDNA concentration present in a complex or pure sample, within a 
range of 1-25 μg/mL. Lastly, to study the effectiveness of miR-375 in the treatment of cervical 
cancer, in vitro studies were performed to evaluate the effect displayed by mcDNA-pri-miR-
375 in the expression of E6 an E7 oncoproteins. Therefore, CaSki cell line model was used, 
which consists in metastatic cervical cancer cells infected by HPV-16. Also, a fibroblast cell line 
was used as a non-carcinogenic model for control. It was possible to identify the correct 
expression of miR-375, coupled with a decrease in E6 and E7 transcript and protein levels. 
Furthermore, it was observed that fibroblast viability was not affected, instead observing a 
decrease in transfected CaSki proliferation and viability. Thus, the application of mcDNA-pri-
miR-375 as a possible therapeutic strategy should be more amply studied in the future. In the 
end, this thesis presents a scientific work that intends to contribute towards the scientific 
community with useful information for the potential development of new approaches for 
cervical cancer treatment, through the implementation of two biotechnological platforms. One 
of the strategies is based on the obtainment of a DNA vaccine, encoding E6 and E7 HPV antigens 
with the aim of activating two pathways of the immune system, the preventive/humoral and 
the therapeutic/cellular pathways, allowing the consequent elimination of the antigen-
expressing and HPV-infected cervical cancer cells. The second strategy is focused on the 
obtainment of innovative gene therapy mcDNA vector, encoding pri-miR-375, to silence E6 and 
E7 HPV oncoproteins, allowing the direct targeting of infected cervical cancer cells, through 
the re-establishment of tumor suppressor proteins expression or function. 
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This thesis is structured in five main chapters. The first chapter accounts for a literature review 
of the main topics, which will be addressed in the thesis, to contextualize the reader, and 
comprises two different sections. The first section provides a literature review of E6 and E7 
oncoprotein actions in the development of cervical cancer and discusses different 
biotechnological strategies, which have been studied and explored for the treatment of this 
disease, presented in a paper review form (Paper I. Cervical cancer and HPV-Infection: ongoing 
therapeutic research to counteract the action of E6 and E7 oncoproteins). The second section 
consists in a brief literature review of minicircle DNA vectors, explaining the main differences 
presented by minicircle DNA and plasmid DNA vectors, while providing a succinct review in the 
different methodologies currently implemented for mcDNA manufacturing. This section will 
also be presented as a paper review form (Paper II. Minicircle DNA – The future for DNA-based 
vectors?). 
The second chapter includes the global aims established for the current thesis project.  
The third chapter presents the main results obtained for the application of a DNA vaccine 
targeting E6 and E7 oncoproteins, with the respective discussion. This chapter comprises two 
sections in the form of original research papers, respectively: 
Paper III. HPV-16 Targeted DNA Vaccine Expression: The Role of Purification 
Paper IV. Purification and delivery of a Human Papillomavirus supercoiled plasmid DNA vaccine 
The fourth chapter presents the implementation of suitable methodologies to obtain pure sc 
mcDNA, as well as an analytical methodology for its recovery and quality assessment and finally 
the evaluation of sc mcDNA-miR-375 therapeutic potential in the silencing of E6 and E7 
oncoproteins. Thus, this chapter comprises four sections in the form of original research papers, 
respectively: 
Paper V. Minicircle DNA purification: Performance of chromatographic monoliths bearing lysine 
and cadaverine ligands 
Paper VI. The use of size-exclusion chromatography in the isolation of supercoiled minicircle 
DNA from Escherichia coli lysate. 
Paper VII. Quality assessment of supercoiled minicircle DNA by cadaverine-modified analytical 
chromatographic monolith 
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Paper VIII. Silencing Human Papillomaviruses E6 and E7 oncoproteins with a minicircle DNA 
vector encoding pri-miR-375 
 
Finally, the fifth chapter summarizes the results obtained throughout this research project and 
comprises two different sections. These sections are the concluding remarks and the future 
trends for this thesis, alongside additional research work that should be performed to culminate 
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Teaser Novel nucleic acid-based therapeutic approaches as a promising non-invasive
solution for the treatment of cervical cancer caused by Human Papillomavirus.
Cervical cancer and HPV infection:
ongoing therapeutic research to
counteract the action of E6 and E7
oncoproteins
Ana M. Almeida, João A. Queiroz, Fani Sousa and
Ângela Sousa
CICS-UBI — Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique,
6200-506 Covilhã, Portugal
Cervical cancer is the fourth most common cancer among women
worldwide and its development is mainly associated with human
papillomavirus infection, a highly sexually transmissible virus. The
expression of E6 and E7 viral oncoproteins deregulates cell repairing
mechanisms through impairment of tumor suppressor protein functions,
such as p53 or retinoblastoma protein. Although the implementation of
new preventive vaccines has decreased the infection rate and cervical
cancer progression, there are still many women who are affected by this
pathology. Nowadays, the main treatment often requires the use of
invasive techniques. From well-established strategies, like DNA vaccines
and gene therapy, to innovative gene silencing technologies; different
methodologies are currently under scrutiny that target the E6 and E7
oncoproteins and/or their modes of action.
Introduction
The connection between human papillomavirus (HPV) and cancer development, more specifi-
cally cervical cancer, was first established in 1983 by Harald zur Hausen and co-workers [1]. At the
time, it had already been possible to correlate the development of certain carcinomas in animals
with the infection of specific viruses – leading scientists to pursue the same line of thought and
study HPV in cancer biopsies, given that HPV DNA had been reported in genital warts [2]. Hence,
for the first time, zur Hausen was able to identify HPV type 16 and demonstrated its presence in
several malignant tumor biopsies [1]. Later on, zur Hausen’s research group found the presence of
HPV-16 and HPV-18 DNA in cervical cancer cell lines, as well as in cervical carcinoma biopsies [3].
The first steps to understand the development of cervical cancer were taken, and the ground-
breaking work performed by the German scientist was later recognized in the form of a Nobel
prize. Ever since such scientific discoveries were performed, many efforts have been made toward
the establishment of new detection, screening, preventive and therapeutic methodologies against
cervical cancer, mainly by exploring the crucial role of HPV in the development of this pathology.
Although the incidence of cervical cancer has been slowly decreasing with the advances in this
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mandatory to search for new methodologies that will help to overcome this problem. To fully
understand the ultimate treatment for this disease, it is first necessary to unveil the background of
cervical cancer, to decode the mechanisms responsible for the development and progression of
HPV infection and to explore different and promising therapeutic approaches.
Cervical cancer worldwide
Cancers are some of the deadliest pathological conditions globally. In particular, cervical cancer is
considered the fourth most common cancer in women, accounting for 266 000 deaths in 2012 [4].
When consulting data collected and provided by GLOBOCAN 2018, it is possible to infer that the
cervical cancer burden is higher in less developed countries [5]. Actually, in Eastern and Central
Africa, this cancer is known as the primary cancer found in women. This might be strongly
associated with the fact that less developed countries present very poor health resources in
comparison to developed countries, perhaps leading to a late diagnosis [6]. In addition, the recent
distribution of several HPV vaccines worldwide probably contributed to a decrease in HPV
infection, and a consequent decrease in the number of the cervical cancer cases in countries
with easy access to vaccination, such as developed countries. Given its severe implication in the
development of cervical cancer, it is therefore very important to understand the biological
mechanisms by which HPV operates within the cervical epithelium and further develop suitable
strategies that might prevent or overturn its infection and tumorigenicity.
HPV infection and cervical cancer development
According to World Cancer Reports, ‘persistent epithelial infection with one or more oncogenic
types of HPV may lead to the development of precancerous lesions . . . which may progress to
invasive cervical cancer’ [6]. As a matter of fact, between 79% and 100% of invasive cervical cancer
cases worldwide account with the presence of DNA belonging to high-risk HPV types, from which
~70% are related to HPV-16 and HPV-18 [7,8]. Even though HPV is directly associated with cervical
cancer, other cancers have also been found to be correlated with HPV infection such as anal,
vaginal, vulvar, penile and head and neck cancers [9]. Indeed, there are about 200 HPV genotypes
currently documented; however, only some present carcinogenic potential and are known to
have the ability of inducing cancer [10]. The fact that different HPV types are related to different
clinical symptoms has led scientists to classify each HPV type according to the severity of the
clinical outcomes, namely by low, intermediate and high risk. The high-risk types encompass
HPV that can induce the development of tumor cells [11]. The severity of the symptoms is usually
associated with the affinity presented by E6 and E7 oncoproteins within each HPV type toward
the target proteins: tumor suppressors p53 and retinoblastoma protein (pRB), respectively.
HPV is a small double-stranded DNA virus, belonging to the family Papillomaviridae, and one of
the most common sexually transmissible viruses worldwide. It presents a nonenveloped icosa-
hedral structure and its genome contains eight open reading frames (ORFs) [12]. These ORFs are
responsible for coding eight proteins, which can be divided into early stage (E1, E2, E4-E7) and
late stage (L1 and L2). As the name implies, early proteins are the proteins to be first expressed
upon virus infection of the host cell and are associated with the infection itself and the possible
transformation of infected cells. By contrast, late proteins constitute the viral capsid and
contribute to the spreading of the infection through the host system, via the release of virus
particles within the superficial epithelial cells [12].
Figure 1a illustrates the normal cell repairing pathway. Viral infection with HPV begins when
the virus can penetrate the cervical epithelium through micro-abrasions. Then, the E1 and E2
protein expression leads to regulation of the viral replication within infected cells, resulting on
the expression of other early-stage proteins. At this point, E5, E6 and E7 oncoproteins begin to be
expressed, contributing to cell survival and uncontrolled proliferation, as presented in Fig. 1b
[13–15]. Such a carcinogenic mechanism is strongly dependent on the HPV ability in mainly
expressing E6 and E7 viral oncoproteins. Both proteins are known to interfere with cell-cycle
regulation, affecting the signaling pathways for cell repair and apoptosis [13,14].
The E6 protein can induce tumor suppressor p53 degradation, hindering its function as an
apoptosis signaling cascade regulator, through E6AP protein binding. The latter is unable to bind
itself to p53, in normal circumstances. However, in the presence of E6 protein, E6AP and E6 form a
protein complex that can recognize and bind to p53. Such attachment can impair transcriptional
activation or repression of p53-responsive promoters by preventing its binding to specific DNA
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FIGURE 1
Schematic representation of cell-repairing systems in normal cells vs cells infected with human papilloma virus (HPV). (a) Normal cell. When a stressful event
leads to cell damage, different mechanisms are triggered to induce cell quiescence or death. Tumor suppressor protein p53 is expressed at high levels and
different targets are either activated or repressed. In the nucleus, p300 acetylates p53 and induces its ability to act as a transcription promoter for p21 (between
other targets) expression. Then, p21 triggers a series of events that will result in cell-cycle arrest. p53 represses the transcription of Bcl-2, an antiapoptotic protein.
Thus, Bak and Bax apoptotic proteins induce C cytochrome production, which will in turn trigger the caspase cascade, leading to apoptosis induction. FAS
receptors are also able to trigger the caspase cascade when triggered by FASL binding. Additionally, pRB, p107 and p130 bind to E2F transcription factor,
impeding its action as a cell-cycle promoter. (b) HPV-infected cell. Upon production of E5, E6 and E7 HPV oncoproteins, the cell repairing systems are altered. E5
presence leads to inappropriate activation of EGFR, triggering a series of events that culminate in VEGF production, thus promoting angiogenesis, one of the
hallmarks of cancer progression. E6 production leads to the repression of several signaling systems. E6 can form a complex with E6AP able to mark p53 for
degradation, thus decreasing the levels of this tumor suppressor protein. Such degradation of p53 leaves Bcl-2 expression deregulated, leading to Bax inhibition.
Moreover, E6 can mark Bak for degradation, an important proapoptotic protein, and can bind to p300, thus inhibiting its p53 activation mechanism. Besides, E6
has the ability to bind to FAS and accelerate its degradation. All these mechanisms triggered by E6 result in apoptosis protection. E7 has the ability to bind to
tumor suppressors pRB, p107 and p130, which are regulator proteins of the E2F transcription factor. This binding frees E2F, which in turn can continuously induce
cell-cycle progression. Overall, HPV protein interference leads to the uncontrolled proliferation of cells. Abbreviations: E6AP, E6AP ubiquitin-protein ligase; EGF,











IEWmotifs and ultimately lead p53 to degradation through ubiquiti-
nation, resulting in a decrease in p53 levels [13,16]. The inactiva-
tion of p53 function favors the continuous replication of damaged
DNA and abnormal cell survival, which would otherwise be
repaired or eliminated by apoptosis induction if p53 was expressed
in normal levels (Fig. 1a) [13]. Moreover, E6 has been shown to be
able to interact with other proteins that also regulate cell signaling
pathways. For instance, E6 can also interact with p300, a promoter
that activates p53 through acetylation in an E6AP-independent
manner [17]. Also, E6 can target for degradation of other proteins
involved in the signaling cascade for apoptosis, namely Bak, the
adaptor molecule Fas-associated death domain (FADD) and pro-
caspase 8 [17]. Taking these interactions altogether, the disruptive
effect that E6 can exert on the regulation of cell-cycle proliferation
and repair is notorious. By contrast, E7 protein is involved in the
impairment of tumor suppressor pRB function. As portrayed in
Fig. 1a, whereas p53 activates apoptosis, pRB functions mainly rely
on the inactivation of transcription factors, such as E2F. This
molecule, when freely available, stimulates cellular cycle transi-
tion to S phase. Thus, upon viral infection, E7 is expressed and
binds to pRB, disrupting its complex with E2F and contributing to
2046 www.drugdiscoverytoday.comcontinuous cell proliferation (Fig. 1b) [14,18]. Moreover, E7 onco-
protein is also involved with the interference of p107 and p130
functions, two proteins that also regulate cell-cycle proliferation
through E2F transcription factor binding. The ultimate inhibition
of pRB, p107 and p130 by E7 viral protein contributes to the
uncontrolled cell proliferation and progression to malignant
transformation seen in HPV-infected cervical epithelium
[14,19]. Although E6 and E7 proteins are considered the main
causative agents for HPV-infected cell transformation, E5 also
presents carcinogenic activity. This protein has the ability to
enhance cell proliferation through interaction with epidermal
growth factor (EFG), a known stimulator of cell growth, therefore
contributing to tumor progression (Fig. 1b) [15].
With the evolution of HPV infection, normal cervical tissue
begins to lose its normal features and cells become more undiffer-
entiated. The progression of the disease leads to the establishment
of cervical intraepithelial neoplasia (CIN), which can be mild
(CIN1) or moderate (CIN2) and characterized by cytologic abnor-
malities in the tissue. Without suitable treatment and as a result of
persistent infections, CIN2 can evolve into high-grade lesions such
as severe CIN (CIN3) or invasive carcinoma [20]. Therefore, given7 
the timeline of HPV infection and possible progression into
cervical cancer, it is crucial to detect and treat the HPV infection
before its evolution into more serious conditions.
HPV infection and cervical cancer: prevention and
therapy
With the understanding of the HPV role in the development of
cervical cancer, and other genital diseases, researchers have fo-
cused on developing suitable strategies to detect and prevent the
disease. Suitable screening techniques are currently available, such
as Papanicolaou stain or HPV DNA testing, allowing physicians to
detect HPV infection at an early stage and prevent its evolution
into invasive cervical cancer [21]. In 2002 a monovalent vaccine
was studied, which consisted in the development of HPV-16 L1
capsid virus-like particles (VLPs) [22]. Scientists were able to verify
a decrease in the incidence of HPV-16 infection in the population
vaccinated with this particular vaccine, suggesting this vaccine
was able to confer protection against this particular type of HPV
and reduce the risk of developing cervical cancer [22–24]. Consid-
ering the fact that there is a wide range of HPV types associated
with serious infections that can ultimately lead to the onset of
cancer, HPV vaccine research began to focus on developing new
vaccines that could provide protection against multiple HPV
types. In 2005, a Phase II clinical trial was published regarding
the administration of a quadrivalent HPV vaccine, which could
supposedly confer protection against four HPV types, responsible
for 70% of cervical cancer cases (HPV-16 and HPV-18) and 90% of
genital warts (HPV-6 and HPV-11) [25]. According to the data,
vaccinated women presented a 90% reduction of combined inci-
dence of persistent infection or disease with the four HPV types, in
comparison to women assigned with the placebo [25]. Given the
success demonstrated in Phase II and Phase III clinical trials
[25–29], this quadrivalent vaccine was later approved and licensed
by the FDA, followed by its launch under the name of Gardasil1,
by Merck. Simultaneously, a bivalent vaccine was developed with
the main goal of preventing cervical cancer, therefore containing
only L1 VLPs of HPV-16 and HPV-18 [30,31]. Some studies revealed
that the bivalent vaccine could elicit higher antibody production
than the quadrivalent vaccine, suggesting that it could persist
longer [32]. The bivalent vaccine was launched as Cervarix1 by
GlaxoSmithKline in Europe and the USA in 2007 and 2009,
respectively. Cervarix1 and Gardasil1 have been shown to be
protective over 10 years (time that has elapsed since the initial
clinical trials) [33,34]. More recently, Merck developed a new
vaccine named Gardasil1-9 which confers protection against nine
HPV types (HPV6, 11, 16, 18, 31, 33, 45, 52 and 58)
that, together, have been found in 85% of invasive cervical cancers
worldwide [7,35,36]. By expanding the vaccination coverage
worldwide, cervical cancer and other HPV-associated cancer rates
are expected to decrease. However, to increase the protection and
possibly eradicate these high-risk HPV types, vaccination of men
must also be considered, given that HPV can also be responsible for
the development of anal or penile cancers [37]. As a matter of fact,
some countries have implemented a gender-neutral vaccination
system with this purpose. Nevertheless, modern antivaccination
movements, led by organizations who believe in a cause–effect
relationship between immunization and development of severe
adverse reactions, has been contributing to a decrease in the
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general opinion [38,39]. Also, considering that HPV virions can
infect the epithelium through the existence of micro-abrasions, it
is very important to vaccinate individuals at an early age, prefera-
bly before initiating an active sexual life, given these vaccines do
not exert any therapeutic effect against an ongoing HPV infection.
Therefore, it is also necessary to focus on the development of
suitable cervical cancer treatment options.
Currently, the main guidelines for cervical cancer treatment at
an early disease state describe the use of surgery to remove the
cancerous tissue, sometimes accompanied by chemotherapy or
radiotherapy [40]. Surgery can vary from conization to radical
hysterectomy, sometimes implying loss of fertility. The coupling
with radiotherapy is very common in the treatment of several
cancers, presenting satisfactory results in numerous cases and
currently representing the most suitable treatment for local and
nonmetastatic cancer [40]. When the treatment turns out to be
ineffective or it is necessary to expand its range to the entire body,
owing to tumor metastasis, chemotherapy is the next logical step
[41]. Chemotherapy involves the administration of cytotoxic
substances that can interfere with cell-cycle proliferation, there-
fore preventing tumor growth and leading to cancer cell death
[41]. However, given that radiotherapy and chemotherapy treat-
ments are unable to differentiate cancerous tissue from healthy
tissue, there is a significant cytotoxicity associated that usually
leads to the appearance of side effects and can cause significant
discomfort to the patient [41]. Therefore, the design and develop-
ment of anticancer therapeutics that are efficient and targeted
toward the unhealthy tissue is imperative.
Cervical cancer and HPV infection: ongoing
therapeutic research
DNA is, without doubt, a crucial molecule in all living organisms
owing to its coding functions within the cell, providing the
necessary information for protein synthesis as well as for regula-
tion of cell mechanisms. With advances in biotechnology, DNA
recombinant technology was born and continues to grow. The
possibility for rearranging different genes and manipulating their
functions has led scientists to dedicate their research to the
development of new gene-based therapies. RNA has also been
gaining attention because of the discoveries made, regarding its
ability to control gene expression, allowing modification and
regulation of cell signaling pathways. With the knowledge ac-
quired through the study of these molecules, researchers were able
to propose and explore innovative strategies for the treatment of
different pathologies. Currently, several of these cutting-edge
technologies are under study to prevent or treat cervical cancer.
DNA vaccines
DNA vaccines have been categorized as the third generation of
vaccines, promising humoral and cellular immune responses, with
low cost production, thermostability and easy distribution in
comparison to conventional vaccines [42]. Such immunological
technology is based on the delivery of genetic information with
the intent of inducing an immune response against a specific
antigen. After inoculation, the treated individual should be capa-
ble of producing a strong immune response against the antigen for
















chosen to be encoded in the DNA vaccine must be related with a
given pathology [43]. Such an immune response is triggered
mainly as a result of the transfection of antigen-presenting cells
(APCs) and non-APCs that will later express the antigen encoded
in the DNA vaccine. As depicted in Fig. 2, there are two pathways
that can lead to antigen presentation. In Fig. 2a, cells transfected
with the DNA vaccine can directly present the antigen to CD8+ T
lymphocytes, through major histocompatibility complex (MHC)
class I [43,44]. This activation leads to the maturation of cytotoxic
T lymphocytes (CTLs), effector cells, which can identify cells that
present the target antigen through MHC class I. Once these cells
are found by the CTLs, cell death is triggered via different path-
ways. Such a pathway represents the therapeutic effect of the DNA
vaccine [45]. By contrast, antigen production by non-APCs can
lead to APCs taking up the antigen exogenously, resulting in the
presentation of the latter to CD4+ T lymphocytes via MHC class II,
as portrayed in Fig. 2b. Such activated lymphocytes can activate B
cells, which are white blood cells that can produce antibodies
against specific antigens. The secretion of such antibodies can lead
to neutralization of the microbe responsible for the production of
the target antigen (in this case, the virus) [46]. Also, memory B cells
are formed from this activation. Such cells are responsible for the
induction of a strong immune response when reinfection occurs,
thus representing the preventive effect of the DNA vaccine [46].
The combination of both pathways leads to the emergence of a
strong humoral and cellular immune response, contrarily to pro-
phylactic vaccines [43,44].
Although one of the advantages of DNA vaccines over prophylac-
ticvaccines is the broadrangeoftheelicited immuneresponse, this is
not the only great feature presented by this technology. DNA
vaccines are much more economic to manufacture than prophylac-






























Antigen presentation schematics. (a) Endogenous antigen presentation. APCs trans
antigen will be presented by MHC class I to naive CD8+ T cells, activating them as C
that is used for their activation. When such identification is successful, the cell prese
paths that mainly lead to apoptosis induction. (b) Exogenous antigen presentation.
the DNA vaccine, and present them by MHC class II to naive CD4+ T cells, activatin
antibodies. These antibodies are released and can trigger different pathways that l
cytotoxic T Lymphocyte; MHC, major histocompatibility complex; TCR, T cell rece
2048 www.drugdiscoverytoday.com[47]. DNA vaccines can be easily obtained in large quantities and
high-grade purity, owing to the fact that DNA is a molecule easier
to manipulate than the peptides from which prophylactic vaccines
are made [48]. This also accounts the fact that DNA is more stable,
facilitating its transportation and storage. Moreover, DNA vaccines
have the potential of providing longer in vivo exposure to antigens,
which could lead to the increase of immunogenicity and to a
decrease in the number of required immunizations [49].
Given that DNA vaccines can exert preventive and therapeutic
effects, they are being currently explored in the treatment of
cancer. Many cancers exhibit specific antigens that could be used
in the development of a DNA vaccine to elicit a specific immune
response against those antigens [50]. Thus, given all the advan-
tages inherent to DNA vaccines, much effort has been devoted to
developing suitable DNA vaccines for cervical cancer. Considering
the main role that E6 and E7 oncoproteins display in cancer
development, therapeutic DNA vaccines are currently being de-
veloped by using these oncoproteins as antigenic agents. So far,
there are many research studies that have been conducted with the
aim of developing a suitable DNA vaccine against HPV. From
codon optimization to the inclusion of different fusion proteins
to facilitate the antigen-presenting process, many approaches
have been studied for this matter [51–53]. Such approaches are
crucial to induce a strong immune response, because they can
significantly alter the immunogenicity for a given DNA vaccine
[54]. Codon optimization is used to increase antigen production,
principally in heterologous expression systems. This need emerges
with the fact that different sets of nucleotides can code for the
same amino acid, thus constituting a codon. However, not all
organisms are known to make use of all the existing codons. As a
matter of fact, a preference for some codons has been shown for
different organisms. This can lead to an ineffective translational
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fected with DNA vaccine can endogenously produce the target antigen. This
TLs. Then, CTLs identify cells expressing MHC class I coupled with the antigen
nting the antigen is destroyed by CTLs as a result of the activation of different
 APCs can take exogenous antigens, produced by other cells transfected with
g them. Then, these cells activate B cells into the producing antigen-specific
ead to virus neutralization. Abbreviations: APC, antigen-presenting cell; CTL,
ptor.
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process and result in decreased protein expression [43]. Thus,
codon optimization might be necessary to improve antigen ex-
pression and increase immune response. Adjuvants can also be
used to improve the outcome of DNA vaccines. These adjuvants
might come in as separate molecules or can be included in the
antigen design as fusion proteins [43]. Whereas the former might
be obtained through the concomitant administration of a plasmid
encoding these adjuvants, for example, the latter are constructed
by genetically engineering the gene encoding the antigen to
produce a protein fused to one, or more, proteins. Such engineer-
ing can be used to take advantage of different protein domains. For
instance, it can be used to increase the uptake or the stability of a
given antigen [43,52]. Table 1 lists a few selected examples of
proteins that have been included in the design of different DNA
vaccines and their functions in the optimization of this strategy.
Some of these proteins have been included in the design of DNA
vaccines that have reached clinical trials, such as HSP70, a heat
shock protein that facilitates antigen presentation and concomi-
tantly exhibits antiproliferation effects, or the more recently stud-
ied interleukin (IL)-10 receptor, which can inhibit the action of IL-
10, which can interfere with triggering of the immune response
[53,55]. As mentioned above, different molecules with different
roles can be used to optimize the therapeutic effect of a DNA
Drug Discovery Today Volume 24, Number 10 October 2019 TABLE 1
Examples of proteins that have been selected to improve DNA vacc
Year Protein Function 
2008–2017 CRT Ca2+-binding protein able to associate with ER
transportation molecules, aiding in the antigen
presentation through MHC class I
2009–2014 Flt3L Growth factor able to expand DC and increase
population of lymphocytes, improving CD8+ T
cell and NK cell activation
2009 HSP70 Heat-shock protein able to improve the uptake
of the linked antigen by APC and aid in the
antigen presentation through MHC class I and
class II, eliciting proinflammatory responses
2017 IL-2 Interleukin able to induce T and B cell
proliferation as well as immunoglobulin
synthesis, eliciting strong and robust immune
response
2011–2017 TTFC Foreign molecule able to elicit CD4+ T helper
response and provide more stability to the
antigen, improving its half life
2018 MLT Immunomodulatory hormone able to induce
lymphocyte activation and exert proapoptotic
effects
2019 SA-4-1BBL Artificial ligand for TNF receptor that promotes
the proliferation and survival of CD8 + T cells
and induces production of different
proinflammatory cytokines
2019 IL-10 receptor Inhibits IL-10, which is an interleukin that
interferes with antigen presentation and
reduces CD8+ T responses
Abbreviations: APC, antigen-presenting cells; CRT, calreticulin; DC, dendritic cells; ER, endoplasm
protein; IL, interleukin; NK, natural killer; MLT, melatonin; TNF, tumor necrosis factor; TTFC, te
10 vaccine, altering significantly the performance of the immunolog-
ical response.
Although several DNA vaccines have been designed in the past
years toward E6 and E7 antigens, few have reached clinical trials
for cervical cancer. Cornelia Trimble and her research group have
been dedicating their research to developing and improving DNA
vaccines for cervical cancer treatment, having published a Phase I
clinical trial (NCT00121173) regarding the use of pNGVL4a-Sig/E7
(detox)-HSP70 in 2009 [53]. This DNA vaccine encodes the HPV-16
E7 oncoprotein modified, so that it is unable to bind to pRB. The
DNA vaccine was also coupled to a signal peptide to facilitate the
release from cells through a secretory pathway, coupled to HSP70
[53]. In this study it was found that 33% of the patients presented
histologic regression. Later on, in 2014, another Phase I study
(NCT00788164) was conducted with this particular vaccine, where
a robust, localized and effective immune response was detected in
the treated patients [56]. Recently, a Phase II trial began to explore
the effect of this vaccine coupled with TA-CIN vaccine, a protein
vaccine that comprises L2/E6/E7 proteins from HPV-16
(NCT03911076). In 2015, Trimble’s research group conducted a
Phase II clinical trial (NCT01304524) in patients with CIN2/3 by
using VGX-3100, a DNA vaccine consisting of an equal mixture of
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E6/E7 fusion protein of HPV-16 or HPV-18 [57]. This particular
vaccine had the advantage of possibly being offered as a treatment
for two of the HPV strains most associated with cervical cancer:
HPV-16 and HPV-18. The results were shown to be promising,
given that histologic regression was observed in 49.5% of treated
patients, without major adverse reactions. These findings sug-
gested that this DNA vaccine could be a suitable alternative to
more-invasive techniques such as surgery [57]. Following this line
of thought, a Phase III clinical trial, entitled REVEAL 1 – Evaluation
of VGX-3100 and Electroporation for the Treatment of Cervical
HSIL (NCT03185013), was initiated in 2017 by Inovio Pharma-
ceuticals with the intent of further proving the safety and effec-
tiveness of the VGX-3100 vaccine. This study is expected to end in
2021 and bring support to the commercialization of this vaccine
[58].
In 2016, Trimble and co-workers also published data regarding a
Phase I clinical trial (NCT00988559) that was conducted with
pNGVL4a-CRT/E7 (detox), a DNA vaccine specifically designed
to target HPV-16 E7 oncoprotein. This pDNA molecule expresses
the E7 protein, with a modification that prevents its ability to
transform healthy cells, coupled to calreticulin, a heat-shock
protein similar to HSP70 [59]. In the conducted study, 30% of
the patients, who exhibited CIN2/3, demonstrated histologic
regression and well tolerability toward the vaccine administration
[59]. However, in comparison to VGX-3100, this DNA vaccine is
limited to HPV-16 infections, which can be considered as a disad-
vantage by not targeting HPV-18 infections as well, limiting its
coverage.
Another DNA vaccine that has reached clinical trials, this time
developed by Kim and co-workers, is the GX-188E HPV DNA
vaccine. This DNA vaccine was designed to express shuffled
HPV-16 E6 and E7 proteins, to prevent the interaction with tumor
suppressors p53 and pRB, coupled to an extracellular domain of
Flt3L and the signal sequence of tissue plasminogen activator (tpa)
[51]. The latter sequences were included to promote antigen
presentation and to enhance the release of the fused protein
through the secretory pathway, respectively [51]. In this Phase I
study (NCT01634503), which was also conducted in patients with
CIN2/3, 78% of treated patients demonstrated histologic regres-
sion and 89% displayed enhanced HPV-specific CD8 T cell re-
sponse, suggesting this DNA vaccine can be a promising
noninvasive therapeutic strategy for patients with cervical dyspla-
sia [51]. A Phase Ib/II study is currently being carried out to assess
the effect of GX-188E coupled with pembrolizumab, a monoclonal
antibody, in patients with advanced and nonresectable HPV-posi-
tive cervical cancer (NCT03444376).
Overall, DNA vaccine research is evolving accompanied by very
interesting results, suggesting that this therapeutic pathway can be
promising to cervical cancer treatment. Nevertheless, researchers
have generally found that the majority of DNA vaccines developed
so far do not present the high-level immunogenicity observed in
mouse models, thus justifying the lack of DNA vaccines approved
for human use [48,60]. New methodologies are currently under
study to improve the clinical outcome of DNA vaccines. These
methodologies derive from the outstanding progress that has been
observed in the past years for this field of studies [60]. Moreover,
cases like VGX-3100, which stands out as the current HPV DNA












IEWvaccine to be commercially available for humans might be
launched in the near future.
Gene therapy
Gene therapy has been in the research spotlight for years. The gene
therapy premise involves the delivery of a foreign DNA sequence
to the host cells with the intent of altering the function of a given
molecule that could play an important part in disease develop-
ment [61]. The potential of this field for the treatment of
‘incurable’ diseases resultant from inherited mutations has led
researchers to focus their efforts on the search for the next ‘miracle’
cure. Although its popularity has been affected owing to the threat
posed by some severe adverse reactions that occurred in some
initial clinical studies and as a result of the lack of significant
therapeutic results, researchers have been able to turn the tables
through the knowledge acquired during the past decades [62,63].
In recent years, more efforts have been made in the development
of gene therapy strategies suitable for cancer treatment. As a matter
of fact, the majority of the gene therapy clinical trials performed to
date have been directed toward cancer treatment (65%) [64].
Therefore, there has been an increased interest in studying tumor
suppressor proteins in the development of such strategies. For
instance, pRB is a tumor suppressor protein, the action of which is
inhibited owing to HPV viral activity, more precisely the expres-
sion of oncoprotein E7. As stated before, its function is mainly
involved in regulating cell-cycle proliferation through the inacti-
vation of transcription factor E2F. In 2001, Ip and co-workers
designed a gene therapy study to evaluate the therapeutic poten-
tial of an adenovirus (AV) expressing pRB [65]. However, their
findings suggested that pRB is not a suitable candidate for the
development of a cervical cancer therapy because no inhibitory
effect was found in the cell growth of three different cervical
cancer cell lines, as opposed to an osteosarcoma cell line [65].
Moreover, they evaluated the use of a p53-expressing AV in the
same cell lines and apoptosis induction was detected through flow
cytometry [65]. The main reason for such different outcomes is
probably related to the fact that p53 activates a signaling pathway
responsible for apoptosis induction, whereas pRB is mainly in-
volved in regulating cell proliferation, leading to G1 phase arrest
and cell senescence but not necessarily contributing to cell death
[18]. Additionally, a few reports state that E2F activates apoptosis
p53-independently, and normal function can be impaired in the
presence of overexpressed pRB [66]. Nevertheless, the poor results
obtained with the pRB-based gene therapy protocol for the treat-
ment of cervical cancer led this strategy to fall into oblivion.
By contrast, the p53 gene has been considered the main tumor
suppressor gene chosen for the development of gene therapy
strategies, sometimes combined with other conventional thera-
pies such as chemotherapy or radiotherapy [64]. Although 50% of
the cancer cases worldwide result from mutations in the p53 gene,
rendering the protein unable to regulate cell proliferation and to
activate the apoptosis cascade [67], in cervical cancer p53 is
degraded because of the presence of E6 viral oncoprotein [13].
Restoring p53 levels could be a suitable strategy for inducing
tumor cell apoptosis, which could be accomplished by transfecting
malignant cells with a p53 expression vector. The use of such a
strategy has been controversial according to the literature, given
that some researchers claim that this type of gene therapy might
Drug Discovery Today Volume 24, Number 10 October 201911 
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FIGURE 3
Schematic representation of different gene silencing strategies. (a) Artificial RNA-based therapies. Such therapies include AsRNA, shRNA and siRNA. AsRNA and
shRNA must be delivered to the nucleus via a vector encoding these molecules, whereas siRNA molecules are delivered directly to the cytoplasm. Upon excretion
to the cytoplasm, AsRNA binds to the target mRNA, forming a mutant dsRNA that will be marked to degradation by RNase H. By contrast, shRNA will be excreted
and processed by Dicer before forming the RISC complex. shRNA and siRNA follow the same process after RISC complex formation, leading to target mRNA
identification and degradation. Such a strategy might be used to mark E6 and E7 mRNA to degradation. (b) CRISPR/cas9 systems. Cas9-sgRNA can be delivered to
the nucleus, via an encoding vector, or directly delivered to the cytoplasm, when produced in vitro. Its assembly and nucleus entering will allow editing of the
target sequence to which the sgRNA was designed, leading to genomic DNA definitive alteration. Such genomic editing might be used to delete the human
















rennot be completely effective owing to E6-mediated degradation of
p53 protein resulting from de novo synthesis [68]. To surpass this
problem and avoid the E6 direct action on the p53 expressed by the
gene therapy vector, in 1998, Prabhu and co-workers published a
study regarding the development of an AV that could express
p73b, a homolog for p53 protein that displays similar functions
to the p53 tumor suppressor [68]. This protein can induce apopto-
sis in a p53-dependent manner but is usually expressed in low
levels, because its activation is generally a response to stress. In the
study, HPV-E6-expressing cells were transfected with either p53- or
p73b-expressing AV. Cellular proliferation was only suppressed in
cells transfected with p73b-AV, as opposed to cells transfected
with p53-AV. In addition, p73b-AV displayed apoptosis induction
in transfected cells, suggesting that the E6 mechanisms responsi-
ble for p53 degradation are unable to interfere with p73b signaling
[68]. In 2003, such findings were sustained by a study conducted
by Das and co-workers, where they developed a nonreplicating
p73b-AV, for biosafety purposes, and compared its efficiency with
a p53-AV, recording very similar data to those reported previously
by Prabhu [68,69]. In 2006, Das et al. gave continuity to the
research and published a study based on the use of nonreplicating
p73b-AV in vitro and in vivo [70]. The growth inhibition of HPV-
positive cervical cancer cells was accomplished with administra-
tion of this biopharmaceutical product, followed by apoptosis
induction, in in vitro and in vivo models. Overall, these results
suggested that p73b might be a promising strategy for scientists to
pursue a next generation HPV-induced cancer treatment. Howev-
er, no new information regarding the use of this vector has been
released to date.
Despite the studies developed by Prabhu and Das, other
researchers kept on exploring the use of p53 gene therapy in
HPV-induced cervical cancer and good results have been obtained.
As a matter of fact, Gendicine, the first known gene therapy
product to be released for cancer treatment, the approval of which
was restricted to China, consists of a recombinant AV that
expresses human p53 protein [71,72]. Twelve years since its market
release, >30 000 patients have received this biopharmaceutical
drug as cancer treatment. No serious adverse reactions have been
reported so far, except high fevers in the first hours upon receiving
the treatment [73]. Nevertheless, its approval in other countries
was controversial because the methodology used for data collec-
tion in China was not comparable to that used by the FDA [73]. In
the particular case of cervical cancer, it was demonstrated that the
coadministration of Gendicine with radiotherapy resulted in the
significant increase of 5-year survival rate in comparison to radio-
therapy alone, suggesting that the use of this gene therapy ap-
proach can have a synergistic effect in the treatment of this cancer
[72]. Although there are interesting results published regarding the
use of p53 expressing AV in cervical cancer, the fact that E6-
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DICER, as mature miRNA, to integrate into the RISC complex, an RNA-induced silenc
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2052 www.drugdiscoverytoday.compositive cells can interfere with the production of p53 can be
hiding the full potential of this method. To overcome this issue,
the use of a gene therapy strategy targeting the overexpression of
p53 or pRB concomitantly with the silencing of E6 or E7 onco-
proteins could be very promising in unravelling the full potential
of this approach in the future.
Gene silencing
With the fast and innovative advances in the gene therapy field, a
new approach has been taken into consideration: why not directly
silence the expression of proteins involved in the disease emer-
gence? Since the discovery of antisense RNA technology in 1981 by
Tomizawa and co-workers [74], followed by the accidental discov-
ery of RNA interference by Guo et al. [75] and the study of its
implication in gene expression by Fire et al. [76], such a strategy
became easier to pursue. Thus, many scientists have been explor-
ing the implementation of this technology in different diseases. In
cervical cancer induced by HPV, the most obvious pathway to
follow is the downregulation of E6 and E7 oncoproteins. With this
in mind, several HPV oncoprotein silencing studies have been
performed in the past years. In Fig. 3 the main technologies used
for this purpose are represented: antisense RNA (AsRNA), small
interfering RNA (siRNA), short hairpin RNA (shRNA), the clustered
regularly interspaced short palindromic repeats associated with
Cas9 (CRISPR/cas9) system and microRNA. In next subsections,
the promising roles of these technologies will be discussed for the
treatment of HPV-induced cancer.
Artificial RNA-based therapies
Artificial RNA-based therapies encompass antisense RNA (AsRNA),
a single-stranded antisense RNA complementary to the target
mRNA; siRNA, a double-stranded RNA complementary to mRNA;
and shRNA, a double-stranded RNA that originates siRNA. As
schematized by Fig. 3a, these systems can interfere with protein
expression by binding to the mRNA of the target protein through
perfect complementarity, targeting this molecule to degradation.
In 1988, the first attempt at silencing the expression of E6 and E7
oncoproteins was performed, when von Knebel Doeberitz and co-
workers transfected a C4-1 cell line, a cervical carcinoma bearing
HPV-18, with a plasmid containing HPV-18 E6 and E7 AsRNA
sequences [77]. Here, they were able to verify that cell growth was
affected by such an experiment, given that, in the presence of
dexamethasone, transfected cells revealed a reduction in its
growth rate comparatively to nontransfected cells. Since then,
many studies have been conducted regarding the silencing of
E6 and E7 oncoproteins in an independent manner or simulta-
neously. It is noteworthy to mention that E6 and E7 mRNAs are
bicistronically transcribed from the same promoter in HPV-
infected cells. Thus, some silencing sequences can be designed
to simultaneously target both oncoproteins.
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t cellular pathways. Thus, these molecules are first transcribed in the nucleus,
miRNA. In the nucleus, this transcript is processed by Drosha and DGCR8
pre-miRNA molecule is exported to the cytoplasm, where it is processed by
ing complex formed by DICER, AGO, PACT and TRBP. Such a complex is able to
tion of these mRNAs. Abbreviations: AGO, argonaute; AsRNA, antisense RNA;
lindromic repeats; DGCR8, protein DiGeorge syndrome critical region gene 8;
ase R-activating protein; RISC, RNA-induced silencing complex; sgRNA, single
A-binding protein.
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In 2000, Choo and co-workers developed a retrovirus for an
AsRNA strategy targeted against HPV-16 E7 oncoprotein, with the
intent of studying its impact in the tumorigenicity of HPV-16-
positive cervical cancer cells [78]. In that study, cell growth
inhibition was observed, from a decrease in E7 oncoprotein
levels. However, such inhibition was unable to result in tumor
cell death, rather resulting in cell differentiation, a cell feature
that is lost in cancer progression [78]. By contrast, Cho and co-
workers conducted a study in 2002 by using a plasmid encoding
an AsRNA for HPV-16 E6 oncoprotein in the same cell model used
in Choo’s research [79]. They were able to verify that, after
transfection, cell growth was inhibited and an apoptotic mor-
phology was acquired by the cells, which was confirmed by an
increase in p53 levels [79]. These results suggested that E6 silenc-
ing leads to a more preeminent function in tumor suppression
than E7 silencing.
Curiously, Yamato and co-workers took advantage of the bicis-
tronic transcript and conducted a study with two synthetic siR-
NAs, designed to target different splicing variants of HPV-18 E6
mRNA. One of them was able to knockdown E6 and E7 expression
and the other could successfully knockdown E6 levels but was
unable to inhibit E7 as efficiently as the former [80]. Their findings
showed that the isolated E6 suppression exerted a more significant
tumor cell death effect comparatively to concomitant suppression
of E6 and E7, suggesting that targeting E6 oncoprotein could be
crucial when developing a siRNA-based strategy for cervical cancer
induced by HPV [80]. Although these results seem to be in accor-
dance with the investigation previously conducted by either Choo
and Cho’s research groups [78,79], it goes against the work devel-
oped by Jiang and Milner [81]. In 2002, the researchers published a
study reporting the comparative use of synthetic siRNAs against
either E6 or E7 HPV-16 oncoproteins. However, in contrast to
what Choo et al. and Yamato et al. found in their studies [78,80],
Jiang and Milner reported a reduced cell growth derived from E6
silencing and apoptosis induction from E7 inhibition [81]. These
apparently contradictory results can be explained by the differ-
ences shown in study design, namely because different types of
HPV were studied, distinct methods were used for silencing, the
Drug Discovery Today Volume 24, Number 10 October 2019 TABLE 2
Recent E6 and E7 silencing studies performed for AsRNA, shRNA an
Year Silencing type Antigen silencing TargetedHPV
type
2007 AsRNA Simultaneous HPV-16 
2013 shRNA Simultaneous HPV-16 
2016 siRNA Simultaneous HPV-16
HPV-18
2017 siRNA Simultaneous HPV-16 HPV-18 
2018 shRNA Simultaneous HPV-16 
2018 AsRNA Separate HPV-16 
Abbreviations: AsRNA, antisense RNA; shRNA, short hairpin RNA; siRNA, small interfering RN
14 bicistronic nature of the transcription of which E6 and E7 mRNA
are originated from, and considering the diverse splicing variants
that can arise from such process. Moreover, as presented in Fig. 3a,
the artificial RNA-based therapies integrate different pathways
before interfering with E6 and E7 oncoprotein translation, which
can result in different mRNA degradation levels. The delivery of
these molecules, which can occur directly to the nucleus, through
the use of an expression vector (such as shRNA), or to the cyto-
plasm after chemical synthesis (like siRNA molecules), can result
in different outcomes, because it can lead to different levels of the
intended RNA molecule [82]. In addition, different RNA structures
present different stability and resistance to degradation, which
can also affect the therapeutic outcome of these molecules [83].
Still, the use of shRNA appears to be more advantageous given that
it can express, in a continuous form, silencing molecules that
naturally integrate the endogenous miRNA pathway, leading to a
stronger and more effective silencing effect than chemically
synthetized siRNA [84]. Nevertheless, many studies have been
dedicated in the past decade to the concomitant silencing of E6
and E7 oncoproteins with artificial RNA-based therapies. The most
recent studies that have been performed by using AsRNA, siRNA or
shRNA for simultaneous E6 and E7 silencing, as well as any major
findings, are represented in Table 2. However, several obstacles
have been found that can impair the implementation of these
techniques. These limitations rely on the fact that RNA molecules
are very unstable and can be rapidly degraded because of host
RNase action [83]. Also, exogenous RNA molecules can present
motifs that trigger immune responses owing to interferon stimu-
lation, which can result in the development of severe adverse
reactions [85]. To overcome this problem, many efforts have been
focused on chemically altering the RNA structure to make it more
stable and disable the stimulation of interferon [85]. Moreover,
the development of suitable delivery strategies that protect the
RNA molecule and direct it to the target tissue is crucial to increase
the bioavailability of these biopharmaceuticals, and is currently
the main goal of researchers working in this field [83,85]. Thus,


















p53 expression was significantly increased, followed by apoptosis
and senescence detection in SiHa cells
[108]
Tumor suppressor protein levels were increased in HPV-positive
cell models and treated mice demonstrated lower tumor growth
and higher survival rates than control
[109]
Growth of subcutaneously injected HPV-positive cancer cells was
suppressed in mice through systemic administration of siRNA by
actively targeted polyion complex micelles
[110]
Coupled with cisplatin or paclitaxel, tumor growth was
suppressed in mice owing to synergistic effect between siRNA
and chemotherapeutics
[111]
Almost complete eradication of tumor mass in mice without
adverse reactions
[112]





Gene editing with CRISPR/cas9 systems
More recently, CRISPR/cas9 systems have been described as the
new cutting-edge technology of gene silencing strategies. The
technology consists of a programmable RNA-guided endonuclease
system that can be used to edit defective genes [86]. This technol-
ogy, as represented in Fig. 3b, allows disruption of the DNA
sequence of a target gene with the help of an RNA-guide strand,
rendering the gene unable to be expressed.
Its application in HPV-induced cancers is more recent, Hu and
co-workers developed a study, in 2014, regarding the use of CRISPR
technology for the disruption of HPV-16 E7 gene in HPV-16-
positive human cancer cell lines [87]. Apoptosis induction and
decreased E7 oncoprotein levels were found in HPV-16-positive
cancer cell lines such as CaSki and SiHa as opposed to HPV-16-
negative cancer cell lines (C33A and HEK293). These findings
highlighted the promising future of CRISPR/cas9 in HPV-induced
cancer treatment. In a different approach, Zhen and co-workers
used this system for the disruption of the HPV-16 E6/E7 promoter
coupled with cisplastin, a chemical drug, in the HPV-16-positive
cancer cell line SiHa. In this study, it was possible to verify that cell
viability was lower in cells transfected with CRISPR/cas9 in com-
parison with cells only treated with cisplatin. However, when
combining both strategies, a synergistic effect was detected, sug-
gesting CRISPR/Cas was able to sensitize cells to cisplatin [88]. This
study showed that CRISP/cas9 could be used concomitantly with
chemotherapeutic drugs to potentiate its effect. Nevertheless,
suitable delivery systems should be considered given that chemo-
therapeutic drugs are known to affect healthy tissues. Later on,
Kennedy and co-workers also developed a CRISPR/cas9 system
targeting E6 or E7 genes that was able to decrease the content
of these oncoproteins and thus activate the p53 or pRB signaling
pathway, respectively, in HPV-16- and HPV-18-positive cancer cell
lines [89]. The CRISPR/cas9 systems used in this study were
designed specifically for each type of protein (E6 and E7) and each
type of HPV (16 and 18), resulting in four different CRISPR/cas9
systems.
More recently, Zhu et al. developed nanoparticles for the deliv-
ery of plasmid DNA encoding either CRISPR/cas9 or shRNA specific
for E7 silencing [90]. Their findings suggested that shRNA is more
effective in silencing the target protein owing to its functional
status right upon plasmid transcription, whereas CRISPR/cas9
technology requires protein translation to function. Also, consid-
ering the permanent knockout condition of CRISPR/cas9 technol-
ogy, and considering the possible off-targets that this technology
can present, the use of shRNA is considered safer [90]. Neverthe-
less, despite the overall popularity and promising features of this
technology, new findings suggest that its utilization could lead to
large rearrangements in the genome, posing a severe threat to the
regular cell function and perhaps leading to the emergence of
pathological conditions [91]. Therefore, new studies must be
performed accompanied by exhaustive genome examination, to
guarantee the safe use of CRISPR/cas9 in humans.
microRNAs: an emergent silencing alternative
Lately, the study of microRNA profiling in cancer has been very
important in detecting these molecules, because their expression
levels can be used as prognostic markers. Several studies
have revealed that, in different tissues, microRNAs can present












IEWcontribute to a phenotypic cancer state. For instance, microRNA
upregulation can contribute to the downregulation of proteins
where function is fundamental for cell growth regulation, and
vice versa [92]. Besides the fact that miRNA levels provide crucial
information regarding the cellular mechanisms that can contrib-
ute to the onset of the disease, it can also indicate useful path-
ways to explore when trying to find a cure. These small
noncoding RNAs that present 19–25 nucleotides are naturally
expressed from miRNA-encoding genomic sequences [93,94].
First, as portrayed in Fig. 3c, its expression renders a long primary
transcript (pri-miRNA), which will be cleaved by a complex
formed by Drosha and protein DiGeorge syndrome critical re-
gion gene 8 (DGCR8) [93]. The processing of pri-miRNA by this
complex results in a long hairpin molecule, the precursor of
miRNA (pre-miRNA). As presented in Fig. 3c, this whole process
occurs in the nucleus. Then, pre-miRNA is exported into the
cytoplasm so that it can be cleaved by Dicer, which is coupled
with Tar RNA-binding protein (TRBP) and kinase R-activating
protein (PACT) [93]. This process presents a double-stranded
mature miRNA. The antisense miRNA strand consists in the
guide-strand for RNA-induced silencing complex (RISC), which
will be loaded onto this complex once Dicer processing is com-
plete. Then, the complex is able to identify target mRNAs that
present some complementarity to the miRNA sequence [93].
Different outcomes can result according to the complementarity
between RNA molecules, namely: degradation, destabilization or
translation repression of target mRNA [93,95]. The main differ-
ence between siRNA and miRNA systems is the fact that miRNA
can regulate hundreds of different target molecules whereas
siRNA is only able to interfere with the expression of molecules
with 100% complementarity [93,95]. This feature might be seen
as a threat, given that miRNA interaction with off-targets can
lead to severe cell deregulation. However, considering that miR-
NAs can regulate molecules and processes within similar func-
tions and signaling pathways, the exploration of these molecules
in therapy could also pose as an advantage in comparison to
siRNA technology, because it could be used to simultaneously
regulate different oncotargets. For instance, the research work
developed by Wei and co-workers demonstrated that miR-17-5p
was able to target tumor protein p53-induced nuclear protein 1
(TP53INP1) in cervical cancer cells – a protein that is usually
upregulated in this type of tumor and is responsible for regula-
tion of p53 transcriptional activity [96]. In this study, a plasmid
expressing pri-miR-17-5p was able to inhibit the proliferation
and the viability of cervical cancer cells.
Another microRNA where the tumor-suppressive function has
been studied in cervical cancer is miR-125. In vivo studies per-
formed by Cui et al. demonstrated that overexpression of miR-
125b would decrease the ability of injected HeLa cells to form
tumors in mice [97]. Moreover, Fan and co-workers were able to
prove that miR-125a overexpression was able to suppress the
metastasis of cervical cancer cells by targeting STAT3, leading
to tumor growth inhibition and impairing metastasis formation
in mice [98]. In this study, it was also possible to verify that the
presence of HPV viral oncoproteins E6 and E7 would suppress the
p53-mediated activation of miR-125a, suggesting that the down-
regulation of this microRNA is caused by the presence of the viral
oncoproteins. Although these studies provide remarkable path-
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ways that could be used for the treatment of cervical cancer, it
still suggests that HPV infection might offer resistance to such
treatments. Nevertheless, Jung et al. were able to prove that
overexpression of miR-375 was able to directly downregulate
E6 and E7 expression in HPV-16- and HPV-18-positive cervical
cancer cell lines, rescuing p53 and pRB pathway signaling [99].
Moreover, the downregulation of E6AP, CIP2A and 14-3-3z on-
cogenic proteins was also seen in this study, contributing to a
reduction of 35% telomerase activity and ultimately leading to
cell-cycle arrest and inhibition of tumor cell proliferation [99].
The fact that this particular microRNA is able to silence E6 and E7
expression while downregulating other oncogenic proteins that
are upregulated in cervical cancer cells suggests that the role of
miR-375 in HPV-positive cervical cancer might be crucial. The
exploration of therapeutic approaches that involve the expres-
sion of microRNAs able to regulate HPV-16 and HPV-18 tran-
scripts and promote tumor suppressor protein expression, such as
miR-375, can pose as a promising option in the future search for
the ultimate HPV-induced cervical cancer treatment. Neverthe-
less, such a deed might still be remote, considering the amount of
study and research that is necessary before exploring this strategy
in humans.
Concluding remarks and future perspectives
The HPV impact in women’s health is undeniable. It is crucial to
invest in the prevention of this infection through the develop-
ment of vaccines that cover the high-risk HPV types. It is also
necessary to make sure these are affordable and can be easily
distributed in less developed countries, which are currently the
most affected by this virus. Given that vaccination has become a
Drug Discovery Today Volume 24, Number 10 October 2019 16 controversial issue recently, owing to increasing popular belief in a
link between vaccines and severe adverse reactions, one must
consider that full vaccination coverage and HPV eradication might
be difficult to achieve in the near future. Therefore, suitable
noninvasive and effective strategies should be explored to provide
a comfortable and burden-free cervical cancer treatment to
patients, as opposed to the currently available treatments. Here,
we discussed three approaches that are currently being explored by
researchers as a possible pathway that can lead to the discovery of
such treatment. Each of these technologies: DNA vaccines, gene
therapy and gene silencing, present their advantages and draw-
backs. Currently, DNA vaccines stand as the most likely strategy to
be implemented more rapidly for HPV treatment, when compar-
ing their achievements in clinical trials with the remaining
approaches. Nevertheless, the potential of gene therapy and gene
silencing is undeniable and is currently under intensive study.
Thus, the exploration and combination of these approaches poses
as a fruitful and promising strategy in the future of HPV-induced
cervical cancer treatment.
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Minicircle DNA (mcDNA) is a smalle
and safer version of non-viral DNA
vectors that results from a cutting
edge in vivo recombination proces
to excise prokaryotic sequence
from plasmid DNA (pDNA). Con
sidering the molecule’s potentia
and increasing interest as a non
viral DNA-based therapeutic, bio
manufacturing methodologies nee
to be improved, especially in down
stream processing.
mcDNA
mcDNA has attracted significant atten
tion as a gene therapy vector, DN
vaccine, or intermediate in cell-base
therapies due to its strong performanc
and safety as a non-viral DNA vector [1
especially in comparison with the popula
pDNA vector (Box 1). Although mcDN
was designed specifically to overcom
the limitations of pDNA, its origin derive
from a pDNA-like structure called
parental plasmid (PP). A PP contain
specific sequences, such as att, loxP




Box 1. mcDNA versus pDNA Biomanufacturin
pDNA is the most popular non-viral vector, having be
than most known viral strategies, pDNA contains b
therapeutic effects is often lower than that of viral ve
is widely used as a selectionmarker for pDNA produc
studies regarding pDNA production and purification.
non-viral vector that can overcome the difficulties pres
suggest that pDNA expression is often silenced by c
for mcDNA vectors (Figure I). However, upstream and
on the basis of low selectivity and yields rendered bythat allow its recombination into two
different molecules: mcDNA and mini-
plasmid (mP) (Box 2) [2]. Despite the
well-documented potential of this out-
standing biopharmaceutic, showing better
performance than pDNA in cell transfection
and gene expression in different fields,
little attention has been given to mcDNA
manufacturing restrictions and recent
progress that has been made to overcome
them. These points are crucial to under-
stand how to further improve the yield and
purity and reduce the costs of mcDNA

















While a mP inherits all the prokaryotic
sequences necessary for PP amplification
within the prokaryotic system, including
the replication origin and selection
markers, mcDNA retains the eukaryotic
sequences required for the therapeutic
effect, such as the promoter and gene of
interest [2]. PP production begins similarly
to pDNA production, and induced in vivo
recombination of the PP into mP and
mcDNA follows. Simultaneously, in some
particular systems, certain events can
occur to promote the cleavage and elimi-
nation of mP and unrecombined PP impu-
rities (Box 2). Each system can have a
different impact on its downstream pro-
cessing since variable mcDNA, PP, and
mP content can result from the recombi-
nation process, affecting not only the final

























en widely studied and characterized for delivering foreign genet
acterial sequences that may trigger immunological reactions
ctors [1,2]. These bacterial sequences can contribute to antib
tion [2]. pDNAmanufacturing is less expensive than the manufa
Thus, mcDNA, which is a smaller molecule devoid of potentially
ented by pDNA (Figure I). This innovativemolecule can enter eu
ellular mechanisms related to the presence of bacterial sequen
downstream processes can lead to mcDNA contamination wit
common pDNA purification methodologies.
T
ownstream Processing
ue to its peculiar production features,
cDNA upstream processing still requires
timization since mcDNA is often con-
minated with the PP. Moreover, the
ethods used to purify pDNA are not as
ficient for purifying mcDNA. This unfortu-
te situation is mainly due to the similar
netic composition of the mcDNA, PP,
d mP molecules. The PP and mP impu-
ies contain analogous structural and
emical properties to mcDNA, which
mpers the purification process because
e impurities interact similarly with the
romatographic matrix. These draw-
acks have prompted the use of affinityackbone Modification
ntil 2016, the methods used to purify
cDNA strongly depended on custom
ackbone modification. For instance, in
08, a strategy for mcDNA purification
as developed that involved modifying
e PP backbone to include a lactose op-
ator (LacOp) sequence in the mcDNA
mplate [3]. The sample would be loaded
to a chromatographic column modified
ith a LacOp repressor protein. Given
e specific LacOp sequence, mcDNA
ould bind to the column, while the re-
aining contaminants would be eluted.
owever, this approach requires full PP
combination since the presence of the
P would impair the purity of mcDNA
e to the shared LacOp sequence.
2015, a different approach, based on
e negative purification of mcDNA, wasic information [12]. Despite being regarded as safer
after administration, and its efficiency in eliciting
iotic resistance, given that this expression pattern
cture of viral vectors, so there have been numerous
harmful sequences, has emerged as an improved
karyotic cells more easily than pDNA. Some studies
ces whose absence renders prolonged expression
h PP, and the similarity between these molecules is
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Figure I. Biomanufacturing Comparison between Plasmid DNA (pDNA) and Minicircle DNA (mcDNA) Vectors, from Production to Purification and
Delivery. Abbreviations: gDNA, genomic DNA; GOI, gene of interest; mP, miniplasmid; ORI, origin of replication; PP, parental plasmid; Prom, promotor; recSite,
recombination site; selMark, selection marker.
Trends in Biotechnology













































Box 2. mcDNA Recombination Systems
Four major PP–mcDNA recombination systems have been explored, each presenting different outcomes in recombination efficiency and contaminant elimination.
Table I gives a comparative analysis of current mcDNA production systems [13]. Despite these interesting results, there have been several more successful strategies
for producing the rival molecular pDNA in the biopharmaceutical market. In general, mcDNA yields in published studies vary between 0.1 and 8.84 mg/l of fermentation.
Compared with pDNA yields, which can reach 2.2 g/l, mcDNA yields are very low, which constitutes a drawback for this technology. Despite the innovative character of
mcDNA technology, the yield of mcDNA is presently controlled by the yield of PP and by its recombination efficiency. The fact that full recombination might not occur
automatically hampers the mcDNA yield, which is illustrated by the yield disparity observed between these molecules under similar production conditions. Nonetheless,
with its increasing popularity, some studies have recently proposed improvements tomcDNA production by adjusting fermentation conditions, such as temperature and
induction time [14], or by genetically improving the strains for better yields [15]. These results suggest that further efforts should be focused on overcoming mcDNA
upstream processing limitations.
Table I. mcDNA Production Systems to Induce PP In Vivo Recombination







of att hybrid sites with the aid






binding to loxP sites
Serine recombinase, which
performs an irreversible and
unidirectional recombination
between two identical MRS
sites
Serine recombinase, which mediates
unidirectional recombination between
attP/attB binding sites, while I-SceI








Medium–low (60%) due to
intrinsic toxicity
Medium– MediumVery high (99.5%)low (60%) –high (75%)
Requires the expression ofLimitations
host factors FIS and IHF;
intrinsic toxicity; PP and mP
contamination must be
addressed
PP and mP contamination
must be addressed
mP contamination must be
addressed
PP degradation may reduce mcDNA




REVIEWSdeveloped by capturing the impuritie
from the sample. The PP backbone wa
modified to include a specific triplex DN
(TriD) sequence in the mP region templat
[4]. Magnetic beads were modified wit
specific oligonucleotides that would rec
ognize the TriD sequence. Upon samp
incubation, both PP and mP molecule
would bind to the magnetic beads an
be extracted from the sample, yieldin
94–95% mcDNA. However, both strate
gies raised a similar issue: prepurificatio
with a commercial anion-exchange co
umn was necessary to eliminate hos
impurities.
To address this issue, in a different ap
proach, the PP backbone was designe
to contain a recognition site for Nb.BbvC
enzyme in the PP/mP template [5,6
After bacterial lysis, the sample is digeste
with the nicking Nb.BbvCl enzyme tl
convert supercoiled (sc) mP and PP to
the respective open circular (oc) forms.
This digestion step helps to separate sc
mcDNA from mP and unrecombined PP
through hydrophobic interaction chroma-
tography (HIC). One adaptation of this
method substitutes HIC for multimodal
chromatography with Capto adhere ligand
[7]. Using increasing NaCl gradients,
this strategy allowed a near 40% mcDNA
recovery with 93.5% purity. Although
prepurification is not required in this strat-
egy, the need for PP backbone modifica-
tion and the use of enzyme digestion
render this process costly for effective
industrial scale-up.
A Universal Purification Approach
To overcome these hurdles, a method was
implemented in 2016 that used amonolithic
column coupled with diethylaminoethyl






















P, PP, and host impurities with a single
romatographic run, requiring little NaCl
adient manipulation, and representing a
eat advance towards developing a cost-
fective mcDNA purification strategy with
duced environmental impact. However,
e mcDNA elution was distributed in
o different peaks, lowering the mcDNA
covery (~50%) compared with some
her strategies.
2019, a different strategy was imple-
ented to increase mcDNA recovery
eld by exploring cadaverine as a new
romatographic ligand. After recombi-
tion, sc mcDNA was purified from all
ntaminants and host impurities by
ing a cadaverine-modified monolith
d a smooth NaCl gradient [9]. This
proach resulted in a sc mcDNA recov-
y yield of 78.6% with 98.4% purity in a
ngle peak. Nonetheless, small amounts of















































































REVIEWSpure sc mcDNA were recovered (1.97 μg
requiring this process to be repeate
many times to obtain high amounts of pur
fied sc mcDNA.
Later, size-exclusion chromatography wa
explored for sc mcDNA isolation from
clarified lysate sample [10]. In this study
sc mcDNA was isolated by a Sephacr
SF-1000 matrix with a recovery yield o
66%. Although a slightly lower yield wa
observed, higher sc mcDNA mass wa
recovered (24.02 μg) despite the lon
chromatographic runs [10]. Moreove
this strategy was implemented wit
two differently sized PP–mcDNA pairs
highlighting the universal applicability o
this approach. Overall, it has becom
clear that mcDNA isolation and purifica
tion methodologies have been evolving
Nonetheless, more effort should b
placed on developing more specific
selective, robust, and low-cost strate
gies, which can be easily implemente
for high-yield recovery of pure mcDN
from different complex samples, so tha
the full potential of mcDNA can be reache
in an affordable way.
Quantitative Analysis
Many strategies to detect host impur
ties are currently commercially available
However, methodologies to evaluat
and characterize the sc mcDNA qualit
and purity with respect to other nuclei
acids are expensive and limited. PP, mP
and mcDNA content has been evaluate
by real-time polymerase chain reactio
(qPCR) and horizontal electrophores
[8,9]. While qPCR is quantitative, accu
rate, expensive, and time consuming
electrophoretic analysis is fast an
cheap but mainly qualitative and unabl
to quantify mcDNA content. In 2020,
chromatographic methodology for s
mcDNA quantitative analysis was im
plemented for the first time, using th
previously developed cadaverine mod
fied monolith [11]. This methodolog
quantified sc mcDNA from a comple
4 Trends in Biotechnology, Month 2020, Vol. xx, No. xx24 l
lysate sample in 40 minutes and could
be easily adapted for differently sized
mcDNA–PP pairs. This hallmark in
mcDNA downstream processing was
only possible due to the recent interest
in pursuing lower costs for mcDNA
biomanufacturing.
Concluding Remarks and Future
Perspectives
mcDNA has outstanding therapeutic out-
comes that highlight the versatility of inno-
vative vector design and open the door
to a new generation of DNA vectors. The
potential utility of mcDNA will ideally
prompt further research into overcoming
some challenges associated with its man-
ufacture, especially regarding its produc-
tion yield and purification costs. Pursuing
genetic strain modifications and exploring
different culture conditions is useful to in-
crease the overall mcDNA yield in different
systems. It is important to place more
effort into studying the recombination
process in order to decrease the degree
of PP and mP contamination in the up-
stream process. This will allow investments
in simple, robust, and cost-effective purifi-
cation strategies to obtain large amounts
of pure sc mcDNA and can promote
the success of this molecule within the
pharmaceutical industry for biomedical
applications.
Scaling up currently available purification
strategies still represents an increased
cost and adds more variability for mcDNA
manufacturing due to the use of very
specific ligands, backbone modifications,
and enzyme digestion, along with time
consumption and underachieved yields.
More validation and reproducibility assays
regarding the preparation of these methods
and their use in different mcDNA samples
should be performed. This will assure the
development of suitable and robust tech-
niques that can be applied to different
types of mcDNA. Improvements to these
strategies should be coupled with the







































chniques for mcDNA quality control. It
uld be interesting to explore emerging
chniques, such as aqueous two-phase
stems or microfluidic devices, in the
traction, isolation, or even detection
mcDNA. Once mcDNA mechanisms
ve become well understood and strate-
es for manufacturing it have been widely
plemented, mcDNA can replace pDNA
the most popular non-viral DNA vectorcknowledgments
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Considering the impact of Human Papillomavirus (HPV) infection has in our society, especially 
in the development of cervical cancer, the global aim of this thesis is to explore different 
therapeutic strategies that could potentially be used on the treatment of HPV infection. Such 
aim will rely on the implementation of two different biotechnological platforms for the 
production and purification of a DNA vaccine and a silencing gene therapy. Also, the assessment 
of the therapeutic potential displayed by these systems, coupled with the optimization of the 
transfection conditions to maximize such therapeutic potential, will be performed. While the 
DNA vaccine will be based on a pDNA molecule encoding E6 and E7 antigens and delivered to 
dendritic cells into a calcium carbonate system coupled with gelatin, the silencing strategy will 
be carried out with innovative minicircle DNA non-viral vector. Considering the newfound role 
of miR-375 in silencing E6 and E7 transcripts, pri-miR-375 gene will be inserted into a mcDNA 
vector and its effect in E6 and E7 protein will be assessed. Nonetheless, suitable downstream 
strategies for mcDNA processing will be explored and assessed to guarantee the optimized 
preparation of this innovative vector. 
 
Thus, to accomplish the proposed aims, the following tasks should be carried out: 
 
1 – Analysis of the impact that vector purity might present in the therapeutic outcome of the 
DNA vector through the comparison of E6 and E7 in vitro expression displayed by the DNA 
vaccine purified by two different methodologies. 
2 – Development and characterization of suitable nanocarriers to deliver the DNA vaccine to 
cells by exploring the formulation of calcium carbonate systems coupled with gelatin and 
assessing its ability to deliver DNA vaccine to dendritic cells. 
3 – Study of different chromatographic matrices to appropriately purify mcDNA in its supercoiled 
isoform accordingly with the purity specifications imposed by regulatory agencies, resorting to 
affinity chromatography and size-exclusion chromatography.  
4 – Implementation of an analytical chromatographic method able to characterize mcDNA 
content in a complex sample, to further decrease costs associated with downstream mcDNA 
processing, by exploring cadaverine-modified monolith performance as an analytical technique. 
5 – Construction of mcDNA vector able to express miR-375 to evaluate the effect presented by 
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DNA vaccines have come to light in the last decades as an alternative method to prevent
many infectious diseases, but they can also be used for the treatment of specific diseases, such
as cervical cancer caused by Human Papillomavirus (HPV). This virus produces E6 and E7
oncoproteins, which alter the cell cycle regulation and can interfere with the DNA repairing
system. These features can ultimately lead to the progression of cervical cancer, after cell infec-
tion by HPV. Thus, the development of a DNA vaccine targeting both proteins arises as an
interesting option in the treatment of this pathology. Nonetheless, before evaluating its therapeu-
tic potential, the purity levels of a biopharmaceutical must meet the regulatory agency specifica-
tions. Previously, our research group successfully purified the supercoiled isoform of the
recombinant HPV-16 E6/E7 DNA vaccine with virtual 100% purity by affinity chromatography.
The present work was designed to evaluate the effect that pDNA sample purity levels may exert
in the expression of a target protein. Thus, in vitro studies were performed to assess the vaccine
ability to produce the target proteins and to compare the expression efficiency between the
pDNA sample obtained by affinity chromatography, which only presents the sc isoform and ful-
fils the regulatory agency recommendations, and the same DNA vaccine retrieved by a commer-
cial purification kit, which contains different pDNA isoforms. Our achievements suggest that the
E6/E7 DNA vaccine purified by affinity chromatography promotes higher E6 and E7 mRNA
and protein expression levels than the DNA vaccine purified with the commercial kit. Overall,
these results underline the importance that a purification strategy may present in the therapeutic
outcome of recombinant DNA vaccines, envisaging their further application as biopharmaceuti-
cals. VC 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:546–551, 2018
Keywords: affinity chromatography, HPV16 E6/E7 DNA vaccine, supercoiled pDNA isoform,
protein expression
Introduction
Human Papillomavirus (HPV) is a sexually transmitted
virus highly known for its tumorigenic role in cervical can-
cer development and progress. So far, over 100 subtypes
have been identified, each presenting different outcome in
infection and disease development. The different subtypes
can be classified by either low, probable high-risk and high
risk, accordingly to its ability to induce cancer.1 HPV DNA
has been found in a range of 77.2 to 100% of invasive
Correspondence concerning this article should be addressed to A. Sousa at angela@fcsaude.ubi.pt.
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cervical cancer cases worldwide, to which 70% are estimated
to be associated with high risk subtypes HPV-16 and HPV-
18.1–3 Both subtypes have been subjected to an intensive
study in the past decades with the intent of unravelling the
pathways by which infection and carcinogenesis are induced.
E6 and E7 proteins were identified as the major contributors
to the development of a cancer disease state in HPV-infected
cells, due to its inhibitory role over tumor suppressor pro-
teins p53 and pRB, respectively.4,5 These oncoproteins are
responsible for modulating keratinocyte differentiation, and
stimulating cell proliferation and survival.4 As a matter of
fact, the ability of both proteins to interfere with the cell
cycle proliferation mechanisms is correlated with the low to
high risk classification of the different existing HPV subtypes.5
DNA vaccines arise as an immunological therapeutic
approach whose popularity has increased in the past years, pre-
senting many advantages when compared to conventional vac-
cines. While conventional vaccines are only able to trigger an
immune response mediated by T helper cells, preventing the
intended infection through antibody production, DNA vaccines
can induce different immune responses, which culminate in a
preventive and therapeutic effect against the infection, once
they also stimulate CD81 T cells.6 Considering the importance
of E6 and E7 HPV oncoproteins in the induction of invasive
cervical cancer, the selection of both proteins as antigens for the
implementation of a new immunotherapy method seems the
next logical step in cervical cancer treatment.
To accomplish this, improved biotechnological processes
are required to obtain highly pure and effective DNA vac-
cines. Affinity chromatography is a purification technique
that takes advantage of different naturally occurring interac-
tions between a ligand and a target biomolecule, allowing its
isolation and purification. This procedure becomes essential
in the development of new biopharmaceuticals, as its produc-
tion must comply with several specifications, to be safely
considered for therapeutic administration. Regarding plasmid
DNA (pDNA), the supercoiled (sc) conformation is not only
the most produced isoform by Escherichia coli (E.coli), as it
is also responsible for a more pronounced and desired bio-
logical function, providing greater transfection and gene
expression rates than other isoforms.7 Thereby, the isolation
of sc isoform from other less-effective pDNA topologies, such
as open circular (oc), and from bacterial components is
extremely important to enhance the transfection rate as well as
the effectiveness and biosafety for therapeutic administration.
In the past few years, our research group has been focused
on the production and purification of the recombinant pDNA
vaccine encoding E6 and E7 HPV16 oncoproteins.8–10
Thereby, the main purpose of this work was to conduct a
differential in vitro comparison study to assess the expres-
sion of E6 and E7 proteins, resorting to the transfection of
mammalian cells with pDNA samples obtained by different
methods. For this, it was our interest to compare a pDNA
with 100% sc isoform homogeneity obtained with arginine
monolith with a native pDNA sample, containing oc and sc
isoform, retrieved by a commercial anion-exchange purifica-
tion kit. First, cell live imaging was performed to follow the
pDNA entry into the cell and nucleus. Subsequently, to fur-
ther comprehend the ability of these different pDNA samples
to correctly express the intended oncoproteins, real-time
quantitative polymerase chain reaction (RT-qPCR) and
immunocytochemistry techniques were performed for the
detection of E6 and E7 transcripts and proteins, respectively.
Materials and Methods
Bacterial growth and pDNA isolation
HPV-16 E6/E7 pDNA (plasmid 8641 from Addgene,
Cambridge, MA)11 was amplified through E. coli DH5a
culture, as previously described.10 To obtain the native
pDNA sample (containing oc and sc isoform), NZYMaxi-
prep commercial kit (NZYTech, Lisbon, Portugal) was
used accordingly to the manufacturer’s instructions. Sev-
eral extractions were performed and homogenized before
transfections for more reliable results. For affinity chro-
matographic experiments, a complex pDNA sample was
isolated by resorting to the modified alkaline lysis
method.12 Then, concentration and clarification of the
resulting sample was carried out as described by Diogo
et al.13 Finally, ammonium sulfate present in the superna-
tant was removed from the sample using PD-10 desalting
columns (GE Healthcare, Buckinghamshire, UK) according
to manufacturer’s instructions.
Affinity chromatography and purity assessment
All chromatographic experiments were carried out using
an AKTA P€ure system (GE Healthcare, Buckinghamshire,
UK), a compact separation unit and a personal computer
with UNICORNTM 6.3 software. The arginine monolith
used for pDNA separation was prepared and kindly pro-
vided by BIA Separations (Ajdovsčina, Slovenia). The
purification strategy was previously developed and opti-
mized by our research group.8,10 All chromatographic peak
fractions were collected, concentrated, and desalted by
Vivaspin
VR
6 Centrifugal Concentrator (Vivaproducts, Lit-
tleton, MA), at 800 g for further analysis and experiments.
The evaluation of purity and recovery was carried out
resorting to CIMacTM analytical column, as described by
Sousa et al.14 In similarity to native pDNA preparation,
several purified sc pDNA samples were homogenized
before transfection.
Cell culture and transfection
Mouse Fibroblasts and Chinese hamster ovary (CHO) cells
were cultured in Dulbecco’s Modified Eagle Medium-F12
High Glucose supplemented with 10% (v:v) of fetal bovine
serum (FBS) and a mixture of penicillin (100 lg/mL) and
streptomycin (100 lg/mL). Cells were seeded at 2 3 105
cellscper well and grown at 378C in a humidified atmosphere
with 5% of CO2 in 12-well plates for equal time in each
experiment, until reaching an 80–90% confluence. Then,
cells were incubated with medium without antibiotic and
FBS for 24 h. Cells transfection with native and sc pDNA
samples was performed with Lipofectamine 2000 (Invitro-
gen, Life Technology) transfection reagent, accordingly to
the manufacturer’s protocol. On transfection, cells were cul-
tured for 24, 48, and 72 h to perform RNA extraction and
analysis or immunocytochemistry. For each technique, three
independent transfections were performed (N 5 3).
Live cell imaging
Fibroblasts cells were grown in m-slide 8 well (Ibidi, Mar-
tinsried, Germany) until 80–90% confluence was reached.
Before transfection, the purified sc pDNA sample was
labeled with fluorescein isothiocyanate isomer I (FITC, Invi-
trogen, Life Technology). Briefly, FITC was prepared with
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sterile anhydrous dimethyl sulfoxide (500 mg/mL) and
added to a reaction mixture containing labeling buffer
(0.1 M Sodium Tetraborate, pH 5 8.5), deionized water
and sc pDNA, followed by 4 h incubation at room temper-
ature in a shaker oscillating at low speed. The resulting
FITC-labeled pDNA was encapsulated with Lipofectamine
2000 and real live transfection was visualized using a
LSM710 confocal laser scanning microscope (Carl Zeiss,
Germany) under a 633 magnification and analyzed with
the Zeiss LSM 710 laser scanning confocal microscope
(Carl Zeiss SMT, Inc., Oberkochen, Germany) Throughout
this experiment, cells were maintained at 378C with 5% of
CO2.
E6 and E7 mRNA expression detection by RT-qPCR
Total RNA extraction was performed with TripleXtractor
reagent (Grisp Research Solutions, Porto, Portugal), follow-
ing the manufacturer’s instructions. RNA quantification was
performed by spectrophotometry at 260 nm and its integrity
assessed by agarose gel electrophoresis (data not shown).
1mg of total RNA was reversed transcribed into cDNA with
the RevertAid First Strand cDNA Synthesis Kit (Thermo
Scientific, Molecular Biology), according to the manufac-
turer’s instructions. RT-qPCR reactions were performed with
1 mL cDNA in a final volume of 20 lL with the Maxima
SYBR Green/Fluorescein qPCR Master Mix (23) (Thermo
Scientific, Molecular Biology) and 0.3 lM of each primer
in a CFX Connect Real-time System (Bio-Rad Laborato-
ries, Hercules, CA). Primers were designed specifically
for E6 (Fw: 50-CAGGAGCGAAGAAAGCCCTT-30, Rv:
5-ATAGTCTACCAGCTCACGTCGT-3) and E7 (Fw: 50-
TCCACAAGCAGCTGGACCGGA-30, Rv: 50-GCACACA-
ATTCCTGTTAGGCCCAT-30). GADPH (Fw: 50-
TGACGTGCCGCCTGGAGAAA-30, Rv: 50-AGTGTAGC-
CGCCCAAGATCAGCTT-30) was used as the housekeeping
gene. Cycling parameters were: denaturation at 958C for 3
min; 35 cycles of denaturation at 958C for 30 s, annealing at
608C for 30 s and extension at 728C for 30 s. Relative quanti-
fication was performed based on the comparative threshold
cycle (CT) method, in which the amount of the target was
determined to be 22(DCT target2DCT calibrator) normalized to
levels of GADPH and relative to the native pDNA transfected
cells.
Immunocytochemistry
CHO cells were cultured in 12-well plates with glass cov-
erslips. Transfection protocol was performed, as previously
described, with sc and native pDNA. Immunocytochemistry
protocol was performed 72 h after transfection.15 Mouse
anti-E6 IgG monoclonal antibody sc-460 or mouse anti-E7
IgG monoclonal antibody sc-6981 (Santa Cruz Biotechonol-
ogy, Heidelberg, Germany) were used (1:50). Alexa 488
goat anti-mouse and Alexa goat anti-mouse 546 (Life Tech-
nologies, CA, United States of America) were applied for E6
or E7 primary antibody stained cells, respectively. Coverslips
were placed on glass slides and analyzed using a Zeiss LSM
710 laser scanning confocal microscope (Carl Zeiss SMT,
Inc., Oberkochen, Germany) under a 633 amplification with
the Zeiss Zen software (2010). Immunofluorescence analysis
was performed with ImageJ 1.48u software. Statistical analy-
sis was performed with GraphPad Prism version 6.04 trial
software.
Results and Discussion
Non-viral DNA vectors have been studied for safe and
alternative treatments of several diseases. However, soon it
was perceived that many factors could interfere with the
expression of the target molecule, leading to a decay of its
therapeutic effect.16 The elimination of impurities resultant
from the production of these biopharmaceuticals in the
recombinant host, such as gDNA, endotoxins, and other bio-
molecules is mandatory, because these impurities may
restrict the transfection efficiency by inducing toxicity and
secondary effects such as inflammation, septic shock and
organ failure.17–20 Conversely, sc pDNA is more compact
than other pDNA isoforms, resulting in higher ability to pen-
etrate the eukaryotic cell membrane, and does not present
any structural damage that might impair the expression cas-
sette functioning. Thereby, the sc molecule is considered
more biologically active than other isoforms, such as oc or
linear,7 and regulatory agencies have established that recom-
binant DNA used for therapy should present at least 97% of
sc pDNA content. Thus, the lack of impurities coupled with
the increased sc homogeneity can contribute to higher
expression efficiency.
To answer this challenge, our research group has spent the
past years studying and developing purification strategies to
isolate the sc pDNA, by exploiting its specific interaction
with several amino acids, used as affinity ligands.21 As a
matter of fact, we were previously able to purify the sc iso-
form of the recombinant HPV-16 E6/E7 pDNA vaccine
using an arginine monolith, based on a biorecognition mech-
anism toward sc pDNA.8,10 In Figure 1A, it is presented the
chromatogram of this approach and in the Figure 1B1 is the
corresponding electrophoresis of the peak of interest, show-
ing the sc pDNA isolated from other impurities, which were
eliminated in the binding and washing steps. The use of argi-
nine monolith allowed to develop a suitable purification
strategy, by applying a smooth salt increasing step gradient
for sc pDNA elution. With this strategy, 83% of sc pDNA
was recovered with 100% virtual purity.8 For comparison, in
Figure 1B2 is depicted an electrophoresis of a pDNA sample
retrieved by a commercial purification kit, presenting both sc
and oc pDNA isoforms. Usually, the purification strategies
available on the market are based on the use of anion-
exchange chromatography. This approach relies on binding
the target molecule to a ligand with opposite charge, allow-
ing the fractionation of several molecules present in the sam-
ple by charge differences.22 However, with this technique it
is more difficult to separate molecules that present similar
chemical and physical properties, for example the sc and oc
pDNA isoforms.21 Also, such commercial strategies make
use of RNase enzyme for easier RNA elimination.23 This
impairs the use of such samples for therapeutic studies, as
regulatory agencies do not allow the use of animal originated
enzymes, to prevent harmful effects.24
Hence, in vitro comparative transfection studies were
designed to assess the effect that overall pDNA purity can
display in the expression of E6 and E7 proteins, and to prove
the added value of this purification strategy in comparison to
commercially available pDNA purification kits. Initially, and
considering that the target DNA vaccine presents a signifi-
cant size (7.9 kb) because it encodes two proteins, it was
important to assess if the pDNA molecule can reach the cell
nucleus. This study was accomplished using live cell imag-
ing to follow the pDNA passage through the cell membrane
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and the access to nucleus. Figure 2 presents an orthogonal
view of cells 1 h after addition of the DNA-stained com-
plexes. In this image, it is possible to identify FITC-labeled
pDNA in the nucleus of fibroblasts suggesting that fibro-
blasts are transfected with the target sc pDNA vaccine, and
that it enters the nucleus regardless of its larger size.
Purification of HPV 16 E6/E7 DNA vaccine by arginine monolith.Figure 1.
(A) Arginine monolith chromatogram performed with 501 mM NaCl in 10 mM Tris-EDTA (pH 5 7.9) for binding step, 650 mM NaCl in 10 mM
Tris-EDTA (pH 5 7.9) for washing step and 1 M NaCl in 10 mM Tris-EDTA (pH 5 7.9) for elution step. (B) Electrophoresis of different pDNA
samples. 1 – sc pDNA sample purified by arginine monolith; 2 - pDNA sample purified by the commercial kit, presenting oc and sc isoforms.
Orthogonal view of live cell imaging 1 h after pDNA complexes addition to fibroblasts cells.Figure 2.
The blue staining represents the cell’s nucleus and the green staining represents FITC-labeled pDNA.
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Therefore, it was also inferred that these transfection condi-
tions are suitable for further experiments.
E6 and E7 gene expression was evaluated, after cell trans-
fection, to compare pDNA samples obtained with the two
purification strategies: commercial kit and arginine monolith.
As depicted in Figure 3A,B, RT-qPCR results revealed a sig-
nificant difference in E6 and E7 expression in cells trans-
fected with native pDNA (obtained with the commercial kit)
and sc pDNA (obtained with Arg-monolith), both at 24 and
48 h. At these time points, sc pDNA transfected cells pre-
sented higher levels of E6 and E7 transcripts than native
pDNA transfected cells, highlighting the importance of
delivering highly pure sc pDNA. Such differences may be
explained by the fact that oc isoform is damaged in compari-
son to sc isoform, presenting nicks in its structure that can
interfere with important gene location, such as eukaryotic
expression cassette genes.25 Concomitantly, the damaging of
this molecule leads to a more relaxed form, contributing to
an increased size of the nanocarrier.26 In addition, these
results suggest that 24 h after transfection, the expression of
both mRNA transcripts is higher than after 48 h, a pattern
that it is usually associated with transient transfection, as the
effect brought by transfected cells begins to dilute between
cells newly originated by mitosis.27
Although these results strongly indicate that protein
expression is higher in cells transfected with sc pDNA than
cells transfected with native pDNA, mRNA translation into
protein sometimes can be impaired by different mechanisms.28
Therefore, to evaluate if the E6 and E7 protein levels follow
the same tendency previously observed for mRNA, their
quantification was performed using immunocytochemistry. In
Figure 4A, it is portrayed the E6 fluorescent staining of non-
transfected cells (control cells), and cells transfected with
native and sc pDNA. According to these results, it can be
perceived that cells transfected with sc pDNA present higher
immunofluorescence (green staining) than the remaining
samples. In Figure 4B, it is represented the total immuno-
fluorescence quantification for E6 fluorescent staining of
images taken from the different assays (N 5 3, for each N
were taken 5 images). As it can be observed, cells trans-
fected with sc pDNA present immunofluorescence signifi-
cantly higher than control cells and cells transfected with
native pDNA for E6 protein staining, suggesting higher pro-
tein production levels and thus corroborating the results pre-
viously obtained for mRNA quantification. After confirming
the sc pDNA ability to express higher levels of E6 protein
than native pDNA, and given that this pDNA vector is
expected to express both E6 and E7 proteins, immunocyto-
chemistry was also performed, only for control and sc
pDNA transfected cells, to verify E7 concomitant expression.
As predicted, on quantification of total immunofluorescence
it was verified that cells transfected with sc pDNA presented
significantly higher immunofluorescence for E7 protein stain-
ing than control cells (data not shown). Overall, these results
suggest that E6 and E7 mRNAs are being correctly trans-
lated into E6 and E7 proteins.
E6 (A) and E7 (B) mRNA relative expression between native and sc pDNA transfected cells, 24 and 48 h after transfectionFigure 3.
(N 5 3, Unpaired t-test * P< 0.05; *** P< 0.001).
E6 protein levels analysis by immunofluorescence.Figure 4.
(A) CHO-1 cells immunocytochemistry images for E6 staining. 1: Control group; 2: native pDNA transfected cells; 3: sc pDNA transfected cells.
(B) E6 protein immunofluorescence comparison between the different groups by one-way ANOVA test (N 5 3, ** P< 0.01, *** P< 0.001).
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Altogether, HPV-16 E6/E7 pDNA vaccine provided the
correct E6 and E7 protein expression. Also, a difference was
observed regarding their expression levels when studying
differently obtained pDNA samples. Actually, it was possible
to verify that the pDNA biopharmaceutical purity is
extremely important, affecting mRNA and protein expression
levels. Confirmed the efficiency of the DNA vaccine at
inducing E6 and E7 expression, in the future, in vitro and
in vivo studies should be carried out to assess its ability to
induce an immune response against the target proteins.
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A B S T R A C T
New biotechnological strategies are being explored, aimed at rapid and economic manufacture of large quan-
tities of DNA vaccines with the required purity for therapeutic applications, as well as their correct delivery as
biopharmaceuticals to target cells. This report describes the purification of supercoiled (sc) HPV-16 E6/E7
plasmid DNA (pDNA) vaccine from a bacterial lysate, using an arginine-based monolith, presenting a spacer arm
in its configuration. To enhance the performance of the purification process, monolith modification with the
spacer arm can improve accessibility of the arginine ligand. By using a low NaCl concentration at pH 7.0, a
condition to eliminate the RNA impurity directly in the flow through was established. The pH increase to 7.5
allowed the elimination of non-functional pDNA isoforms, the sc pDNA being recovered by increasing the ionic
strength. As well as a binding capacity of 2.53mg/mL obtained with a pre-purified sc pDNA sample, the column
also purified sc pDNA from high lysate loading, with capacities above 1mg/mL. Due to the sample displacement
phenomena, non-functional pDNA isoforms were eliminated throughout column loading, favoring the degree of
purity of final sc pDNA of 93.3%–98.5%. Thereafter, purified sc pDNA was successfully encapsulated into
CaCO3-gelatin nano-complexes. Delivery of the pDNA-carriers to THP-1 cells was assessed through pDNA cel-
lular uptake evaluation and correct E6 expression was verified by mRNA and protein detection. A biotechno-
logical platform was established for sc pDNA purification and delivery to dendritic cells, stimulating further in
vivo studies.
Introduction
Human papillomavirus (HPV) infection is a widespread sexually
transmitted disease, that can ultimately lead to different cancer types
[1,2]. Cancer progression is caused by expression of the E6 and E7
oncoproteins, which are responsible for viral replication and host cell
transformation and immortalization [3]. Popularity of plasmid DNA
(pDNA) vaccines for treatment of HPV infection has increased ex-
ponentially, due to their dual role as a preventive and therapeutic ap-
proach for cancer treatment, as well their safety, lack of toxicity, simple
manufacture and application of this biomolecule compared to conven-
tional prophylactic vaccines [4–6]. Nevertheless, some of the currently
employed plasmid purification techniques involve multiple chromato-
graphic steps, leading to low recoveries and high operating costs. For
instance, three chromatographic procedures (ion exchange
chromatography, hydrophobic interaction chromatography and size
exclusion chromatography) were employed sequentially for the pur-
ification of large amounts of a pharmaceutical-grade pDNA with a
global recovery yield of 48 % [7]. Hence, efficient purification strate-
gies are essential to maximize the purity and recovery of pDNA vaccines
and minimize manufacturing costs.
Convective interaction media (CIM®) monoliths are innovative
chromatographic supports, suited to fast purification of large biomo-
lecules due to continuous and highly porous beds with interconnected
network channels, which confer high dynamic binding capacity (DBC)
and good mass transfer properties to the support [8]. However, the
success of pDNA purification mostly depends on selectivity towards the
target biomolecule and the interactions promoted by the ligands im-
mobilized on the chromatographic supports. Affinity chromatography
exploits the selective biorecognition of target biomolecules by specific
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ligands based on their biological function or chemical structure [8,9].
Amino acids have been often used as ligands, since they are natural and
safe compounds that promote specific interactions with nucleic acids
[9]. The immobilization of these ligands or derivatives in monolithic
supports has been demonstrated to be a successful combination for
pDNA purification [8,10,11]. The performance of histidine-, histamine-
and agmatine-based monoliths was dependent on the use of harsh
binding and elution conditions, such as acid pH and high ammonium
sulphate concentrations, which can represent an economic and en-
vironmental impact when applied industrially. Arginine monolith have
allowed the isolation of supercoiled (sc) pDNA under mild ionic con-
ditions, with recovery improved from 39 % to 83.5 % by using an ex-
perimental design tool [12]. The present work takes advantage of the
versatility of the monolithic support and selectivity and specificity of
the arginine ligand, to evaluate the impact of ligand accessibility, due to
the presence of a spacer arm, on establishing additional interactions.
The influence of spacer arm in the arginine modified monolith was
explored in sc HPV-16 E6/E7 pDNA vaccine purification from 200 μL of
Escherichia coli lysate, by manipulating the salt concentration and pH of
the elution buffer. Column performance in sc pDNA purification from a
loading of 68mL of lysate was also tested. Purity and recovery of sc
pDNA obtained by different loading approaches were evaluated. The
dynamic binding capacity (DBC) of the arginine monolith with a spacer
arm (arg-spacer monolith) was determined by using a pre-purified sc
pDNA sample.
Although sc pDNA content has been shown to influence target gene
expression highly [13], the formulation of pDNA in specific delivery
systems can also affect its therapeutic outcome [14]. After successful sc
pDNA purification, pDNA-CaCO3-gelatin formulations were prepared to
deliver the DNA vaccine to dendritic cells. CaCO3-gelatin nanoplexes
were characterized by scanning electron microscopy (SEM) and trans-
mission electron microscopy (TEM). The size and zeta-potential of the
nanoplexes were also evaluated, alongside the pDNA encapsulation
efficiency (EE). To determine the CaCO3-gelatin carrier ability to
transfect cells and direct the pDNA to the nucleus, THP-1 cells were




The HPV-16 E6/E7 plasmid (plasmid 8641) was purchased from
Addgene (Cambridge, USA) [15] and amplified through E. coli DH5α
fermentation, as described elsewhere [12].
Sample preparation
The lysate sample was obtained using the modified alkaline lysis
method [16] and the supernatant was prepared as previously described
[17]. The final sample was desalted by passing through PD-10 desalting
columns (GE Healthcare, Uppsala, Sweden), following the manu-
facturer’s instructions and applying 10mM Tris-HCl and 10mM EDTA
buffer (Tris-EDTA buffer), pH 8.0. The pre-purified pDNA sample was
prepared with the NZYMaxiprep commercial kit from NZYTech (Lisbon,
Portugal), according to manufacturer’s instructions.
Affinity chromatography
All chromatographic experiments were performed on an AKTA Pure
system (GE Healthcare Biosciences Uppsala, Sweden) and Unicorn 6.3
software. Four epoxy monoliths, (i) non-modified, (ii) modified with 2-
allyloxyethanol spacer arm, (iii) modified with arginine and (iv) mod-
ified with 2-allyloxyethanol spacer arm and arginine, 0.34mL column
bed volume, were kindly prepared and provided by BIA Separations
(Ajdovščina, Slovenia). Spacer arm immobilization was performed by
washing two epoxy monoliths with 3mL of 1,4-dioxane reagent using a
syringe and further incubating with the same reagent for 2 h at room
temperature. Each monolith was inserted into a housing and rinsed
with 3mL of 2-allyloxyethanol solution (4mL 2-allyloxyethanol
+0.2mL BF3xEt2O dissolved in 10mL 1,4-dioxane), with subsequent
incubation in the same solution for 2 h at 30 °C. Each disk was then
rinsed with 2-chlorometaperoxybenzoic acid (MCPBA) solution
(5.151 g MCPBA in 15mL of 1,4-dioxane) and incubated in the same
solution for 24 h at 60 °C. Finally, the disks modified with the 2-ally-
loxyethanol spacer arm were washed with 1,4-dioxane. One of the
monoliths was used for arginine immobilization by pumping an argi-
nine solution (4 g arginine, 16mL H2O, 0.64mL HCl) and subsequent
incubation for 48 h at 60 °C. Both monoliths were washed with water
and 0.5M H2SO4 to deactivate the remaining epoxy groups. To assess
ionic density of arg-spacer and arginine modified monoliths, the pro-
tocol implemented in [18] was used. To characterize the chromato-
graphic behavior of each monolith with a pre-purified pDNA sample,
linear gradients were performed with decreasing (NH4)2SO4 con-
centration from 3M to 0M (hydrophobic elution conditions) or in-
creasing the NaCl concentration from 0 to 3M (ionic elution conditions)
in Tris-EDTA, pH 8.0, during 15min.
Several elution strategies were explored with the arg-spacer
monolith, by increasing the NaCl concentration and pH manipulation
from 7 to 9, to determine the optimal conditions for sc pDNA isolation.
Thus, sc pDNA purification was achieved after equilibrating the arg-
spacer monolith at 680mM NaCl in Tris-EDTA, pH 7.0, injection of
200 μL (7.2 μg of pDNA/mL) of lysate sample and two elution steps by
increasing pH to 7.5, maintaining the NaCl concentration (680mM
NaCl in Tris-EDTA buffer, pH 7.5) and then increasing the NaCl con-
centration to 1M maintaining the pH (1M NaCl in Tris-EDTA, pH 7.5),
at 1 mL/min.
Purification of sc pDNA was also conducted with the arg-spacer
monolith with larger volumes of lysate sample.The column was equi-
librated as previously described and overloaded with 68mL of lysate
sample (5 μg of pDNA/mL), prepared in the same buffer. All experi-
ments were carried out at room temperature and absorbance was
constantly monitored at 260 nm. Fractions were concentrated and de-
salted with 3mL Tris-EDTA in Vivaspin® 6 Centrifugal Concentrator
(Vivaproducts, Littleton, MA, USA) cut-off 10,000MW, at 1000 g.
Agarose gel electrophoresis
Samples were analyzed by horizontal electrophoresis in a 15 cm
long 0.8 % agarose gel (Hoefer, Holliston, MA, USA) and stained with
0.012 μL/mL greensafe (NZYTech, Lisbon, Portugal) as previously de-
scribed [12].
Plasmid DNA quantification
The sc pDNA purity and recovery evaluation was carried out with
CIMac™ pDNA analytical column, by applying a modified analytical
method [18].
Dynamic binding capacity
Capacity experiments were carried out at 1mL/min and a pDNA
concentration of 0.05mg/mL. The arg-spacer column was equilibrated
with Tris-EDTA, pH 8.0 and overloaded with the plasmid sample in the
same buffer. DBC was determined by the amount of bound pDNA/mL of
support at 10 % breakthrough curve, discounting the void volume.
Finally, to elute the bound plasmid, ionic strength was increased to 1M
NaCl.
Plasmid DNA quality assessment
Protein and endotoxin concentrations were measured by the micro-
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bicinchoninic acid (BCA) protein assay kit from Pierce (Rockford, USA)
and ToxinSensor™ Chromogenic Limulus Amoebocyte Lysate (LAL)
Endotoxin Assay Kit from GenScript (Piscataway, USA, Inc.), respec-
tively, following the manufacturer’s instructions. Genomic DNA quan-
tification was measured by real-time PCR in an iQ5Multicolor Real-
Time PCR Detection System (Bio-Rad, Hemel Hempstead, UK), as pre-
viously described [19].
pDNA-CaCO3 formulation and characterization
For nanoplex formulation, an optimization of the methodology
previously established [20] was performed through modification of the
co-precipitation method previously described [21]. 5 μL (5 μg) of pur-
ified pDNA was added to 245 μL of 0.5 M CaCl2 as solution A. For so-
lution B, 187.5 μL of 0.005M Na2CO3 were mixed with 62.5 μL of ge-
latin (gel strength 160, Fluka/ Sigma-Aldrich, Steinheim, Germany)
(5 mg/mL). Solution A was added dropwise to solution B, while the
latter was placed in a vortex. The pDNA/CaCO3 complexes were re-
covered by centrifugation throughout 30min. at 20,000 × g. The re-
sulting supernatant was used to calculate the encapsulation efficiency:
EE (%) = [(Total pDNA amount-pDNA supernatant amount)/Total
pDNA amount] ∗ 100
The pellet of nanoplexes was resuspended in water. Size and surface
charge (zeta potential) were measured by Dynamic Light Scattering
(DLS), with a Zetasizer NanoZS particle analyzer (Malvern Instruments,
Worcestershire, UK), equipped with a He-Ne laser, as described by
others [22]. Freshly prepared samples were used to measure particle
diameters at 25 °C, with 173° scattering angle in fully automatic mode.
Moreover, the surface charges (zeta potential) of the nanoparticles were
determined in disposable capillary cells and computed by using Henry’s
[F(Ka)1.5], and Smoluchowsky models, at 25 °C [23–26]. In both cases,
the average values of size and zeta potential measurements were cal-
culated with the data obtained from three samples ± SD. For the na-
noparticle morphology assessment, (SEM) (Hitachi S-2700, Tokyo,
Japan) was used (20 kV) after treating the nanoplexes with tungsten (1
%) and drying overnight. TEM (Hitachi, Japan) was also performed
after resuspension of nanoplexes in deionized water and sonication.
Cell culture
THP-1 dendritic cells, kindly provided by Professor Maria Rosete,
Center for Neurosciences and Cell Biology, University of Coimbra,
Portugal, were grown in suspension with RPMI medium supplemented
with 10 % fetal bovine serum and 1 % streptomycin/penicillin (SP)
solution. For transfection purposes, cells were previously differentiated
with 10 ng/mL phorbol 12-myristate 13-acetate and SP was withdrawn
the day before transfection.
pDNA cellular uptake
To follow the entry of pDNA/CaCO3 complexes into THP-1 cells,
pDNA was stained with fluorescein isothiocyanate isomer I (FITC) be-
fore transfection, as described [13]. Prior to transfection, cells were
seeded in 12-well plates with glass coverslips. Cells were transfected
with the labeled FITC pDNA-CaCO3-gelatin complexes for 8, 16 and
24 h. Coverslips were placed on glass slides and visualized using a Zeiss
LSM710 laser scanning confocal microscope (Carl Zeiss SMT, Inc.,
Oberkochen, Germany) under 63 × amplification with the Zeiss Zen
software (2010).
PCR and RT-PCR
To confirm pDNA nuclear delivery by nanoplexes, cells were re-
covered 24 h after transfection as described in [27], followed by PCR
for E6 gene detection of transfected cells. To detect E6 mRNA expres-
sion, total RNA extraction was performed 24 h after transfection
followed by cDNA synthesis. PCR detection of E6 mRNA was carried out
according to conditions previously described [13].
Western blot
To detect E6 protein expression, western blotting was used. Briefly,
12.5 % polyacrylamide gel electrophoresis was performed with pooled
fractions of total protein extracted from transfected and control cells.
Samples were prepared with 30 μg of each protein sample, the volume
of which was calculated from the calibration curve constructed by
protein quantification. Electroblotting was carried out for 10min in the
standard protocol of the TransBlot Turbo system (Bio-Rad, Hemel
Hempstead, UK). Mouse anti-E6 IgG monoclonal antibody (Santa Cruz
Biotechonology, Heidelberg, Germany) was incubated overnight (1:200
dilution) at 4 °C, followed by washing and incubation with mouse anti-
β-actin monoclonal antibody (Sigma-Aldrich, MO, United States of
America) (1:20000) for 8 h at 4 °C. After, membrane was washed and
incubated with goat anti-mouse IgG polyclonal antibody (Santa Cruz
Biotechnology) for 1 h at room temperature. Membrane was finally
incubated for 5min with enhanced chemifluorescence (ECF) (GE
Healthcare, Buckinghamshire, United Kingdom) and visualized in a
BioRad FX-Pro-plus (Bio-Rad, Hemel Hempstead, UK).
Results and discussion
Plasmid DNA purification
For the pharmaceutical application of sc isoform HPV-16 E6/E7
pDNA vaccine, elimination of impurities must be assured according to
regulatory agency criteria: sample homogeneity> 97 % of supercoiled
pDNA, proteins and RNA undetectable by the micro-bicinchoninic acid
(BCA) method and 0.8 % agarose gel electrophoresis, respectively,
genomic (g) DNA under 2 ng/μg plasmid by real-time PCR and en-
dotoxins under 0.1 EU/μg plasmid by limulus amebocyte lysate (LAL)
assay [28]. To purify sc pDNA isoform from a complex E. coli lysate
sample, different strategies can be explored, such as the use of a com-
petitive ligand or the manipulation of pH, ionic strength or polarity,
depending on the ligand and target biomolecule characteristics [5].
Epoxy monolith modifications
The chromatographic behavior of pDNA was evaluated on different
monoliths to further understand the influence of each ligand config-
uration. Thus, decreasing linear gradients from 3.0 to 0M (NH4)2SO4
(hydrophobic elution conditions) and increasing linear gradients from 0
to 3.0 M NaCl (ionic elution conditions) in Tris-EDTA, pH 8.0, were
performed for 15min. Through retention time (RT) analysis summar-
ized in Table 1, the non-modified epoxy monolith retained pDNA only
under hydrophobic binding and elution conditions, eluting at around
11min. This chromatographic behavior was expected, resulting from
the presence of hydrophobic epoxy groups that retain nucleic acids in
the presence of (NH4)2SO4 [29]. The addition of a 2-allyloxyethanol
Table 1
Evaluation of the retention time (min) of four epoxy monoliths (non-modified,
modified with 2-allyloxyethanol spacer arm, modified with arginine amino acid
and modified with 2-allyloxyethanol spacer arm and arginine), under hydro-
phobic (decreasing linear gradient from 3 to 0M of (NH4)2SO4) and ionic (in-
creasing linear gradient from 0 to 3M of NaCl) elution conditions in Tris-EDTA
buffer, pH 8.0, during 15min (mean ± SD, n= 3).
Monoliths Ionic conditionsHydrophobic conditions
Epoxy 10.7 ± 0.2 0
Epoxy with spacer arm 12.0 ± 0.3 0
Epoxy with arginine 0 10.0 ± 0.1
0Epoxy with spacer arm and arginine 8.6 ± 0.2
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spacer arm resulted in a pDNA RT of 12min solely under hydrophobic
elution conditions, suggesting a slight increase in the ligand hydro-
phobicity and additional hydrogen bonds. The epoxy monolith mod-
ification with arginine resulted in an altered chromatographic behavior,
retaining pDNA only under ionic conditions, which eluted after 10min.
Finally, the epoxy monolith modified with 2-allyloxyethanol spacer and
arginine showed a lower RT (8.6 min) than arginine monolith, also only
under ionic elution conditions, suggesting a mild influence on the pDNA
interaction by the spacer arm. The electronegative character of the 2-
allyloxyethanol group may repel pDNA phosphate groups, decreasing
the interaction strength with the arginine ligand. A similar behavior
was observed in previous studies with arginine and agmatine monoliths
[8,11]. The agmatine ligand derives from arginine decarboxylation. The
absence of the electronegative carboxyl group favored multiple non-
covalent interactions, leading to higher pDNA retention and requiring a
higher NaCl concentration (> 1.8M) for pDNA elution [11], compared
to the arginine ligand (795mM NaCl) [8]. The arg-spacer monolith was
explored further for sc pDNA purification.
pDNA vaccine purification
pH manipulation can improve arginine ligand selectivity and in-
crease sc pDNA recovery yield [12]. Thus, a strategy to purify sc pDNA
was explored with different pH values (9, 8, 7.5 and 7), since previous
studies have indicated that a pH increase can reduce pDNA retention
[12]. Hence the arg-spacer monolith was equilibrated with 680mM
NaCl in Tris-EDTA, pH 7.0, at 1mL/min, and after injection of 200 μL
lysate sample (7.2 μg of pDNA/mL), the unbound species were eluted in
the flowthrough. However, non-functional pDNA isoforms remained
bound to the matrix. Thereafter, two steps were performed, either by
increasing NaCl concentration or using different pH buffers, to study
the elution profile of the retained biomolecules. Although pH 7.0 was
essential to eliminate RNA and simultaneously bind pDNA, this strategy
was found to lack enough selectivity for sc pDNA isolation. The best
outcome for sc pDNA purification was at pH 7.5, which allowed elim-
ination of non-functional pDNA isoforms. Thus, a chromatographic
method was established comprising a binding step at 680mM NaCl in
Tris-EDTA buffer, pH 7.0, and after the elimination of RNA in the
flowthrough, two elution steps were applied at 680mM and 1M NaCl in
Tris-EDTA, pH 7.5 (Figure 1A). Agarose gel electrophoresis shows se-
lective elution of non-functional pDNA isoforms in the second peak,
with increased pH in the elution buffer, and the sc pDNA recovery in the
third peak, by increasing the NaCl concentration (Fig. 1B, lanes 2 and
3).
The differential interactions between nucleic acids present in the
lysate sample and the arg-spacer monolith complied with that pre-
viously described [8,12]. Given that the pKa of arginine is 12 [30], the
lower working pH can increase the effectiveness of arginine positive
charges, leading to predominant electrostatic interactions, mostly with
nucleic acids negative phosphate groups. However, such ionic interac-
tions can be weakened by competition with increased NaCl con-
centration in the elution buffer, reducing the effective net charge be-
tween the ligand and the species with lower affinity [31]. RNA was
eluted in the flowthrough with 680mM NaCl, due to its small size and
lower charge density associated with the single stranded structure.
Furthermore, the specific biorecognition of the sc pDNA compared to
other pDNA isoforms can be explained by the involvement of additional
non-covalent interactions with arginine, such as cation-п interactions,
bifurcate hydrogen bonds and hydrogen-п interactions, mainly with the
more exposed bases of this conformation caused by the supercoiled
structure [32,33]. Therefore, the slight increase in buffer pH allowed
the elution of species with lower affinity (oc and linear pDNA isoforms)
and the increase ionic strength induced the final recovery of sc pDNA in
the last peak.
The purity and recovery of a sc pDNA sample obtained from the
injection of a 200 μL volume of lysate into the arg-spacer monolith were
evaluated by CIMac™ pDNA analytical column, according to the pre-
viously adapted method [18]. The purity of 93.3 % reinforces the fact
that the arg-spacer monolith can purify sc pDNA more efficiently from a
lysate sample. The recovery yield of 72 % indicated that some pDNA
can be loss during the recovery, concentration and desalting steps
[8,34]. Nonetheless, such loss cannot be quantified separately con-
sidering that all steps must be performed before the analytical evalua-
tion, since ionic strength would interfere with pDNA interaction with
the CIMac™ column and a much diluted sample would render the pDNA
undetectable by this method. Though this recovery yield is lower than
the 86 % obtained with the arginine monolith [8], it is satisfactory
compared to other chromatographic strategies, such as the 62 % of
recovery yield obtained with anion exchange [35] and the triplex af-
finity chromatography [36], as well as 70 % attained with hydrophobic
interaction chromatography [17].
The limitation of several chromatographic matrices for sc pDNA
purification is related to the translation of laboratory to preparative
scale, given that high loading generally affects final sample purity and
Fig. 1. (A) Chromatographic profile of sc pDNA purification from lysate sample (loading of 200 μL), through an arg-spacer monolith. (B) Corresponding agarose gel
electrophoresis: lane A: lysate sample; lane 1-3: peaks 1–3, respectively.
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process productivity. However, the principle of sample displacement
chromatography has led to successful purity results at large pDNA-
sample loading [10,37]. Thus, this principle was explored here, when
the column was loaded with 68mL of diluted E. coli lysate (5 μg of
pDNA/mL), prepared in equilibrium buffer (680mM NaCl in Tris-
EDTA, pH 7.0), corresponding to 1mg pDNA loaded per mL of column
(Fig. 2A). Agarose electrophoresis showed RNA continuous elution from
start of the loading step, followed by elution of non-functional pDNA
species with lower affinity towards the column during the loading step
and finally the partial elution of sc pDNA (Fig. 2B). Considering the
elution behavior and the sample displacement observed throughout
loading, an elution step was performed subsequently only by increasing
the ionic strength (1M NaCl in Tris-EDTA, pH 7.0) to elute bound
species. Lane 9 of Fig. 2B shows the sc pDNA recovery in the elution
step, almost free from other pDNA isoforms. In fact, the results obtained
in the analytical column indicated a sc pDNA homogeneity of 98.5 %.
Also, in this assay, sc pDNA preferential retention was verified, re-
covered by a simple elution step, since non-functional pDNA isoforms
were previously eluted during the loading. This suggests the
involvement of sample displacement chromatography, since the high
loading did not affect final sample purity [10,37]. Contrary to what was
observed with lower injection volumes, no intermediate step was ne-
cessary to remove non-biologically active pDNA isoforms from the
sample, causing pH alteration to be unnecessary. Moreover, it was
verified that this monolith can be successfully adapted to preparative
chromatography, taking advantage of its DNA binding capacity.
Host impurity assessment
To reduce adverse reactions, pDNA samples for therapeutic appli-
cation should be free from contaminants and host impurities [38]. The
analysis in Table 2 indicates a significant reduction of impurities in the
purified samples. The protein and RNA content were undetectable and
residual amounts of gDNA and endotoxins were below the limits re-
commended by regulatory agencies [28]. Thus, both samples could be
applied in further in vitro and in vivo studies, minimizing the possibility
of bacterial impurities provoking adverse reactions, such as in-
flammation, septic shock and organ failure [39,40].
Fig. 2. (A) Chromatographic profile of lysate loading (68mL) onto arg-spacer monolith, prepared in 680mM NaCl in Tris-EDTA, pH 7.0. Plasmid elution with 1M
NaCl in Tris-EDTA, pH 7.0. (B) Corresponding agarose gel electrophoresis: lane A: lysate sample; lane 1-9: fractions 1–9, respectively.
Table 2
Measurement of proteins, gDNA and endotoxins in sc pDNA recovered fractions from 200 μL- and 68mL-loading approaches.
Approach Sample Proteins (mg/mL) RNA (mg/mL) gDNA (ng/μg of pDNA) Endotoxins (EU/μg of pDNA)
Small volume injection sc pDNA Undetectable Undetectable 0.090 0.011
Column loading sc pDNA Undetectable Undetectable 0.680 0.003
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Dynamic Binding Capacity (DBC)
As described previously, monoliths have higher DBC than particu-
late chromatographic supports [8].The arg-spacer monolith was char-
acterized in terms of DBC. Breakthrough experiments were performed
at 1mL/min, with 0.05mg/mL of a pre-purified pDNA sample (data not
shown). The DBC at 10 % of breakthrough curve was 2.53mg/mL,
which is lower than the 3.55mg/mL of the arginine monolith [8]. This
difference can be related to the lower number of available ligands, since
the arg-spacer occupies a larger area than simple arginine. To confirm
this hypothesis, ionic density was evaluated for both monoliths with a
technique developed in [41]. This relies on the determination of ionic
groups available for interaction by assessing a pH transient with two
solutions at different salt concentrations (20 and 500mM phosphate)
but at the same pH (6.8). Regeneration with NaOH was necessary be-
fore saturating monoliths with the more concentrated solution, in order
to guarantee that all ionic groups were available for interaction. After
achieving saturation, the mobile phase was suddenly changed to the
less concentrated solution for pH transient measurement. The time
between alteration of the mobile phases and the 50 % breakthrough
achievement was assessed to determine the ionic capacity of each
monolith. The arg-spacer monolith presented an ionic capacity of
135mM phosphate/L column, while arginine monolith presented
146mM phosphate/L column. The latter displays a higher ionic capa-
city than arg-spacer monolith, supporting the results obtained for DBC.
Plasmid DNA delivery
Nanoparticle characterization
When developing DNA-based therapies, an obstacle usually arises
regarding safe delivery of the designed biomolecule to the intended cell
niche. A carrier system lacking any cytotoxicity towards healthy cells
and concomitantly very specific in identifying and delivering its content
to the target tissue must be developed [42,43]. At the same time, DNA
delivery must be high and efficient to exert a reasonable therapeutic
effect. CaCO3 systems are popular nanosystems due to its simplicity,
biocompatibility and economical preparation [44]. Here, CaCO3 na-
noplexes were formulated by co-precipitation, including the purified sc
pDNA sample, and modified with gelatin, as a natural and biodegrad-
able biopolymer. Gelatin has been shown to add stability to pDNA
nanoplexes and to increase compaction, allowing the formation of
smaller nanoparticles [20]. Fig. 3A,B shows SEM and TEM images of the
pDNA-CaCO3-gelatin systems, presenting a spherical shape, which is an
important feature as this morphology allows a rapid absorption by the
cell membrane, facilitating vector internalization. Table 3 shows the
average of size, zeta potential and pDNA EE determined for pDNA-
CaCO3-gelatin formulated complexes. The nanoparticles were approxi-
mately 200 nm in size, with a negative surface charge, and were able to
load and encapsulate pDNA to a high degree. With some exception for
the zeta potential, where a negative value can disfavor cell membrane
interaction, pDNA-based carrier properties seem to be adequate for
cellular uptake, internalization and consequently transfection. It has
been documented that spherical vectors with sizes< 300 nm can pro-
mote cellular uptake. Nevertheless, vector internalization success and,
therefore, gene transfection efficiency are at the same time dependent
on the set of physicochemical vehicle properties and the cell type [45].
EE demonstrated that nearly 81 % of the pDNA was successfully
encapsulated, indicating that each nanoparticle batch carried approxi-
mately 4.05 μg of pDNA. Thus, the quantity of nanoparticles prepared
can be suitably adjusted accordingly with the surface area of the well
for in vitro transfection studies. Compared to a previous study, in which
pDNA was encapsulated into rhodamine-CaCO3-gelatin nanoplexes for
mitochondrial targeting, a higher EE was achieved with rhodamine-free
CaCO3-gelatin nanoparticles [20]. Moreover, the nanoplexes as for-
mulated here presented an average size that was slightly higher than
rhodamine-CaCO3-gelatin. This might be explained by the fact that
rhodamine presents positive charges that may help pDNA condensation
through electrostatic binding, leading to smaller nanoplexes. However,
the average size of CaCO3-gelatin complexes is still within the range for
optimal cell transfection. The CaCO3-gelatin vectors formulated were of
lower zeta potential than the former nanoplexes, perhaps because
rhodamine is a positively charged fluorochrome. Rhodamine has been
applied to direct delivery systems towards mitochondria in a gene
therapy protocol, which is not the current aim. Overall, the CaCO3-
gelatin nanoplexes presented suitable characteristics for sc pDNA de-
livery to target cells.
Fig. 3. (A) pDNA-CaCO3-gelatin complexes by scanning electron microscopy (Magnification x10,000). (B) pDNA-CaCO3-gelatin complexes by transmission electron
microscopy.
Table 3
Average encapsulation efficiency, zeta potential and size of pDNA-
CaCO3-gelatin nanoplexes (mean ± SD, n= 3).
Characterization parameters Values
Encapsulation Efficiency (%) 81.5 ± 2.88
Zeta Potential (mV) −2.07 ± 0.45
Size (nm) 203.2 ± 9.0
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DNA vaccine cell delivery
To increase therapeutic potential, DNA vaccine administration
should target dendritic cells, the professional antigen presenting cells
activating cytotoxic and humoral immune responses [46,47]. Thus, it is
essential to develop efficient, biocompatible transfection systems that
can specifically identify dendritic cells, which are known to be difficult
to transfect [48]. To investigate the ability of pDNA-CaCO3-gelatin
complexes to undergo dendritic cell internalization, pDNA was labeled
with FITC and its entry into THP-1 cells, a human monocyte cell line
that can be differentiated into macrophages and dendritic cells, was
monitored. As shown in Fig. 4A, fluorescence was found within cells
24 h after transfection, suggesting that the CaCO3-gelatin complexes
were able to deliver pDNA into the cell successfully. These results in-
dicate potential of the CaCO3-gelatin nanoparticle as a new nanocarrier
for pDNA delivery to dendritic cells. To further assess pDNA cell entry,
24 h after transfection, PCR was performed for E6 gene detection. As
shown in Fig. 4B, the E6 gene was found in 3 independent transfections
of THP-1 cells with pDNA-CaCO3-gelatin nanoplexes (lanes 2–4),
compared to the control (lane 1). The presence of the gene, only found
in HPV-infected cells, adds more evidence that the pDNA was correctly
delivered, supporting the ability of these nanoplexes to deliver pDNA
vaccines. Viability studies showed no cytotoxic effect, as previously
described [20].
DNA vaccine antigen expression
To verify the pDNA expression, cells were transfected and recovered
after 24 h for total RNA extraction. After cDNA synthesis, RT-PCR was
performed for E6 mRNA detection. Fig. 5A shows the resulting gel
electrophoresis, with the presence of E6 mRNA in transfected THP-1
cells (lane 2) compared to non-transfectants (lane 1). A positive control
was also performed with CaSki cells (lane 3), HPV-16 infected cervical
cancer cells. The data suggests that the gene is correctly transcribed into
E6 mRNA, highlighting the CaCO3-gelatin complexes capacity to de-
liver the sc pDNA vaccine to the nucleus. E6 protein detection was
performed by western blotting. Cells were transfected and recovered
after 48 h for protein extraction. Fig. 5B shows a western blot re-
presenting E6 protein staining in non-transfected cells (lane 3) and cells
transfected with pDNA-CaCO3-gelatin complexes (lane 4). The band
density difference between samples, compared to housekeeping β-actin
staining for both samples (lanes 1 and 2, respectively), indicates that
the E6 mRNA was correctly translated into protein. Overall, these data
underline the potential of CaCO3-gelatin nanoplexes as a new pDNA
delivery system, suggesting a promising feature for DNA vaccine ther-
apeutic application.
Conclusion
This work presents a biotechnological platform for HPV-16 E6/E7
pDNA vaccine purification followed by in vitro evaluation of its de-
livery. The use of an arg-spacer monolith confirmed the ligand acces-
sibility and its capability to efficiently remove RNA, oc and linear pDNA
isoforms by two purification strategies of different lysate sample
loading (200 μL and 68mL). Open circular and linear pDNA isoform
displacement during column loading favored the elimination of these
impurities throughout the assay with pDNA binding capacities above
1mg/mL. Moreover, the sc pDNA obtained from large sample loading
eluted in a single step by ionic strength increase, with a higher degree
of purity than in a previous approach. This monolith offers rapid and
successful sc pDNA separation by different loading approaches, in-
dicating its applicability for future industrial scale-up without affecting
process effectiveness and productivity. CaCO3-gelatin complexes were
found to successfully encapsulate sc pDNA. Characterization of nano-
plexes demonstrated good size and zeta-potential features, suggesting
good transfection ability, which was demonstrated by the successful
transfection of dendritic cells, a cell line model which is usually difficult
to transfect. Overall, the CaCO3-gelatin complexes present a promising
future in DNA vaccine delivery. The combination of an innovative
biotechnological strategy to purify sc pDNA with a suitable and high-
performance pDNA delivery system contributes towards progress in the
clinical application of pDNA vaccines.
Fig. 4. (A) Fluorescence detection of FITC-labeled pDNA-CaCO3-gelatin complexes upon different transfection periods (green – pDNA/FITC staining; blue – nucleus
staining). 1 - Non-transfected THP-1 cells; 2 - THP-1 cells 8 h post-transfection; 3 - THP-1 cells 16 h post- transfection; 4 - THP-1 cells 24 h post-transfection. 5 – THP-1
cell nucleus 24 h post-transfection. (B) PCR for pDNA detection in cells 24 h post-transfection. 1 - Non-transfected THP-1 cells; 2–4 -Cells transfected with CaCO3
modified systems.
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A B S T R A C T
Minicircle DNA (mcDNA) technology is in the vanguard of vectors designed for gene therapy, since the absence
of prokaryotic sequences confers to mcDNA higher biosafety in comparison to other DNA vectors. However, the
presence of other isoforms and non-recombined parental molecules hampers the isolation of supercoiled (sc)
mcDNA with the chromatographic methods already established for plasmid purification. In this work, two
monolithic supports were modified with lysine and its decarboxylated derivative, cadaverine, to explore their
performance in the sc mcDNA purification. Increasing NaCl gradients and different pH values (from 6 to 9) were
tested in both modified monoliths. In general, cadaverine modified support established stronger interactions
with mcDNA than lysine modified monolith, at acidic pH. For instance, at pH 6.0 the retention time for RNA and
DNA molecules in lysine modified monolith was 11.58 and 14.59, respectively, while for cadaverine modified
monolith was 20.32 and 27.12, respectively. The lysine modified monolith was able to successfully isolate sc
mcDNA from the lysate sample. However, recovery yield was significantly sacrificed to guarantee high purity
levels of sc mcDNA. The cadaverine modified monolith showed better selectivity than the previous monolith,
achieving the successful sc mcDNA isolation from the lysate sample. The final sc mcDNA sample, obtained by the
column that showed the best performance, was characterized by real-time PCR, presenting 98.4% purity and
78.6% recovery yield. The impurities content, namely genomic DNA, proteins and endotoxins, was found within
the criteria established by regulatory agencies. Overall, a simple and practical chromatographic strategy to
purify sc mcDNA was for the first time implemented by exploring a modified monolithic column, with no sig-
nificant reduction on the purity and recovery and without resorting to backbone modification or specific en-
zymatic digestion. Such features will surely be crucial in the industrial scale-up of this chromatographic strategy
since it will not be associated with significant cost-increase.
1. Introduction
Minicircle DNA (mcDNA) is the newest trend in DNA vectors that
can overcome some limitations presented by conventional plasmid DNA
(pDNA). This cutting edge technology has the ability of excising the
prokaryotic sequences when the vector amplification is completed, re-
sulting in a smaller DNA vector composed mainly by eukaryotic se-
quences [1]. These physical and structural differences result in higher
transfection efficiency, biocompatibility and prolonged expression of
the target gene, when using mcDNA in comparison to pDNA [2].
Briefly, the mcDNA molecule is derived from a parental plasmid (PP),
which contains site-specific sequences recognized by PhiC31 integrase,
in a specifically engineered E. coli strain (ZYCY10P3S2T) [3]. Also, PP
presents several I-SceI restriction sites that lead to the endonuclease-
induced cleavage of the molecule [3,4]. Upon induction with L-arabi-
nose, PhiC31 integrase is expressed and the recombination of PP begins,
originating the mcDNA and the miniplasmid (mP) molecules [3,4].
While mcDNA contains the eukaryotic sequences needed for mamma-
lian gene expression, the mP contains the remaining bacterial sequences
from the PP [3]. Simultaneously, the expression of I-SceI is induced,
leading to the digestion of mP and PP molecules [3]. Nonetheless, the
elimination of mP and PP is not totally effective and trace quantities
may be found even after in vivo recombination [4]. Hence, chromato-
graphic strategies must be explored to retrieve mcDNA with a purity
degree suitable for therapeutic application.
Different chromatographic strategies have been explored for
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supercoiled (sc) mcDNA purification. Mayrhofer and co-workers [5]
described a protocol based on the insertion of a specific sequence into
the PP backbone, corresponding to a mcDNA portion after recombina-
tion. Then, through affinity chromatography, mcDNA is isolated by
exploiting its binding to a specific ligand, the lactose operon repressor
protein, which will recognize the sequence previously inserted [5]. In a
similar way, Hou and colleagues [6] published a study regarding the
purification of mcDNA using specific recognition sequences. However,
in that work, the sequences were inserted in the region corresponding
to the mP, which, in the presence of biotinylated DNA oligonucleotides,
led to a reversible triple-helix structure. Then, these undesirable mo-
lecules were eliminated by binding them to streptavidin-coated mag-
netic beads, resulting in the isolation of mcDNA by negative chroma-
tography. On the other hand, Alves and co-workers [7] established a
purification strategy for sc mcDNA by resorting to in vitro enzymatic
digestion of mP and PP molecules using a specific nicking en-
donuclease. Then, after nicking these molecules, sc mDNA isolation was
achieved by using hydrophobic interaction chromatography. Although
these studies provide good results for mcDNA isolation, it requires the
use of PP molecules modified with specific sequences. Consequently,
this approach cannot be used in other PP molecules available in the
market. Also, some of these strategies do not have enough selectivity to
allow sc isolation from other different mcDNA isoforms since they are
designed to either recognize the contaminants or to bind to specific
sequences shared by all mcDNA isoforms. Ultimately, considering the
characteristics of such strategies, the scale-up would be too expensive to
allow therapeutic mcDNA to be easily affordable. Therefore, the use of a
unique chromatographic strategy that can be applied to mcDNA vectors
with different backbones has great interest, allowing to reduce some of
the purification costs [8]. To overcome these hurdles, our research
group previously published a chromatographic strategy in which the
successful sc mcDNA purification was achieved using CIM DEAE-1
monolith [9]. Nonetheless, this method presented some limitations as-
sociated with the sc mcDNA recovery yield [9], given that only 50% of
the sc mcDNA content was recovered. These results emphasized the
need to explore other options for sc mcDNA purification. Actually, the
lack of selectivity can be related to the fact that weak anion exchange
ligands only establish ionic interactions with the target molecule. In the
presence of other molecules with similar surface charge, the selectivity
of these chromatographic matrices may significantly decrease. In
Table 1 it is presented a comparison between all the strategies here
described for mcDNA purification.
Affinity chromatography has been pointed out as a fruitful tech-
nique in the separation of biomolecules due to the selectivity towards
the target molecule [10]. Such approach exploits the specific recogni-
tion of the target molecule by matrix-attached ligands, based on its
biological function or chemical structure. Thus, given the fact that sc
isoform has specific exposed bases in its compact structure, in com-
parison to other isoforms, affinity chromatography can explore the se-
lectivity of affinity ligands towards these bases for sc isolation. In fact,
our research group has been exploring the role of different amino acids
as ligands for the purification of nucleic acids. These ligands often re-
sulted in high purity and recovery yields for target molecules [11–14].
Chromatographic monoliths are advantageous for large molecules se-
paration due to convection-based mass transfer, enabling high and
flow-independent dynamic binding capacity and resolution [15]. A
combination of monolith with amino acid-based ligands seems to be a
logical step forward in nucleic acid purification activities. Thus, the aim
of the present study was to explore two purification strategies for sc
mcDNA isolation from a bacterial lysate. For the first time, lysine and
its decarboxylated derivative, cadaverine, were used as ligands im-
mobilized in monolithic supports for the purification of sc mcDNA.
Such ligands are usually manipulated for the exploration of electrostatic
interactions. However, these molecules are known to present other
elemental interactions, such as hydrogen bonds, hydrogen-п or cation-π
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der Waals forces, which may ultimately contribute to more selectivity
towards the target molecule, comparatively to commercially available
weak anion exchangers.
2. Materials and methods
2.1. Materials
Lysine and cadaverine ligands were purchased from Alfa Aesar
(Karlsruhe, Germany) and Tokyo Chemical Industry (Tokyo, Japan),
respectively, and immobilized on Convective Interaction Media®
(CIM®) epoxy monoliths with bed volume of 0.1 mL, kindly prepared
and provided by BIA Separations (Ajdovščina, Slovenia). Briefly, the
target ligand was dissolved in water and 5 M NaOH was added to adjust
pH to 10.5. Then, 2 mL of ethanol was added and the resulting solution
was pumped into an epoxy monolith. The monoliths were incubated
along with the immobilization solution during 48 h hours at 60 °C,
washed with water and the remaining epoxy groups were deactivated
with 0.5 M H2SO4. Ionic density capacity was evaluated as described by
Lendero and co-workers [16]. Sodium chloride was purchased from
Panreac (Barcelona, Spain) and tris(hydroxymethyl)aminomethane
(Tris) from Merck (Darmstadt, Germany). All solutions used in chro-
matographic experiments were freshly prepared by using deionized
ultra-pure grade water, purified with a Milli-Q system from Millipore
(Billerica, MA, USA), filtered through a 0.2 μm pore size membrane
(Schleicher Schuell, Germany) and degassed ultrasonically. The E. coli
strain ZYCY10P3S2T and pMC.CMV-MCS-EF1-GFP-SV40 PolyA vector
of 7.06 Kbp were purchased from System Biosciences.
2.2. Methods
2.2.1. Minicircle DNA production and extraction
PP amplification was performed by culturing the E. coli strain
ZYCY10P3S2T, harboring the pMC.CMV-MCS-EF1-GFP-SV40 PolyA
vector, in Terrific Broth medium (20 g/L of tryptone, 24 g/L of yeast
extract, 4 mL/L of glycerol, 0.017 M KH2PO4, 0.072 M K2HPO4) at
42 °C, followed by mcDNA (3.8 Kbp) synthesis induction by adding an
induction mixture containing 0.01% L-arabinose. The induction was
then carried out for 3 h, as previously described by Gaspar and co-
workers [3]. This induction step also leads to expression of I-SceI by this
strain, which is responsible for the mP digestion. In the end, cells were
recovered by centrifugation and stored at −20 °C. A complex mcDNA
sample was prepared making use of the modified alkaline lysis method
described by Diogo and co-workers [17]. The resulting supernatant was
desalted with PD-10 desalting columns (GE Healthcare, Buckingham-
shire, UK). Subsequently, the clarified lysate sample was used for the
chromatographic assays.
2.2.2. Minicircle DNA purification
All chromatographic experiments were performed in an AKTA Püre
system (GE Healthcare, Buckinghamshire, UK), which consists in a
compact separation unit and a personal computer with UNICORN™ 6.3
software. The purification procedure was based on the use of two
monolithic supports modified with lysine and cadaverine ligands, both
with a bed volume of 100 μL. A 100 μL loop was used for sample in-
jection and all experiments were carried out with a 1 mL/min flow rate.
For screening purposes, the chromatographic behavior of the dif-
ferent molecules of the sample was evaluated in both columns, by ap-
plying an increasing linear gradient from 0 to 2 M NaCl in 10 mM Tris-
EDTA buffer (pH 7.0) for 30 min.
Upon several assays, the mcDNA purification was achieved by es-
tablishing a three-step elution strategy in each monolith. In the case of
lysine modified monolith, the equilibration and sample injection were
carried out at 190 mM NaCl in 10 mM Tris-EDTA buffer (pH 7.0), fol-
lowed by a stepwise increase of ionic strength to 250 mM NaCl in
10 mM Tris-EDTA buffer (pH 7.0) for mcDNA recovery. Finally, 1 M
NaCl in 10 mM Tris-EDTA buffer (pH 7.0) was applied to the column for
the elution of molecules that remained bound. On the other hand, ca-
daverine modified monolith equilibration and sample injection were
performed at 1.07 M NaCl in 10 mM Tris-EDTA buffer (pH 7.0), fol-
lowed by a salt increase adjustment to 1.16 M NaCl in 10 mM Tris-EDTA
buffer (pH 7.0).
All experiments were carried out at room temperature and the ab-
sorbance was continuously monitored at 260 nm. Fractions were re-
covered, according to the chromatograms, concentrated and desalted
with Vivaspin® 6 Centrifugal Concentrator (Vivaproducts, Littleton,
MA, USA), for further analysis. Agarose gel electrophoresis was per-
formed [9] and each sample was analyzed for band density through
Quantity software (Bio-Rad Laboratories, Hercules, CA, USA).
2.2.3. mcDNA purity and recovery assessment
To assess the purity and recovery levels of the mcDNA recovered
from the chromatographic assays, real-time polymerase chain reaction
(PCR) was performed in a CFX Connect Real-time System (Bio-Rad
Laboratories, Hercules, CA) [3,5]. For PP detection, primers were de-
signed for pUC19 origin (ColE1) (forward [fw]: 5′-TCCTGTTACCAGT
GGCTGCT; reverse [rv]: 5′-AGTTCGGTGTAGGTCGTTCG), to amplify a
fragment of 151 bp. For mcDNA detection, primers were designed for
the GFP gene, (forward [fw]: 5′- ATGGAGAGCGACGAGAGCGG; reverse
[rv]: 5′-TTAGCGAGATCCGGTGGAGC), amplifying a fragment of
759 bp. For mP detection, primers were designed for the kanamycin
antibiotic resistance gene, (forward [fw]: 5′-TCACGACGAGATCCTCG
CCGTC; reverse [rv]: 5′-CGTTAGGTAGAACAAGTTAGTA), amplifying a
fragment of 561 bp. A calibration curve for each set of primers in the
range of 50–0.5 ng/μL was performed with PP purified with NZYMax-
iprep commercial kit (NZYTech, Lisbon, Portugal), according to the
manufacturer's instructions. Real-time PCR was carried out with 20 μL
reactions containing 10 μL of SYBR green mastermix, 3 μM of each
primer and 1 μL of DNA. The parameters were: denaturation at 95 °C for
10 min; 35 cycles of denaturation at 95 °C for 10 s, annealing at 60 °C
for 30 s and extension at 72 °C for 10 s. The PP, mP and mcDNA content
was calculated resorting to the calibration curve. For mP and mcDNA
quantification, the PP was subtracted, similarly to what has been pre-
viously described by Mayrhofer and co-workers [5].
2.2.4. Genomic DNA, endotoxins and protein quantification
Purified sc mcDNA concentration was determined by spectro-
photometric quantification (A 260 nm). Genomic DNA was quantified
through real time-PCR, with Maxima SYBR Green/Fluorescein qPCR
Master Mix (Thermo Fisher Scientific), as described by Sousa and co-
workers [18]. The calibration curve for gDNA concentration was con-
structed by serial dilutions of the E. coli gDNA in the range of 0.005 to
50 ng/μL. The ToxinSensor™Chromogenic Limulus amoebocyte lysate
assay kit from GenScript (USA, Inc.) was used for endotoxin quantifi-
cation, according to the manufacturer's instructions. The calibration
curve was constructed with 10 endotoxin units (EU)/mL stock solution
provided by the kit (0.005–0.1 EU/mL). For protein assessment, the
Micro-BCA (bicinchoninic acid) protein assay kit from Pierce (Rockford,
USA) was used, according to the manufacturer's instructions. The cali-
bration curve was constructed with Bovine Serum Albumin (BSA) as a
standard protein (0.01–0.1 mg/mL).
2.2.5. Assessment of selectivity in different loading conditions and dynamic
binding capacity
For the evaluation of the effect that different loading conditions may
have in the purification of sc mcDNA, different sample volumes (200 μL,
500 μL and 1 mL) from the same initial batch were loaded onto the
cadaverine monolith, under the optimized chromatographic conditions
previously established.
To perform the dynamic binding capacity, purified mcDNA solution
was prepared with a 20 μg/mL concentration in 10 mM Tris-EDTA
buffer. Cadaverine monolith was equilibrated with 10 mM Tris-EDTA
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buffer (pH 7.0), followed by mcDNA solution overloading.
Determination of dynamic binding capacity was carried out as de-
scribed by Soares and co-workers [19]. Afterwards, the elution of the
bound mcDNA was achieved by increasing the ionic strength to 2 M
NaCl in 10 mM Tris-EDTA buffer.
3. Results and discussion
Lysine and cadaverine were the ligands explored in the present
work to purify sc mcDNA from a lysate sample. Lysine agarose was
already successfully used by our research group in pDNA and pre-
miRNA-29 purification [11,20]. Since cadaverine results from lysine
decarboxylation, its application as a ligand appears to be very pro-
mising as it can favor some interactions with DNA, minimizing some
repulsive effects. Thus, this study allows the evaluation of the carboxyl
group influence in established interactions, by comparing the retention
behavior of mcDNA in both supports. Two monolithic columns were
modified with lysine and cadaverine ligands (Fig. 1) and, to qualita-
tively evaluate the monolith modification, several binding studies were
performed with mcDNA lysate by using ionic and hydrophobic condi-
tions (data not shown). It is known that the epoxy monolith (non-
modified) is capable of binding nucleic acids under hydrophobic con-
ditions, but this retention does not occur when exploring ion-exchange
conditions [19,21]. After coupling the ligands to the column surface,
cadaverine and lysine modified monoliths allowed the retention of DNA
molecules, when loaded in low-conductivity buffers, thus proving the
presence of ligands of ionic character. Also, ionic density of each
monolithic column was evaluated to determine the total number of
ionic groups available for interaction. This method consists in mea-
suring a pH transient by using two solutions with the same pH but with
different salt concentrations (500 mM phosphate and 20 mM Phos-
phate, pH 6.8). All chromatographic supports were regenerated before
equilibration with the higher concentration buffer, until saturation was
achieved. Then, the mobile phase was abruptly changed to the solution
with lower ionic strength and the pH transient was evaluated. The time
passed between switching the mobile phases and reaching 50% of
breakthrough allows to determine the ionic capacity for the chroma-
tographic support under study [16]. We were able to verify that the
unmodified epoxy monolith presented 141 mM phosphate/L column,
while lysine and cadaverine modified monoliths presented 414 mM
phosphate/L and 526 mM phosphate/L, respectively (data not shown).
Given that this relative measure of available ionic groups results from
the coexistence of positive amino groups in cadaverine and lysine li-
gands and negative carboxyl groups in lysine ligand, we can infer that
both monoliths have been correctly modified with the target ligands.
Also, this result may serve as an indicative that cadaverine modified
monolith presents more available ionic groups, when comparing to
lysine modified monolith.
In an attempt of understanding the different interactions displayed
by each column, lysate samples were loaded in both columns and eluted
by using linear gradients of 30 min from 0 to 2 M of NaCl at different pH
values (from 6 to 9). As observed in Fig. 2, the decrease of pH generally
leads to an increased retention of the different molecules present in the
initial sample. This effect can be correlated with the pKa of both li-
gands. While lysine amine groups present a pKa that varies between
8.95 and 10.5, cadaverine amine groups show a pKa that varies be-
tween 9.13 and 10.25. Also, carboxyl group of lysine presents a pKa of
2.2 [22]. Presumably, at lower pH, both ligands are more positively
charged, strengthening the interactions and the binding of the nega-
tively charged nucleic acids [23]. In addition, it can also be observed in
Fig. 2 that nucleic acids generally present higher retention times in the
cadaverine modified support than in the lysine modified monolith,
suggesting that stronger interactions are involved. Briefly, at pH 6.0 the
retention time (RT) for the lysine modified monolith was 11.58 for RNA
and 14.59 for DNA molecules (Fig. 2A), although a small amount of
Fig. 1. Representation of the monoliths modified with: A) Lysine ligand; B)
Cadaverine ligand.
Fig. 2. Chromatographic profile and retention times (RT) of mcDNA-containing lysate sample loaded onto lysine (A) and cadaverine (B) monoliths, when subjected to
buffers with different pH values. Chromatographic runs were performed with linear gradients of 30 min from 0 M to 2 M of NaCl in 10 mM Tris-HCl/EDTA at pH 9, 8,
7 and 6. Next to chromatogram at pH 6 it is the electrophoresis of the corresponding peaks (1, 2 and 3).
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RNA was eluted in the flowthrough (lane 1 from agarose electrophor-
esis). However, cadaverine modified monolith presented a RT of 20.32
for RNA and a RT of 27.12 for DNA molecules (Fig. 2B). These results
are also in agreement with the ionic density data.
In this first approach, it was observed a significant difference in the
chromatographic profiles obtained with both columns. In a first glance,
the fact that lysine modified monolith does not interact with the sample
at pH 8.0 and pH 9.0 stands out, while cadaverine modified monolith
promotes the interaction with the sample at all studied pH conditions.
Considering the pKa of lysine amine groups, working at lower pH can
increase the effectiveness of lysine positive charges and lead to a
stronger interaction with nucleic acids, while higher pH can lead to a
weaker ionic interaction (not disregarding the involvement of other
multiple non-covalent interactions). Also, considering the fact that the
carboxyl group is de-protonated in the studied pH range, the lack of
interaction perceived between the sample and the chromatographic
matrix at pH 8.0 and pH 9.0 may be explained by the electrostatic re-
pulsion displayed by such group towards the phosphate groups of nu-
cleic acids. Some studies have shown that lysine ligand is able to bind to
small DNA fragments in very acidic conditions (pH 4.0), losing this
ability with the pH increase [23].
At pH 6.0 the carboxylic group is de-protonated, therefore inhibiting
the interaction between small RNA molecules and the chromatographic
ligand through electrostatic repulsion [23]. On the other hand, our
research group has previously studied the behavior of nucleic acid in-
teraction with histidine and arginine decarboxylated amino acid deri-
vatives, namely histamine and agmatine [21]. Such study allowed the
identification of a higher pseudo-affinity between pDNA and hista-
mine/agmatine ligands than with histidine/arginine precursors, prob-
ably due to the absence of electrostatic repulsion from the carboxyl
group [21]. Therefore, the collected data suggest that the lysine dec-
arboxylation also enables a stronger interaction with nucleic acids,
perhaps avoiding the phosphate group repulsion through carboxyl
group absence. Simultaneously, the cadaverine ligand can promote
additional non-covalent interactions due to the higher availability of
the carbon chain, which culminates in the higher retention of biomo-
lecules.
Taking advantage of the weak interaction between the lysine ligand
and RNA molecules, few attempts were performed in order to achieve
the purification of sc mcDNA. At first, it seemed the most suitable
strategy, considering the possibility to eliminate the bacterial RNA
impurity directly in the flowthrough, maintaining the ligands available
to bind to other sample components, namely the target mcDNA.
Considering the fact that mcDNA does not interact with the lysine
modified monolith at pH 8.0, and that at pH 7.0 it is possible to elim-
inate more RNA quantity in the flowthough than at pH 6.0, the fol-
lowing studies were performed at pH 7.0. A three-step salt increasing
gradient was used, establishing the column equilibration at 190 mM
NaCl, at a flow rate of 1 mL/min and injecting 100 μL of clarified lysate
sample. After the elution of unbound species in the flowthough, ionic
strength was increased to 240 mM, followed by 1 M NaCl for complete
molecule removal from the support. In Fig. 3, it is presented the chro-
matogram (A) and the corresponding electrophoresis (B) regarding the
purification of sc mcDNA with the lysine modified monolith. As it is
shown, the isolation of the sc mcDNA was achieved by first promoting
total RNA elution at 190 mM NaCl and simultaneously binding the re-
maining DNA species. With the increase of ionic strength to 240 mM
NaCl, a small fraction of sc mcDNA was able to elute in peak 2 apart
from the parental plasmid and open circular isoforms. However, as it is
perceived in lane 3 of the electrophoresis of Fig. 3, a great part of the sc
mcDNA still continued attached to the matrix, eluting together with
other impurities in the third peak, suggesting the purity of the re-
maining mcDNA is not adequate. This elution profile may be related
with the mcDNA smaller size, in comparison to PP molecule, and its
more compact structure, regarding the open circular isoform. Such
compaction degree can lead to different interactions between the lysine
ligand and both isoforms [24].
In an attempt to improve the mcDNA recovery, a similar chroma-
tographic assay was performed with lysine modified monolith only by
changing the second step from 240 to 250 mM NaCl. This adjustment
allowed to improve the recovery of sc mcDNA in the second peak, de-
spite a considered amount still remained attached to the matrix and
only eluted in the third peak (Appendices, Fig. A.1). In addition, this
adjustment in the elution gradient also resulted in the co-elution of
some impurities with the mcDNA, diminishing the purity degree of the
second peak. These data suggest that the selectivity degree of this li-
gand is not totally suitable for the purification of sc mcDNA, as it would
be necessary to greatly sacrifice the recovery to achieve good purity
levels, and vice-versa. Such lack of selectivity can rely on the fact that,
although both PP and mcDNA present different sizes, these molecules
have very similar properties. By sharing common DNA sequences, its
compaction and torsional strain can lead to the exposition of similar
bases that can hamper the distinction of these two molecules. More-
over, previous works have shown that arginine ligand displays stronger
interactions with pDNA than the lysine ligand [25]. The difference of
ionic strength used in each matrix can be associated with the fact that
arginine presents three available amine groups while lysine, as depicted
in Fig. 1, presents solely one amine group available for the exploitation
of several pseudo-affinity interactions, such as electrostatic, multiple
hydrogen bonds or cation-π interactions. Following this line of thought,
lysine limitation to one available amine group can be associated with
the lack of selectivity and difficulty in the establishment of stronger
interactions towards these two similar molecules, PP and mcDNA. Also,
lysine-DNA interaction can be weakened due to the presence of the
carboxyl group, which can cause repulsion of the negatively charged
DNA phosphate groups.
With the intent of improving the sc mcDNA recovery and purity, the
cadaverine modified monolith was also explored. Before proceeding, it
was necessary to consider the results previously obtained in the pH
screening, which are presented in Fig. 2. These experiments demon-
strate the involvement of a multiple non-covalent interaction between
the sample and the cadaverine matrix, suggesting an interaction to-
wards the sample stronger than the one presented by lysine modified
monolith. As a matter of fact, the electrophoresis of the different mo-
lecules eluted from lysine support at pH 6 (Fig. 2A) demonstrates that a
considerable amount of RNA does not bind in salt-free conditions. Thus,
these results indicate that lysine modified monolith promotes a weaker
interaction with RNA, leading to some elution in the flowthrough even
at the lowest pH (6.0). Therefore, higher salt concentrations must be
used with cadaverine ligand, as nucleic acids bind strongly to this li-
gand than to lysine. Thus, preliminary experiments were carried out in
the cadaverine modified monolith by using the same pH and buffer
composition optimized in the lysine modified monolith (Fig. 3), in order
to compare its chromatographic behavior. However, salt concentrations
were adjusted accordingly to the information withdrawn from Fig. 2. To
avoid RNA retention and to allow more ligand availability for target
molecule binding, few screening studies were performed to establish
the NaCl concentration to be used for column equilibration (data not
shown).
Therefore, cadaverine modified monolith was equilibrated with 1 M
NaCl for RNA elution, followed by the application of a linear gradient
from 1 M to 1.19 M NaCl, to understand the interaction behavior of sc
mcDNA towards the cadaverine ligand. Then, the salt concentration
was increased to 1.3 M NaCl, to elute the species that remained bound
to the column. In Fig. 4 it is presented the chromatogram (A) and the
corresponding electrophoresis (B). As shown in lanes 4 and 5 of the
electrophoresis, most of sc mcDNA was eluted earlier than PP mole-
cules, suggesting that a small adjustment of salt concentration can lead
to the complete isolation of sc mcDNA. The sample elution pattern also
suggested that the cadaverine ligand can distinguish between both sc
mcDNA and sc PP. Taking these results into consideration, a 3-step
elution strategy was applied, similarly to the lysine modified monolith
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approach but with higher ionic strength.
Considering that in the previous strategy RNA was still eluting
during the linear gradient, the ionic strength of equilibrium step was
increased in an attempt to eliminate all RNA content in the first step of
the assay. Then, the salt concentration used in the second step of the
gradient was slightly decreased to promote sc mcDNA elution while
maintaining other DNA impurities bound to the matrix. Therefore,
1.07 M NaCl was first used to elute RNA species, allowing to bind the
DNA molecules at the same time. Afterwards, salt concentration was
increased to 1.16 M NaCl, for the recovery of sc mcDNA, followed by
ionic strength increase to 1.3 M NaCl for elution of the remaining
species. In Fig. 5 is portrayed the chromatogram (A) and the electro-
phoresis (B) for this result. In contrast to what was observed with the
lysine modified monolith, higher sc mcDNA content appears to be re-
trieved completely isolated from other molecules. In comparison to
initial and PP samples (Fig. 5B, lane A and PP), the sc mcDNA sample
recovered from the cadaverine modified monolith presents a unique
band (Fig. 5B, lane 3), suggesting that it is isolated from other
Fig. 3. Chromatographic profile and electrophoretic characterization of the clarified E. coli lysate injected onto the lysine monolith. A) Chromatographic run
performed with 190 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0), followed by 240 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0) and 1 M NaCl in 10 mM Tris-HCl/
EDTA (pH 7.0). B) Agarose gel electrophoresis of the different peaks. Lane A – Initial Sample; lane PP – Parental Plasmid Sample; Lane 1–3 - Samples corresponding to
the respective chromatographic peaks.
Fig. 4. Chromatographic profile and electrophoresis of the clarified E. coli lysate injected in the cadaverine monolith. A) Chromatographic run performed with 1 M
NaCl in 10 mM Tris-HCl/EDTA (pH 7.0), followed by a 10 min-linear gradient up to 1.19 M NaCl in 10 mM Tris-HCl/EDTA (pH 7.0) and finally 1.3 M NaCl in 10 mM
Tris-HCl/EDTA (pH 7.0). B) Agarose gel electrophoresis of the different peaks. Lane A – Initial Sample; Lane PP – Parental Plasmid Sample; Lane 1–6 - Samples
corresponding to the respective chromatographic peaks.
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contaminants, such as PP molecules and RNA. Concomitantly, the re-
covery appears to have significantly increased in comparison to the
lysine column strategy. Actually, it was not detected any sc mcDNA
eluting in other steps (Fig. 5B, lane 4), suggesting that the recovery in
the second step is very satisfactory.
Given that no analytical method is available for purity and recovery
yield assessment of sc mcDNA, and considering that currently im-
plemented pDNA analytical methods do not allow the separation be-
tween PP and mcDNA, real-time PCR was performed to evaluate the
purity and the recovery of the obtained mcDNA sample. By designing
specific primers for the PP origin, kanamycin and GFP genes, it was
possible to perform a calibration curve using a PP sample, a molecule
that contains all these sequences. With the PP origin set of primers, it
was possible to determine the specific amount of PP in the sample and
subtract its amount from the calculations performed either for mcDNA
or mP. Thereby, we were able to retrieve the total amount of mcDNA
present in the sample. By using this technique, it was possible to de-
termine the purity of the final sc mcDNA as 98.4% and the recovery as
78.6%. Given that the electrophoresis result does not suggest any loss of
mcDNA in other peak fractions, the recovery determined by real-time
PCR (78.6%) experiments can be related with the fact that the eluted
sample was desalted and concentrated, a process that usually resorts to
the use of concentrators and that may add up to the loss of target
molecule. Regardless, such recovery percentage is relevant and similar
to the recovery percentages usually obtained with monoliths for other
molecules, such as pDNA [13,14].
These distinctive results obtained with each monolith can be related
with cadaverine and lysine structures (Fig. 1). Lysine and cadaverine
ligands are composed by a terminal amine group, which can establish
electrostatic interactions, hydrogen bonds, hydrogen-π interactions,
cation-п interactions and water mediated bonds due to the nitrogen
atom that may act as hydrogen bond donor and acceptor [21]. Both
ligands also present a carbon chain, which can allow additional inter-
actions, such as hydrophobic or van der Waals forces. These interac-
tions occur preferentially with sc mcDNA, which presents higher charge
density of phosphate groups per surface area and more exposed aro-
matic bases due to the supercoiling phenomenon. Considering that
cadaverine does not present a carboxyl group, sc mcDNA can be closer
to this ligand and establish molecular forces (which needs the right
geometry and close distance) in a great extent, such as hydrogen
bonding, van der Walls bonding and others. Therefore, cadaverine li-
gand presents stronger and more selective interactions than lysine,
ultimately facilitating the biorecognition and separation of sc mcDNA
from a complex lysate sample.
To complete the purity characterization, host gDNA, protein, RNA
and endotoxin content of the isolated sc mcDNA sample was assessed to
assure it complies with the regulatory agencies' criteria. In Table 2 is
presented a comparison between the accepted impurity levels and the
impurity levels evaluated in the sc mcDNA purified by cadaverine
modified monolith. As it is perceived, all impurity content is within the
range accepted by FDA for biopharmaceuticals (gDNA < 0.01 μg/μg
pDNA, proteins undetectable, RNA undetectable, endotoxins < 0.01
EU/μg pDNA). This data underlines the ability of cadaverine modified
monolith to purify sc mcDNA from a complex sample. This is a very
important feature that a chromatographic strategy must fulfill when
aiming to obtain biomolecules for further therapeutic application. Ac-
tually, the presence of such contaminants can contribute with harmful
secondary effects such as inflammation, septic shock and organ failure
[26–28]. Comparatively to the literature (Table 1), this study allowed
to establish a purification strategy transposable to other mcDNA
backbones, without resorting to its modification with specific recogni-
tion sequences or the use of specific enzymatic digestion [5–7]. Besides
isolating mcDNA from PP, mP and bacterial contaminants, thus pro-
viding a high-grade purity level, this approach also allowed high re-
covery of the target molecule (78.6%). This is an enormous advantage
in comparison to the strategy already established by Diamantino and
co-workers (~50%), which was also meant to isolate mcDNA with
different backbones [9].
Nonetheless, it is important to assess the sample volume influence in
the purity of mcDNA, when developing purification strategies for a
future industrial application. Thus, different sample loading assays,
from the same initial batch, were performed with the optimized chro-
matographic conditions. In Fig. 6 is presented the resultant
Fig. 5. Chromatographic profile and electrophoresis of the clarified E. coli lysate injected in the cadaverine monolith. A) Chromatographic run performed with 1.07 M
NaCl in 10 Mm Tris-HCl/EDTA (pH 7.0), followed by 1.16 M NaCl in 10 mM Tris-HCl/EDTA (pH 7.0) and 1.3 M NaCl in 10 mM Tris-HCl/EDTA (pH 7.0). B) Agarose
gel electrophoresis of the different peaks. Lane A – Initial Sample; lane PP – Parental Plasmid Sample; Lane 1–4 - Samples corresponding to the respective chro-
matographic peaks.
Table 2
Comparison between FDA criteria and impurity levels evaluated in sc mcDNA
sample obtained from cadaverine monolith [29]. EU – Endotoxin unit.
FDA criteriaImpurities sc mcDNA isolated with cadaverine
monolith
0.00158 μg/μg mcDNA< 0.01 μg/μg pDNAgDNA
undetectableProteins undetectable
undetectableRNA undetectable
0.0097 EU/μg mcDNA< 0.01 EU/μg pDNAEndotoxins
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electrophoresis of the different assays. It can be perceived that mcDNA
purity does not alter when loading 200 and 500 μL of sample (lanes 2
and 5). However, mcDNA does not fully bind to the matrix when using a
sample volume of 1 mL, partially eluting with RNA in the first gradient
step (lane 7). This might be related with the fact that, with such high
sample loading, contaminants may be occupying the available sites for
mcDNA binding, leading to its elution in the first step gradient. Then,
purity is compromised as high weight molecules elute with mcDNA in
the second step of the gradient (lane 8). Such occurrence may also be
related with the fact that different amounts of high weight con-
taminants preferably bind to the matrix, interfering with the separation
of mcDNA. Consequently, the conditions previously established for the
purification of mcDNA demonstrate its inefficiency under high sample
loading conditions, such as 1 mL. However, it must be highlighted the
fact that these assays were performed with a monolithic disk of 100 μL
volume. The increase of the monolithic disk volume may increase the
sample loading volume without compromising mcDNA purity, thus
circumventing this problem. Finally, dynamic binding capacity was
performed with cadaverine monolith. Monoliths are expected to present
higher binding capacity than particulate chromatographic supports
[19]. Breakthrough experiments were performed at 1 mL/min, with
0.02 mg/mL purified mDNA sample. The dynamic binding capacity at
10% of breakthrough curve was 2 mg/mL and 2.44 mg/mL at 50% of
breakthrough. Thus, it is here described for the first time the dynamic
binding of a support utilized for the purification of mcDNA [5,7,9].
4. Conclusion
In the present work, lysine and cadaverine modified monoliths were
explored in the sc mcDNA isolation. First, the monolith modification
was confirmed by considering the ionic density capacity of lysine and
cadaverine modified monoliths (414 mM phosphate/L and 526 mM
phosphate/L, respectively) and the epoxy monolith (141 mM phos-
phate/L). Then, the pH influence in the sample chromatographic be-
havior was studied for both columns. It was possible to observe an in-
crease of interaction between the sample and both monoliths with the
pH decrease. Also, it was shown that cadaverine modified monolith
presented higher retention times than lysine modified monolith, sug-
gesting a stronger interaction between the sample and the matrix. This
distinct chromatographic behavior can be explained by the presence of
a carboxyl group in the lysine modified monolith, which can display
electrostatic repulsion towards the phosphate groups of the nucleic
acids in the sample. The exploitation of several elution strategies in
both monoliths allowed to understand that different interactions were
displayed, which ultimately led to different outcomes for each mono-
lith. At first, lysine modified monolith showed to be able to isolate sc
mcDNA, although rendering low sc mcDNA recovery. However, the
attempt to increase sc mcDNA recovery yield resulted in loss of purity
degree, suggesting low selectivity presented by lysine towards mcDNA.
On the other hand, cadaverine modified monolith was also able to se-
parate sc mcDNA, presenting better recovery yield than lysine column
(78.6%), without loss of purity (98.4%). The stronger and selective
interactions established by cadaverine ligand can be due to the absence
of the carboxyl group exhibited by lysine. In this way, cadaverine
modified monolith has no electrostatic repulsion towards the sc mcDNA
phosphate groups, enabling a closer contact of this molecule with the
ligand. Consequently, some molecular forces (which need the right
geometry and close distance) occur in a great extent, such as hydrogen
bonding, van der Walls bonding, between other. Moreover, the level of
impurities was shown to fulfill the regulatory agency recommendations.
Finally, the dynamic binding capacity for a chromatographic approach
regarding the isolation of mcDNA was evaluated for the first time in the
literature. In general, here is described a low-cost purification strategy
for mcDNA, comparatively to the studies that have been developed so
far. The present work allowed to underline cadaverine modified
monolith potential as a chromatographic strategy for sc mcDNA pur-
ification, given its simplicity and practical use. Also, this ligand seems
suitable to be explored for the implementation of an analytical method
for quantification of sc mcDNA, which does not exist at the moment.
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Appendix A
Chromatographic profile and electrophoretic characterization of the clarified E. coli lysate injected onto the lysine monolith. A) Chromatographic
run performed with 190 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0), followed by 250 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0) and 1 M NaCl in
10 mM Tris-HCl/EDTA (pH 7.0). B) Agarose gel electrophoresis of the different peaks. Lane A – Initial Sample; lane PP – Parental Plasmid Sample;
Lane 1–3 - Samples corresponding to the respective chromatographic peaks.
Fig. A.1. Chromatographic profile and electrophoretic characterization of the clarified E. coli lysate injected onto the lysine monolith. A) Chromatographic run
performed with 190 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0), followed by 250 mM NaCl in 10 mM Tris-HCl/EDTA (pH 7.0) and 1 M NaCl in 10 mM Tris-HCl/
EDTA (pH 7.0). B) Agarose gel electrophoresis of the different peaks. Lane A – Initial Sample; lane PP – Parental Plasmid Sample; Lane 1-3 - Samples corresponding to
the respective chromatographic peaks. gDNA - genomic DNA; mcDNA - minicircle DNA; oc - open circular; PP - parental plasmid; sc - supercoiled;
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Minicircle  DNA (mcDNA) is  the  new  cutting-edge technology which researchers  have  been  exploring for
gene  therapy  and DNA  vaccination. Although  it presents  enormous  advantages in  comparison to  con-
ventional  plasmid  DNA regarding bioactivity and safety, its challenging isolation from parental plasmid
and  miniplasmid has been  setting back its  launching  in biomedical sciences.  In  this work,  it  is demon-
strated  the  use of  a simple  size exclusion  chromatographic method  for  the isolation  of supercoiled  mcDNA.
Sephacryl  S-1000 SF  matrix  was  explored under  different conditions  (flow, peak  fractionation volume  and
sample  loading) to  achieve the best  performance and retrieve  a mcDNA  sample  devoid of  other bacterialinicircle DNA
phacryl
e exclusion chromatography
contaminants  or  plasmid species resultant from the recombination process. This isolation methodology
resulted  in 66.7% of  mcDNA  recovery with 98.1% of  purity.  In addition, to show  the  robustness  of the
method,  the potential of using  this  matrix  for  the isolation of a  larger  mcDNA  was  also evaluated. Upon
adjusting  the  flow  or the column volume, the larger mcDNA molecule was also successfully isolated.

















egunderlining  the  potential  o
 Introduction
The use of plasmid DNA  (pDNA)  as  a  non-viral DNA vector has
en undeniably popular in the  last decades. From its  easy  manip-
ation to its  low-cost production, researchers have found  this
olecule very attractive  as a  carrier for  gene therapy  and DNA  vac-
nation. However,  this  conventional molecule is also known for its
itations comparatively to viral vectors, especially due to lower
pression efficiencies. Although  this  molecule is considered safer
an viral  vectors, it  still presents  prokaryotic sequences,  which
e essential  for the recombinant  pDNA production but  can confer
tibiotic resistance to the  patient and  elicit adverse reactions [1].
inicircle DNA  (mcDNA)  is  an  innovative non-viral DNA vector that
 currently  being presented  as an upgrade  to pDNA. The  production
 this  molecule requires  an original parental pDNA (PP)  molecule
at, upon specific induction, recombines to  form  two different
olecules: mcDNA and miniplasmid (mP). While mcDNA presents
e former PP eukaryotic sequences necessary for the expression
 the target  gene, mP  contains the prokaryotic sequences  required
r the selection of transformed bacteria and PP amplification [2].
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lso,  the  mP and PP  molecules  can present several I-SceI  restric-
on  sites that after  induction will be  recognized  and lead these
ecies to degradation [2].  Nonetheless, such in  vivo recombination
d  enzyme digestion is not 100% effective, rendering a  difficult
paration of  the mcDNA in its  supercoiled (sc) isoform from the
her  mP  and PP species, which present very similar  structures  and
quences. Up  to  now, the purification strategies established for
cDNA isolation  require the  manipulation and insertion  of spe-
fic  sequences in  the PP  backbone, to  improve selectivity, or the
ilization of enzymes, adding  more  costs to the whole process  and
eventing the use  of  such  techniques  in  other  PP  backbones  [3–5].
erefore, the  development  of  an universal strategy for the purifica-
on  of mcDNA stands  as a critical step  to  implement this promising
d  innovative DNA vector in the non-viral vectors therapeutic
ld.  So  far, Diamantino and  co-workers  described the single strat-
y  that has been published within  these specifications [6].  Such
ork  resorts to the use of  a CIM DEAE monolithic disk  for the
paration of  mcDNA through  the exploration of  ionic conditions.
owever, the recovery  yield of  this  strategy remains  in about 50%,
e  to  mcDNA elution in two different chromatographic steps [6].
 the  present work, it  is described the  size-exclusion  chromatog-
phy for  the isolation of  mcDNA  from  a complex lysate  sample,
aking use  of Sephacryl S-1000  SF matrix. This  matrix was chosen
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weight), which may  allow  the  separation  of  macromolecules suc
as genomic DNA  (gDNA),  PP  and mcDNA.
2. Material and  methods
2.1. mcDNA production
The ZYCY10P3S2T E.  coli strains harboring either  the pMC.CMV
MCS-EF1-GFP-SV40 PolyA vector (PP)  (System  Biosciences, USA
with a molecular weight of 7 Kbp, or  the  pMC.CMV-MCS-EF1
GFP-SV40 PolyA vector modified with the p53 insert  (PP 53),  wit
a molecular weight  of  8.2 Kbp, were cultured in  Terrific Brot
medium (20  g/L of  tryptone, 24  g/L of  yeast extract, 4  mL/L of  glyc
erol, 0.017 M  KH2PO4, 0.072 M  K2HPO4)  at  42 ◦C  for  PP  and  PP 5
production. Then,  for  mcDNA  formation  by  inducing the recombi
nation process, 0.01% L-Arabinose was added  and  the  culture wa
maintained for  3  h at 32 ◦C, as described by  Gaspar  and  co-worker
[2]. Once the induction was  completed,  cells  were recovered b
centrifugation and  stored  at  -20 ◦C.
2.2. Lysate preparation  and  mcDNA isolation
To retrieve a  complex mcDNA-containing lysate  sample, th
modified alkaline lysis method described by Diogo and co-worker
was performed [7].  The  resulting  lysate  sample was directly use
for the chromatographic assays, in order to isolate the mcDNA.
All chromatographic experiments were performed in  an AKTA
Püre system  (GE Healthcare,  Buckinghamshire, UK), consisting in 
compact separation unit and a personal computer with UNICORNTM
6.3 software. A 1.6 cm diameter column (bed height 60  cm) wa
used to pack 121  mL  of Sephacryl S-1000 SF  media.  An isocratic gra
dient was kept  with  10  mM Tris-HCl, 10  mM EDTA, 150  mM  NaC
(pH 7.00) buffer.  The sample was  injected directly onto  the  col
umn  (2  mL) and experiments were carried out between 0.2  an
0.45 mL/min,  at  room  temperature and the absorbance was contin
uously monitored at  260 nm.  Fractions were  recovered, accordin
to the chromatograms,  concentrated and desalted  with Vivaspin®
6 Centrifugal Concentrator (Vivaproducts, Littleton, MA, USA), fo
further analysis. All chromatograms were adjusted according t
the total  void volume and  excluded void volume.  Selectivity wa
calculated according  to  the  following equation:
 ̨ = tr2 − t0
tr1 − t0
2.3. mcDNA purity  and  recovery assessment
To assess the purity and  recovery  levels  of  mcDNA present in th
fractions collected from  the chromatographic assays (n = 3),  qPC
was performed in  a  CFX Connect Real-time  System  (Bio-Rad Labo
ratories, Hercules, CA). For PP detection, primers  were designed  fo
pUC19 origin (ColE1) (forward [fw]:  5’-TCCTGTTACCAGTGGCTGCT
reverse [rv]:  5’-AGTTCGGTGTAGGTCGTTCG), amplifying  a frag
ment of  151 bp. For  mcDNA detection,  primers were  designe
for the  GFP gene, (forward  [fw]: 5’- ATGGAGAGCGACGAGAGCGG
reverse [rv]:  5’- TTAGCGAGATCCGGTGGAGC), amplifying a  frag
ment of  759 bp. For  mP  detection, primers were designed  fo
the kanamycin antibiotic resistance gene, (forward  [fw]: 5
TCACGACGAGATCCTCGCCGTC; reverse [rv]: 5’- CGTTAGGTAGAA
CAAGTTAGTA), amplifying a fragment of 561  bp. A calibration  curv
for each set  of  primers in the range  of  0.5–50 ng/L  was  performe
with PP purified with NZYMaxiprep  commercial kit (NZYTech, Lis-
bon, Portugal), according to the manufacturer’s instructions. The
qPCR was  carried  out with 20 L  reactions containing 10 L  of SYBR
green mastermix, 3  M of  each primer  and  1  L  of DNA. Cycling
parameters were:  denaturation at  95 ◦C for 10  min; 35 cycles  of
70 togr. A  1609  (2020)  460444
denaturation at  95 ◦C  for 10 s, annealing at  60 ◦C for  30 s and exten
sion  at 72 ◦C  for 10  s. The content of  PP, mP and mcDNA  wa
calculated resorting to  the  calibration curve. For  mP and mcDNA
quantification, the PP was  subtracted, as similarly reported b
Mayrhofer and co-workers [3].
2.4.  mcDNA impurity assessment
For  gDNA  quantification  qPCR  was  performed  with  Maxim
SYBR  Green/Fluorescein qPCR Master Mix (Thermo Fisher  Scien
tific),  as described by  Sousa  and co-workers [8].  A  calibration
curve  in  the  range  of  0.005  to  50  ng/L was constructed b
serial  dilutions of  the E.  coli gDNA.  For endotoxin  detection
ToxinSensorTMChromogenic Limulus amoebocyte lysate assay ki
from  GenScript (USA, Inc.) was  used according to the  manu
facturer’s  instructions. A calibration curve was  constructed with
10  EU/mL stock solution provided by  the kit (0.005–0.1  EU/mL)
For  protein assessment, the  Micro-BCA (bicinchoninic acid) pro
tein  assay kit from Pierce (Rockford, USA)  was used, accordin
to  the manufacturer’s instructions. A calibration  curve was con
structed  with Bovine Serum  Albumin (BSA) as  standard protein
(0.01–0.1  mg/mL).
3.  Results  and discussion
With  the intent of  exploring the  Sephacryl matrix ability to iso
late  minicircle DNA, few conditions were initially tested. At  first
the  influence of  flow rate  was  evaluated by performing  the exper
iments  at 0.45 mL/min  and  0.3 mL/min. Such  flow rate range wa
selected  after  evaluating different studies performed with  simila
intentions. For  instance, Latulippe and  co-workers, studied the elu
tion  profile of differently sized pDNAs with  a  Sephacryl column o
35  mL [9].  In this work,  a flow rate  of 0.2 mL was applied.  However
Latulippe  results  suggest that low  flow  rates cannot guarantee th
isolation  of these  different pDNAs  due to  diffusivity and  pore acces
sibility  by  smaller plasmids [9]. This seemed  important,  considerin
the  fact  that  sc  mcDNA presents a smaller size than PP molecule
On  the other  hand, different  studies have been performed with
Sephacryl  for the  isolation of sc  pDNA from other  bacterial con
taminants  such as RNA or  gDNA,  which  are other impurities tha
should  be accounted for. While  Ferreira  developed a strategy with
a  19 mL  Sephacryl column for the isolation of a  4.8 Kbp pDNA a
0.5  mL/min, Li and co-workers studied the  use  of  a 180 mL  column
at  0.57 mL/min for  the purification of  a  7.07 Kbp pDNA  molecul
from  a complex sample [10,11]. Considering the flow rates  used in
previous  works,  it seemed logical  to experiment an  intermediat
flow  rate within the range  of  the flow rates  previously  presented
thus  the  0.45  mL/min was selected. Fig. 1A presents the  chro
matogram and  the respective electrophoresis, resulting from th
assay  performed  at  0.45 mL/min. Fractions  of  4 mL  were  recovered
throughout the  whole assay and  few  key fractions were  selected
according  to the  chromatogram, to  proceed for  electrophoresis. A
it  is perceived  from Fig.  1A, and  as expected  in size-exclusion chro
matography [9], most high weight or larger molecules began t
elute  in the  first fractions (peak I). Then,  mcDNA eluted  mostly in
fractions  4 and 5,  together  with some high  weight molecules (pea
II).  Then, a  large peak is  perceivable, composed  mainly by  RNA (pea
III,  fraction 10). The  electrophoresis allowed  the  identification o
the  species eluting in  each  peak. In I, it is  observed the main elution
of  gDNA and  PP molecules, in  peak II  the mcDNA elutes, followed
by  the  elution  of  small  molecules  such  as  RNA  in  III.  This  approach
only  allowed the recovery of  mcDNA co-eluting with other impuri-
ties.  Thus, to explore the effect of  the  flow rate on the separation of
biomolecules and  to  improve peak resolution, expecting a  conse-
quent  improvement on  mcDNA purity, the  flow rate  of  0.3 mL/min
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Fig. 1.  Establishment of  chromatographic conditions for mcDNA isolation  using the Sephacryl support. Main elution  peaks  are  marked as I, II and III. Chromatographic profile
an itions
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thd  corresponding electrophoresis of the selected fractions, using the following cond
 =85  mL;  B – flow-rate of  0.3  mL/min, sample loading of  4  mL and fractionation of  4
4  mL,  Vo = 38  mL; D – flow-rate at  0.3  mL/min, sample loading  of  2  mL and fractiona
as then tested. It  is  known  that in SEC the flow  rate  is  inversely
oportional to  peak resolution  [12,13]. Such  phenomenon derives
m the fact  that,  at high flow rates,  molecules  tend  to lose the
ility to diffuse in and out of matrix pores [12,13]. In Fig. 1B is
esented the chromatogram and  electrophoresis obtained in the
periment using 0.3  mL/min. Taking into  account that mcDNA
ution occurred in  peak II of  the  previous experiment (Fig.  1A),
e fractions chosen  for  electrophoresis were the  corresponding to
is part of  the  chromatogram. Here  it  is perceived that  most  of
cDNA-containing fractions were  less contaminated  than the  pre-
ous assay (fractions 6–8). However,  few adjustments were  still
cessary to  improve its recovery  with higher  purity. As these  pre-
ous assays were performed with  the  injection  of  4  mL of sample,
d given  the fact that  sample volume has  been shown  to affect
e resolution in  SEC [14],  the injection of  a  smaller volume  was
sted to  evaluate its  effect in mcDNA  isolation. Thus,  an assay  was
rformed with 2  mL  of  sample loading, using  0.3 mL/min  as flow-
te. In  Fig.  1C is  presented the corresponding chromatogram and
 electrophoresis.  As it  is perceived,  few impurities  are detected  in
e fractions where  mcDNA is mainly eluting  (fractions 9–11), sug-
sting that  the reduction  of the  sample volume was advantageous
r mcDNA isolation.  Nonetheless, the dilution factor  can  be consid-
ed a main  disadvantage of SEC, so  in  order to reduce this  effect and
ying to  recover  a purer and  more concentrated mcDNA sample,
e fraction  size of  the recovery  was modified. Thus,  as all  previ-
s assays were performed  with  4 mL fraction volume,  here it was
justed to  3 mL.  In Fig. 1D  is presented the  resulting chromatogram
d electrophoresis. Here,  it  can  be  perceived  with  more detail the
hole elution pattern  of the injected  complex sample. It  is  also
rified that mcDNA elutes  mainly  between the fractions 10–17,
t in  the  fractions 10–12  it is detected  a high level  of impurities.  A
mparative analysis of  the  selectivity  reached  with these different
romatographic conditions  was performed regarding  mcDNA sep-
ation from  PP. It was  found that  the highest selectivity  (4. 405)
longs to  the last  implemented strategy (1D), while the  lowest
lectivity belongs  to the  first strategy  (1A). This  data is  supported
 the  electrophoresis analysis,  where mcDNA seems to be  almost




sa: A – flow-rate of 0.45 mL/min,  sample loading of  4  mL and fractionation of 4 mL,
o =48 mL;  C – flow-rate at 0.3  mL/min, sample loading of  2  mL and fractionation
f  3  mL, Vo =40 mL.  IS  –  Initial Sample; Vo – Void Volume.
erefore,  fractions  13–17  were  selected  as  the isolated mcDNA
r  further  purity  and recovery analysis.
Impurity  levels  of  the  sc  mcDNA  retrieved from Sephacryl matrix
ere  analyzed. Although the  criteria  have been established  for
NA  product, they  can be  used as  a reference for the quality con-
ol  of  mcDNA samples,  due  to  their similar nature and function.
 this sample, gDNA  levels  were found at  0.002  g /g  mcDNA
d  endotoxins presented levels  of 11  EU/mg mcDNA, while  pro-
ins  and RNA were undetectable. These  data suggest Sephacryl
 able  to retrieve a pure  mcDNA sample, which  meets all the
purity criteria established by  the competent authorities,  such
 FDA (under  0.01 g /g  gDNA/pDNA, protein  and RNA  con-
nt  undetectable and under  40 EU/mg endotoxins/pDNA) [15].
e  low levels obtained for  these impurities might be related  with
e  fact that  Sephacryl presents  a broad  fractionation range. Con-
dering  the fact that most  proteins and RNA have  smaller sizes,
upled  with the  fact that  gDNA is  much larger  than the  remain-
g  molecules,  the  elimination of these impurities is not surprising.
e  large size of gDNA renders this  molecule  unable  to  interact
ith  the matrix pores,  thus first eluting  apart from  the molecule
 interest. On  the other  hand, proteins and  RNA, due  to its  smaller
ze,  are  able  to  enter  into  the  pores, retarding its elution com-
ratively  to mcDNA. In  fact,  other studies have  highlighted the
plication  of this matrix  for the  elimination of such  impurities
0,16].  The assessment of  the impurity  levels is crucial  when devel-
ing  a purification  strategy for a  recombinant therapeutic product,
ven  that  the presence of  such contaminants may  induce adverse
fects  which can potentially harm  the treated individual, by  caus-
g  inflammation, septic shock or organ failure  [17–19].
Also,  the  recovery (66% ±  4.37%) and purity (98.35%  ± 1.56%)
vels  of  mcDNA  in  comparison to other contaminants (PP and
P)  were  determined. These values were obtained as an average
 three  separated experiments, highlighting the  reproducibility of
is  methodology. To obtain such high purity  grade,  the  recovery
as  slightly  sacrificed  to  avoid mcDNA contamination with other
gh  molecular  weight  nucleic  acids,  similarly  to  other  studies  that
ve  been  designed  to  obtain  pure  and safe bioproducts. On  the
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40% with the use of an  arginine  monolith for  sc  pDNA isolation  [21
Considering the importance of  guaranteeing the purity  of the tar
get molecule  for therapeutic applications, sometimes having a ver
high recovery is secondary. Moreover, SEC strategies  usually con
tribute to higher  dilution levels coupled  with less recovery  yield
Thus, taking into  account the  complexity of  the sample and th
mcDNA novelty, perhaps can  be justifiable to  maintain the cur
rent purification strategy. Other  purification strategies have  alread
been established for mcDNA isolation, such as  the  work conducte
by Mayrhofer and co-workers or  Alves and co-workers  [3,4], but n
indication about  the  recovery yield of their processes are provided
Mayrhofer and  co-workers’  strategy,  which  is  based  on  the  use  o
affinity ligands for mcDNA  separation,  does  not allow the  separa
tion of  mcDNA from  PP  molecules, and  the efficiency of  the proces
totally depends on the complete recombination of  PP molecule
to form  mcDNA  and mP. Moreover, this  strategy also requires
the modification of PP backbone to include  the  affinity sequence
that will  be  the  target  for  the  recognition [3]. On the other hand,
Alves and co-workers’ study  presents the added  value of  separating
           
              
                  
     
72 
Fig. 2. Optimization of chromatographic conditions for mcDNA-p53 isolation. 2A – Ch
using the following conditions: A – 60 cm column, flow-rate at 0.3 mL/min and sample
loading of 2 mL, Vo =43 mL; C – 90 cm column, flow-rate at 0.3 mL/min and sample load
Initial Sample; Vo – Void Volume.togr. A 1609 (2020) 460444
mcDNA from other molecules  such as mP, PP and bacterial RNA  [4
However, this study describes  a  lengthy process which  requires  th
use of  enzymes before hydrophobic interaction chromatograph
(HIC). The use of  enzymes and  high  concentration of salts,  typi
cally associated with HIC,  can represent high costs in the industria
scale-up of  this process, thus retrieving  a  more expensive mcDNA
product. Nonetheless, other  mcDNA purification strategies hav
been also published.  Hou and co-workers,  established a  purificatio
strategy resorting  to magnetic beads which allows the separatio
of mcDNA from mP  and PP  [5]. Although it retrieves  a 94–95
recovery yield, it  requires the use of  streptavidin-coated magneti
beads and the modification of  PP backbone for affinity  separatio
[5]. Like the others,  this strategy can  also  be considered a  costl
approach to  scale-up for  industry. Notwithstanding, Diamantin
and co-workers later published  a  strategy using a CIM DEAE  com
mercial column  (BIAseparations) for mcDNA separation  from mP,
PP and bacterial RNA. Such study was pioneer in establishing a scal-
able process for  mcDNA  purification industry, without added costs
such as backbone  modification. However, the recovery  yield of  this
        
                   
                 
romatographic profile and corresponding electrophoresis of the selected fractions,
loading of 2 mL, Vo = 38 mL; B – 60 cm column, flow-rate at 0.2 mL/min and sample
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rategy is about 50%, which should  be  improved to lower the final
opharmaceutical price. More recently, a study  conducted by  our
search group demonstrated the  use of two  monoliths for mcDNA
rification, each  one  modified with either lysine  or  cadaverine
ands [22]. Following the first steps taken by Diamantino and co-
orkers, this work  was  designed with the intent of  being  applicable
 different mcDNAs,  without resorting to special modification of its
ckbone. In  this study, good  results were  reported for  cadaverine
odified monolith, which  was able to  isolate sc mcDNA  with 78.6%
covery yield  and  98.4% purity  [22]. Monoliths are  innovative chro-
atographic structures that have been  under  the  spotlight in the
te years, especially  due to the  possibility of performing  faster
says without  loss of  peak resolution. However, some limitations
ve been found.  For instance, monoliths are  prone to clog  with the
jection of more complex samples, mainly containing high content
 gDNA [23].  The  cadaverine-modified monolith strategy reports
e injection of  100 L  of  initial sample.  Although this strategy  is
uch faster than  the  one  described in the current study,  it  would
so require much more assays to obtain the same amount of pure
cDNA as a  sole assay  in Sephacryl matrix, considering  an assay
ith cadaverine monolith renders only 1.97 g  of pure sc mcDNA
hile an assay with  Sephacryl  renders 24.02 g  of  pure  sc  mcDNA.
us, from  an industrial point  of view,  the utilization  of Sephacryl
uld be cheaper in  terms of assays than cadaverine-modified
onolith. Nonetheless, cadaverine-modified monolith could be a
od approach to  explore for  the implementation of  an analytical
ethod for sc mcDNA assessment.
Thus, the  data reported  in the  present work, allied with what  is
scribed in  the literature,  suggest that  Sephacryl can  be a  lower
st isolation strategy  and an improvement  on what has  been pub-
hed so far regarding mcDNA  downstream processing.
Considering that  SEC strategy is  mainly dependent  on the size  of
e target  product, and  due to the  need to  characterize the  robust-
ss of  the process, it  seemed important to assess  its ability  to
parate mcDNA containing a gene of interest, given that the ini-
l tests were  performed  with  an  empty mcDNA vector and the
clusion of a  gene  will render a  larger  molecule. Thus, a complex
sate sample  of  mcDNA encoding  the p53 was  used. At first,  the
me conditions used for  mcDNA  empty  vector were applied for
cDNA-p53 isolation. In  Fig.  2A it is  presented the corresponding
romatogram and electrophoresis. As  expected, it was verified
e co-elution of  mcDNA  with high molecular weight  impurities
orresponding to PP 53) in a higher extent, when compared with
e empty  mcDNA sample, under the same  conditions. While  the
pty mcDNA vector  has  a molecular weight of  3.8  Kbp,  mcDNA-
3 has a  molecular weight  of  5 Kbp. The  fact that mcDNA-p53
s a larger size  may  hamper its isolation from other  contami-
nts, accounting that this  molecule will have less distribution to
e matrix  pores, than smaller  molecules, therefore, be more  prone
 elute concomitantly with larger molecules [24]. Thus, few adjust-
ents in  this  strategy were  still necessary in  order to improve  the
cDNA-p53 purity. As  previously  mentioned, the flow rate can
fect peak resolution [12,13], while the increase of the column
ight is also known to be an important factor  for  the  separation
 molecules with  similar weights. To  understand the contribution
 both parameters  in mcDNA-p53 isolation two assays were  per-
rmed. The first  one  consisted in the decrease of  the  flow rate to
2 mL/min  and  the  second one was accomplished in  a  new col-
n  containing Sephacryl S-1000 SF  matrix,  with  an increase of
% in  height, resulting  in 90 cm.  In Fig.  2B and  C are respectively
rtrayed the resulting  chromatograms and electrophoresis. The
sults achieved by  changing  the  flow-rate (2B) demonstrated that
e isolation of  mcDNA  was  improved. Actually, the co-elution of
gh weight molecules,  such as PP,  with  the mcDNA was  reduced, in
mparison with the  previous flow conditions (2A),  thus suggest-
g that  lowering the flow  rate can  improve the purity  of mcDNA.
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 Fig. 2C, given that the aim was  to  solely  study  the  effect  of  col-
n  height, the  flow was maintained at 0.3  mL/min and  the sample
ading  was  accordingly adjusted  to column volume  (1.65% of the
lume).  In  comparison  to  Fig.  2A  and  B,  here  it  is noticeable that
cDNA  appears  to  be  further isolated, suggesting that adjusting
e  column height might  be more important and practical  for the
olation  of  higher weight mcDNA molecules  than  lowering the
w.  Selectivity was  also analyzed for  mcDNA-p53 isolation from
-p53.  Although better  sc mcDNA  isolation is  perceived in  the elec-
ophoresis  with  the  increase  of  the column height and decrease
 flow rate, selectivity is lower under  these  conditions.  The  high-
t  selectivity value found was  3.49 for  the  60 cm  column coupled
ith  0.3 mL/min  flow rate (2A),  while  the lowest selectivity  was
und  for the  last strategy  studied (2C). The  low selectivity  results
 the loss of  peak resolution, which Latulippe and  co-workers  have
und  to decrease  at lower  flow rates  [9]. Although low peak res-
ution  is theoretically  undesirable, the  crucial aim  of this  work is
 recover the isolated target molecule. This  achievement is  proven
 electrophoresis and qPCR,  suggesting the low  resolution found
r  the target  peak does  not impair the  implementation of  this
rategy.
In  conclusion, the use of Sephacryl matrix might  be  a  suitable
rategy  to  isolate  different  mcDNA molecules, regardless their
ckbone  and without  resorting to  expensive clarification strate-
es  such  as  the use of enzymes, requiring  only the adjustment of
e  assay  conditions accordingly with mcDNA  size.
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a  b s  t r  a c  t
Minicircle  DNA (mcDNA) is  the  ultimate  non-viral DNA vector,  presenting  higher  biosafety  and thera-
peutic  effect  than conventional plasmid  DNA (pDNA). However,  given  the similarity  between  mcDNA
and  its precursor,  the  parental plasmid (PP),  analytical  methodologies  established for  pDNA  are unable
to  distinguish mcDNA from  PP.  Thus, a new  need  emerged for the  implementation  of  suitable, rapid
and  non-expensive  analytical methodologies  for  the characterization  of  mcDNA samples.  Recently,  our
research  group was  able to  develop a  purification  strategy for  the isolation  of supercoiled  (sc)  mcDNA
resorting  to cadaverine-modified  monolith. Considering  the promising  results obtained  with this  strat-
egy,  a  cadaverine-modified analytical  monolith  was prepared  and  explored for  mcDNA  quantification.
Thus,  a  strategy of  three-step  increasing NaCl  gradient  was considered  to  first elute RNA/protein  content,
then  isolate  sc  mcDNA and finally eliminate PP  and  other  impurities still bounded to  the  matrix.  A calibra-
tion  curve was constructed with different sc mcDNA  standards  within  a  range  of  1−25  g/mL. Linearity,
accuracy,  precision and  selectivity of  this method  were validated  according to  the international  guide-
lines  and  the  limit  of  detection  and  the  lower  limit of quantification were determined as 1 g/mL. For
the  first time, to  the best  of our  knowledge, an  analytical method  for mcDNA  quantification is  described.
Besides  ensuring the safety  of  mcDNA  application by assessing  the  product  purity, such methodology












establishment  of  optimized
 Introduction
Minicircle DNA (mcDNA) is a DNA  vector increasingly  consid-
ed in  gene therapy and DNA vaccines  in the  past recent  years.
ch acceptance  amongst researchers  is based on  the  fact that
is cutting-edge DNA technology renders  a molecule devoid of
okaryotic sequences, which are usually  associated  to  adverse
fects when  administered to patients. The  use  of  specifically mod-
ed E. coli  ZYCY10P3S2T cells  allows the PhiC31  integrase and
SceI endonuclease expression [1].  Upon  recombination induction,
iC31 integrase will  recombine parental plasmid  (PP) into  mcDNA,hile I-SceI expression will lead to the  degradation of  mP  and  unre-
mbined PP molecules, which present the I-SceI  sites.  However,  PP
sidues are still found at the  end of  this process,  most probably due
 its incomplete recombination and  digestion  [2].  So  far, no chro-
Corresponding author at: Centro de Investigaç ão em Ciências da  Saúde,  Univer-
ade da Beira Interior, Av.  Infante  D. Henrique, 6200-506 Covilhã,  Portugal.
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atographic methods for mcDNA analysis have  been  established
d  many difficulties have  been found by  scientists in establish-
g  chromatographic strategies for mcDNA isolation that do  not
sort to  specific modifications to the  backbone  of the PP  plasmid
 enzymatic digestions.
Taking into  account  the  growing  interest  of  the  biotechnolog-
al  research in the study and  application of sc mcDNA, it  has
come crucial to  develop suitable strategies  that can guaran-
e  the biosafety and  therapeutic effect  of this  biopharmaceutical,
nsidering its  prokaryotic production.  Besides the  importance of
onitoring the production/recombination, extraction  and  purifi-
tion of mcDNA throughout  the whole  process, in  the end  it is
cessary to  assure  the  purity and the host component levels  meet
e  specifications imposed by regulatory  agencies. Analytical meth-
s  developed so far for pDNA analysis do not present enough
lectivity towards the  sc mcDNA isolation from oc mcDNA  and
 and sc PP  isoforms. Beyond the  structural  similarities of both
cDNA isoforms and the PP isoforms, differing only  in  size,  mcDNA
so  shares  physicochemical properties,  as  it presents the same
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challenge for the  separation of these  species and, thus,  many effort
have been placed  into  exploring new chromatographic strategie
for mcDNA  purification [3–6].  As  a matter of  fact, our research  grou
has recently published  a study describing  the use  of cadaverine
modified monolith in  the  isolation  and  purification of sc mcDNA
from a clarified  lysate sample [2]. This  particular study yielde
sc mcDNA with 98.4% purity  and  78.6% recovery yield  withou
resorting to PP backbone modification or enzymatic digestion. Suc
analysis was performed by  resorting to real-time PCR,  which i
an expensive and  time-consuming methodology, especially whe
compared to  analytical  chromatography.
Considering the  potential demonstrated by  cadaverine
modified monolith in mcDNA  purification  and the  selectivit
achieved for  the  sc mcDNA isoform,  our research group  decided t
prepare a cadaverine-modified analytical monolith and study th
implementation of an analytical method for mcDNA quantificatio
(Fig. 1).  Thus, this  work describes the  validation of  a rapid  an
cheap quantitative methodology for sc  mcDNA, following  th
international guidelines  [7].
2. Materials and  methods
2.1. Different mcDNA  and  PP  vectors lysate production and
purification
To produce mcDNA,  PP  amplification was first carried  out a
previously described by Diamantino and co-workers [3]. E. co
strain ZYCY10P3S2T was  grown in  Terrific Broth  medium (20  g/
of tryptone,  24 g/L of yeast extract,  4 mL/L of glycerol, 0.017  M
KH2PO4, 0.072 M  K2HPO4) at 42 ◦C, 250 rpm.  Recombination of P
into mcDNA  was  induced through  the addition  of an  inductio
mixture containing 0.01% L-arabinose  diluted in LB  medium, sup
plemented with 0.04 M NaOH. Induction was carried  out  for 3 h  a
32 ◦C, before recovering cells through  centrifugation. To  prepare 
PP clarified  sample, induction step  was not  performed during  th
fermentation procedure. Clarified  lysate samples of  either PP  an
mcDNA were  prepared with the  modified alkaline lysis  protoco
described by  Diogo  and  co-workers [8], followed  by  a  desalting ste
with PD-10 desalting  columns (GE Healthcare,  Buckinghamshire
UK). This  procedure was applied  for the  preparation of three  dif
ferent mcDNA-PP pairs. First, the pMC.CMV-MCS-EF1-GFP-SV4
PolyA vector was used as the standard mcDNA-PP pair (3.8 Kb
and 7.06  Kbp). Then, the  same vector (pMC.CMV-MCS-EF1-GFP
SV40 PolyA) was  subjected to an  enzymatic digestion resultin
in a smaller mcDNA-PP pair  (0.88  Kbp  and  4.88  Kbp). Moreove
a new insert (p53  gene)  was  included in the standard vecto
(pMC.CMV-MCS-EF1-GFP-SV40 PolyA),  allowing  the preparatio
of a larger  mcDNA-PP pair (5  Kbp  and 8.2 Kbp). To  achieve  a s
mcDNA purified sample,  a  strategy  previously implemented wit
cadaverine-modified monolith was used [2].
2.2. Cadaverine modified  analytical monolith preparation
A cadaverine-modified analytical monolith was prepared  a
described by  Almeida and  co-workers [2].  Briefly, a cadaverine  lig
and (Alfa  Aesar,  Karlsruhe, Germany) was  immobilized on  a  0.1  m
bed volume  of  a Convective Interaction Media (CIM®)  analytica
epoxy chromatographic monolith (CIMacTM),  provided  by BIA Sep
arations (Ajdovščina,  Slovenia). Cadaverine  hydrochloride (0.6  g
was dissolved in  water  (3.5  mL), followed by 5  M  NaOH addition to
adjust pH to 10.5.  Afterwards,  2  mL  of  ethanol  was added, followed
by pumping of the reagent through the monolith channels. Then,
the monolith was incubated  together  with  the  immobilization solu-
tion for  48  h at  60 ◦C.  The quenching of  the remaining epoxy  groups
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was  carried out with 0.5 M H2SO4 (5  h  at 65 ◦C),  followed by wash
ing  the  monoliths with water and storing  them  in  20%  ethanol.
2.3.  Analytical chromatographic assays
All  chromatographic experiments were carried out using  an
AKTA  Pure  system (GE Healthcare, Buckinghamshire, UK),  with  
computer  unit controlled by  UNICORNTM 6.3  software. For DNA
standards, samples were  prepared by consecutive  dilution of 
stock  sc  mcDNA sample with  the  equilibration buffer used in
the  chromatographic experiments. All  final  concentrations wer
confirmed with Ultrospec 3000  UV/Visible Spectrophotomete
(Pharmacia Biotech,  Cambridge, England). The  conditions used t
explore  the  implementation of  an  analytical  method  were  based
on  a  mcDNA  purification strategy previously developed by  ou
research  group with cadaverine-modified monolith  [2].  Thus, th
analytical  monolith  was  first  equilibrated with 1.07 M  NaCl  in
10  mM Tris-EDTA buffer  (pH 7.0), followed  by sample injection
(50  L). After  washing out  the unbound species, namely  RNA, 
salt  increase  adjustment to  1.16  M NaCl in 10 mM Tris-EDTA buffe
(pH  7.0) was performed,  for mcDNA elution.  Flow-rate was kep
at  1 mL/min  and UV was monitored  at 260 nm.  Then, to  elut
strongly  bound  PP and other molecules with  higher  molecula
weight,  salt  concentration was increased to 1.3 M NaCl in 10 mM
Tris-EDTA  buffer  (pH  7.0). All experiments were performed at  room
temperature (≈25 ◦C),  a  parameter  that  was  simultaneously mea
sured  together with the conductivity. The conductivity contro
demonstrated to be  crucial, given that it  highly influences mcDNA
selectivity.
2.4.  Agarose gel electrophoresis
All  the  recovered fractions were  desalted and concentrated t
200  L, by  Vivaspin® 6  Centrifugal Concentrator (Vivaproducts,  Lit
tleton,  MA, USA),  before injecting  them onto  the electrophoresis
The  agarose gel was  prepared for  0.8%, stained with  0.016 L/m
Greensafe  premium (NZYTech, Lda. - Genes and Enzymes, Lisbon
Portugal),  and the horizontal  electrophoresis was  carried out a
110  V for  30 min in  TAE buffer  (40 mM  Tris base,  20 mM  acetic acid
and  1  mM  EDTA,  pH8.0),  before  visualizing the gel under UV  ligh
in  a  Vilber  Lourmat system (ILC Lda, Lisbon,  Portugal).
3.  Results  and discussion
The  establishment of an  adequate  analytical method for  th
purity  assessment of a  biotechnological product, such as mcDNA
must  comprise the validation  of different parameters [7]. Mono
liths  are  becoming the new standard in chromatographic columns
offering  the possibility of  establishing  fast methods with  separation
independent of flow  rate. These features  are a  consequence of th
monolith  continuous bed and its interconnectivity between chan
nels,  which allow fast mass  transfer and increased accessibility o
the  target molecule  without loss  of peak  resolution [9].  Given th
lack  of analytical methodologies developed for  mcDNA, the discus
sion  will  be  carried out by taking into account analytical method
established for pDNA quality assessment.
3.1.  Selectivity
Considering the fact that the isolation of  sc  mcDNA with
cadaverine-modified monolith had already been  established [2],  w
decided  to explore the potential  of  this chromatographic strategy
as  an analytical  method, but in this  work, the loading volume was
adjusted  from 200 L to 50  L  to decrease the  amount of  sample
spent  per  assay. First, it was  assessed the selectivity of  the  analytical
monolith  modified with  the  cadaverine  ligand.  The  target  molecule

































































. 1.  Graphical representation of  chromatographic analytic method  for the  mcDNA as
lumn.
ould be distinguished from all  other  contaminants present in
e sample, especially PP. To verify the selectivity of cadaverine
alytical monolith, three chromatographic experiments were per-
rmed with a mcDNA-containing lysate sample (also presenting PP
d other bacterial impurities, such as gDNA,  RNA,  proteins,  etc),  a
-enriched lysate  sample (containing PP  and  other bacterial impu-
ties, but  in  the  absence of mcDNA), and  a  blank  sample. The blank
as performed by injecting the buffer used  for  the preparation of
e standards  (10  mM Tris-EDTA pH  7.0).
In Fig. 2
are represented the  respective chromatograms corresponding
 each  sample: mcDNA lysate  (2A), PP  lysate (2B)  and blank  (2C).
 portrayed  in Fig.  2A  and 2B,  after injection of  50 L  of  sample,
e RNA  present in  each  lysate is  eluted in the  first step at  1.07  M
aCl (peaks  1 and 4).  There is a small  peak, of similar  size, present
 all  three chromatograms (including blank) at  16.05–16.10 min,
st after the  second  step gradient application, which  is  considered
 be a consequence of an absorbance disturbance due  to a sudden
ffer change. Such phenomenon has  been observed in other  stud-
s [10]. Then, different chromatographic profiles  can be  observed
tween the different samples.  The chromatogram of the  mcDNA
sate (Fig.  2A) presents  only one  peak (2) at  retention time  (RT) of
.34 min, occurring  in the second-step  of the gradient  at 1.16 M
aCl and  corresponding to  mcDNA elution,  as observed in  lane 2
 the electrophoresis. However, PP lysate (Fig. 2B) reveals only a
ak (6), at RT  =19.84 min, which  does not  present nucleic  acids
ution, as  verified in lane  6  of electrophoresis. Interestingly, the
cDNA peak does  not begin  to elute  immediately after the step gra-
ent application, but  it  is  delayed  for  approximately 2  min (from
.1 to  18.3 min).  This  might be  related to the  fact that a  small salt
creasing step  (from 1.07 to 1.16  M NaCl) creates  a  semi linear
adient conditions, in  the middle  of which  the mcDNA  content
utes. Finally, PP  molecules are  eluted in  the third-step  gradient
rformed at 1.3  M  NaCl,  as perceivable for both  mcDNA and  PP
sates (peak 3 and  lane 3 of  Fig.  2A and  peak 7 and  lane 7 of  Fig. 2B,





peent  from E.  coli lysate  samples with  the cadaverine-modified analytical  monolithic
cDNA lysate. This  is explained by the  fact  that in the  mcDNA-
ntaining lysate, most  of  PP content belonging  to mcDNA lysate
s  been  recombined into mcDNA, thus  reducing the PP  content.
oreover, molecules  of  high molecular weight, such  as gDNA, are
ncomitantly eluted  with PP (Fig.  2A and  2B). Therefore, it  can be
ncluded that this analytical method presents selectivity  towards
cDNA, as it had been previously verified  [2].
2.  Linearity
The  establishment of  an  analytical method  for mcDNA quantifi-
tion started  with linearity assessment. Thus,  the  injection of six
fferent mcDNA concentrations was  performed under the  chro-
atographic conditions previously  established. A standard curve
as  prepared  by using 3 replicates  of  6 known mcDNA  concentra-
ons  (1,  2.5,  5,  10, 17.5 and 25 g/mL).  In  general,  pDNA  standard
rves used in  the implementation of analytical  methods present
gher concentrations than the ones selected for  this  study.  For
stance, Mota  and co-workers  even performed a  study consid-
ing  two  different ranges (2−20 g/mL  and  20−200 g/mL) for
fferent applications  [11]. However, in the current scenario, sc
cDNA content in lysate samples is  much  lower  than  the  amount
 pDNA  usually observed. Besides the fact that this  is  a  smaller
olecule, its  production results  from an  induction process where
tal  PP recombination does  not  occur, implying a lower mcDNA
al  content. The  standards were  obtained by  diluting a stock
cDNA solution  with 10  mM Tris-EDTA pH  7.0, also used  to prepare
e  chromatographic buffers.  The calibration curve was determined
 calculating the peak area  correspondent to the mcDNA elution
T  = 18.34),  obtained in the second-step  gradient of each chro-
atogram (all  raw  data is available in  Supplementary  Information
.  The obtained calibration  curve, with the equation  Y  = 0.9416
 – 0.2781,  presented a correlation coefficient of 0.999 (the  curve
 available in  Supplementary Information  2). In Fig.  3 the mcDNA
romatographic peaks  are shown for  all prepared  standards. The
ak  of  interest increases proportionally with the  concentration
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Fig.  2. Selectivity evaluation employing  cadaverine-modified chromatographic  col-
umn.  Chromatographic runs performed with 1.07 M  NaCl  in  10  mM Tris−HCl/EDTA
(pH  7.0,  91.01  mS/cm), followed by  1.16  M NaCl in 10 mM  Tris−HCl/EDTA (pH 7.0,
96.72  mS/cm) and 1.3  M NaCl in  10  mM Tris−HCl/EDTA  (pH 7.0, 106.2  mS/cm). A
–  Chromatographic run of mcDNA clarified lysate  sample,  containing also PP and
other  bacterial impurities (gDNA, RNA,  proteins, etc). B  – Chromatographic run  of
Table 1









CVb (%) Mean relative
Errorc(%)
25  24.97 0.43  1.71 0.14
17.5  17.84 1.51  8.49 1.93
12.5  12.02 0.60  5.03 3.87
10  9.45 0.12  1.24 5.49
5  4.97 0.26  5.22 0.60
2.5  2.67 0.01  0.35 6.83
























80 Calibration curve used  (y  = mx +  b): m =  0.9416; b = - 0.2781; R2  =  0.999.
b Coefficient of variation.
c ([(Measured concentration)−(nominal concentration)]/(nominal concentra
tion)) x 100.
increase.  A “ghost” peak with  RT of 16.01 min,  described in Fig. 2C
due  to the buffer exchange,  is observed in  all  samples indepen
dently  of the mcDNA  concentration. The  correlation coefficien
of  0.999  meets  the  values found for correlation coefficients o
other  established pDNA  quantification methods,  therefore it can
be  concluded that the  linearity requirement was  met  by this chro
matographic strategy [11–15].
3.3.  Accuracy
Accuracy  was determined by  back-calculating the concentration
of  each standard, using  the equation provided  by the  calibra
tion  curve. Also, an  intermediate concentration, that  was not used
for  the construction of  the calibration curve,  was  back-calculated
(12.5  g/mL). In Table  1  it is presented the  mean concentration val
ues  found for each nominal concentration (3 replicates), followed
by  the corresponding standard  deviation, coefficient of variation
(CV)  and  mean  relative error. Through Table 1 analysis, we  are  abl
to  infer that the  lowest nominal concentration  (1 g/mL) present
the  highest mean relative error  (10.19%),  as well as the highest coef
ficient  of  variation (10.02%). On the  other hand, the lowest  mean
relative  error  (0.14%) was calculated for  the highest nominal con
centration (25  g/mL) while the lowest coefficient of  variation  wa
presented  by  2.5 g/mL  standard (0.35%). Mota and  co-worker
were  able to establish  an analytical method for sc  pDNA quan
tification  by  resorting to a CIM  DEAE  monolithic disk [11]. In  tha
study,  the coefficients of  variation for accuracy  were found to var
between  0.65% and 3.68%, while the mean relative error was  found
in  a  range  from  0.19% and 2.25%. Although higher coefficient of  vari
ation  and mean relative error  values were found  in  our study, both
are  within the ± 15%  range accepted by the  established  guideline
[7].  Nonetheless, in the current work, a lower nominal concen
tration  (1 g/mL)  was studied in  comparison to  other established
analytical  methods (2 g/mL) [11,13]. These  results are in agree
ment  with data found in other  similar  studies, as for instanc
the  work  developed by Quaak and co-workers, whom established
a  methodology for the quantification of sc  pDNA  pDERMATT  b
resorting  to a TSKgel DNA-NPR analytical column  [14].
3.4.  Limit  of detection and limit of quantificationTable  1 also  allows to  infer the  sensitivity of  the method by
determining the  lower  limit of quantification (LLOQ), which  rep-
resents  the  lowest mcDNA concentration that  can be assessed with
PP clarified  lysate sample, containing PP and  other bacterial impurities  (gDNA, RNA,
proteins, etc)  but  without mcDNA, with  respective electrophoresis. C – Chromato-
graphic run of blank sample  (constituted of 10 mM  Tris-EDTA pH 7.0).
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Fig.  3.  mcDNA  linearity assessment. Second  step profile obtained for  6  sc mcDNA
standards  with the concentration of  1,  2.5, 5,  10, 17.5 and  25 g/mL.  Chro-
matographic  runs  performed  with  1.07  M NaCl in 10 mM Tris−HCl/EDTA (pH
7.0,  91.01 mS/cm), followed by  1.16 M  NaCl in  10 mM  Tris−HCl/EDTA (pH 7.0,
96.72  mS/cm) and 1.3 M  NaCl  in  10 mM Tris−HCl/EDTA  (pH  7.0, 106.2 mS/cm).
Table  2









CVb (%) Mean relative
Errorc (%)
17.5 16.54  0.60 3.60 5.48
5 5.00  0.04 0.90  0.01
2.5 2.67  0.01 0.35 6.83









































CVb (%)  Mean relative
Errorc (%)
17.5 17.13 0.90  5.27 2.10
5  5.04 0.06  1.11 0.70
2.5  2.67 0.20  7.59 6.74
a Calibration curve used (y  =  mx +  b): m =  0.9416; b = - 0.2781; R2 =  0.999.
b Coefficient of variation.
c ([(Measured concentration)−(nominal concentration)]/(nominal concentra-
tion)) x 100.
Table 4
Assessment of  sc  pDNA in lysate  samples enriched with sc  pDNA in different con-









CVb (%)  Mean relative
Errorc (%)
10 10.76 0.14  1.31 7.60
5  5.60 0.25  4.45 12.02





































concentration through peak area,  as performed  for the  accuracyCoefficient  of  variation.
([(Measured  concentration)−(nominal concentration)]/(nominal concentra-
n))  x  100.
itable precision and adequate accuracy  (± 20%  of the nomi-
l concentration)  [7].  Taking into account the data displayed in
ble 1, it  is possible to establish the LLOQ of this  strategy as
g/mL, which presents  a coefficient of  variation of 10.02% and
ean  relative error of 10.19%, lower than the 20% limit  range
cepted by  the  guidelines. The limit of detection (LOD), which is
scribed by the guidelines  as a signal-to-noise ratio of 3:1 between
e measured signals of  known  low mcDNA concentration sam-
s and the  blank samples,  was also  determined. This  allows to
tablish the minimum concentration  limit at which mcDNA can
 detected [7]. Thus,  the chromatogram of  Fig. 2C, correspond-
 to  the blank sample, was integrated and a  comparative  analysis
s performed  between  the peak area of  this  assay and the peak
a observed  for the lowest standard  at  RT of 18.34  min. Since the
nk did not present  any  peak corresponding to  this RT, it was
ssible to  identify 1 g/mL  as  the LOD for this  method,  similarly
what was described  by  Diogo and  co-workers  [12]. Despite the
t that the same  LOD was verified  for both  studies, Diogo’s work
s implemented for total pDNA  quantification, and this concen-
tion would  correspond  to  both  sc and oc isoforms. In the  current
dy, however,  this  LOD was observed for mcDNA exclusively in
conformation.
. Precision
To  evaluate the precision of this analytical method, repro-
cibility and  repeatability studies were  performed  according to
e guidelines [7].  The  repeatability (or  intra-day) assessment for
DNA quantification is  shown in Table  2.  Three different stan-




tioCalibration curve used (y  =  mx +  b): m =  0.9416; b =  -  0.2781; R2 =  0.999.
Coefficient of variation.
([(Measured concentration)−(nominal concentration)]/(nominal concentra-
n)) x 100.
peatability. As presented in Table 2, the standard with  highest
ean relative error  was 2.5 g/mL  (6.83%) and the  standard  with
ghest variation was  17.5 g/mL  (3.60%). Such values  are very
se to  the ones found by Sousa  and co-workers,  6.86% and  3.45%
spectively, who  were able  to develop an  analytical method  based
 arginine-affinity chromatography for  oc and sc pDNA isoform
paration [13].  Thus, both values  remain below the  15%  range
cepted by  the guidelines,  consequently highlighting the  repeata-
ity of  this analytical method [7].  On the  other  hand, in  Table 3
is portrayed  the method’s reproducibility (or inter-day)  eval-
tion. To assess  this  parameter, three different standards were
jected throughout three  different days. In  Table 3,  it is possible  to
alyse that  the standard with highest mean  relative error  (6.74%)
d highest  coefficient of  variation (7.59%) was  2.5 g/mL.  Again,
ilar values were  found by  Sousa and co-workers  (4.03% and
3%, respectively) [13]. These  values remain  below the 15%  range
cepted by  the guidelines, therefore  suggesting this  analytical
ethod is  reproducible. Thus, both reproducibility and  repeatabil-
 studies  prove and emphasize, respectively, the precision and
curacy presented by  this  method for mcDNA quantification.
. mcDNA assessment  in  process solutions
After completing  the validation of  the method through  these
fferent required parameters, it was  necessary to  evaluate in  a
ore real context  the  ability of this chromatographic strategy to
sess mcDNA  content in a complex sample.  In order  to verify  this,
 clarified lysate  samples were prepared and  supplemented with
own amount  of purified  sc mcDNA  to  obtain known mcDNA
ncentrations in a complex  sample  (2.5,  5 and 10  g/mL). The
spective chromatograms (4A) and electrophoresis (4B) are col-
ted in  Fig.  4. As it  is  perceivable, RNA  is  promptly eluted  in  the
st step, followed by  mcDNA  elution  in  the  second step and elu-
n of  high-weight molecules (PP) in  the third  step. Each of  these
says were  performed three times  for  the assessment of  mcDNAdies. The back-calculated concentrations are gathered in  Table 4.
e standard with the  highest  mean  relative error (12.02%) was
g/mL,  while the standard presenting highest  coefficient  of varia-
n (10.04%) was  2.5 g/mL.  Mota and co-workers  obtained similar
81 























































Fig. 4.  Chromatographic profile and  electrophoresis of the PP  clarified  E. coli
lysate supplemented with  known mcDNA concentrations in the  cadaverine-
modified monolith.  Chromatographic runs  performed with  1.07 M NaCl  in 10 mM
Tris−HCl/EDTA (pH  7.0, 91.01  mS/cm), followed by 1.16 M NaCl  in 10 mM
Tris−HCl/EDTA (pH 7.0,  96.72 mS/cm)  and 1.3  M NaCl  in 10  mM Tris−HCl/EDTA (pH
7.0, 106.2 mS/cm).  A)  Chromatographic runs for PP clarified lysate  sample  supple-
mented with 2.5,  5  and 10 g/mL.  B)  Agarose gel  electrophoresis of the different
peaks. Lane IS  2.5 g/mL –  Initial Sample of  PP  lysate supplemented with 2.5 g/mL;
Lane 1–3 -  Samples corresponding to  the respective chromatographic peaks; Lane
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values (8.94% and 11.26%, respectively) to the ones obtained in thi
study [11]. Such high values might be related with the fact tha
these samples present a more  diversified  content,  due  to  the pres
ence of several host impurities. Nonetheless, both values remai
below the 15%  limit  range accepted by the  guidelines, therefore sug
gesting this  analytical method can  be  reliably applied in  a  comple
mixture. Besides proving  its  application, this assay highlights th
selectivity presented by this  analytical method  for sc mcDNA  quan
tification. Such feature, coupled with  the novelty  of this  mcDNA
study, underlines the  potential of cadaverine as  an amino-aci
derivative affinity-chromatography ligand [16].
Further applicability of the  discussed methodology was teste
in the mcDNA lysate sample, such as the one presented in Fig. 2A
This technique has  potential in  Process Analytical Technology  (PAT
for monitoring the  amount  of  mcDNA  and  impurities in laborator
and/or industrial upstream and downstream processing. To quan
tify the amount  of  mcDNA present in the sample  it  is  essential t
use the calibration curve previously obtained, while relative nuclei
acid purity is assessed by  calculating  the  area  percentage of mcDNA
peak versus  the total area  of  all found peaks.  By using this  approach
it was possible to  quantify  the  presence of 8.9 g/mL sc mcDNA an
determine a  purity  of  3% in the chromatographic run  correspondin
to Fig.  2A. Such low  purity was  expected, accounting for the  pres
ence of RNA and PP in  the  lysate  sample.  This  result reassures th
standard curve range was  suitably  selected,  considering this resul
is within its range  (1−25  g/mL).
3.7. Robustness
The fact  that this strategy requires the  use of  a very specific ioni
strength for  mcDNA isolation, suggests  that this approach  is indee
very sensitive and  selective. In the beginning of  this  study it wa
found that temperature,  together  with the buffer  ionic strength
can affect the final conductivity, increasing  the  mcDNA molecule
retention as a consequence of the temperature increase. This le
to the close  monitoring  of  the temperature throughout all assay
by working in  a controlled and  climatized room, with  the inten
tion of keeping  it at 25 ◦C.  This allowed to  achieve reliable result
between different assays. Nonetheless, the composition and struc
ture of the  target  molecule can also interfere with  such selectivit
[17]. For  example, a comparative study  based on the  injection o
different oligonucleotides (differing in  size and composition) i
different amino  acid-based chromatographic matrices (histidine
arginine and lysine)  has  shown that each  one of these  ligands inter
act differently with  the  diverse  oligonucleotides [18]. Also, for th
same ligand, different  retention patterns were achieved  for  th
oligonucleotides in  study,  depending on their size and bases com
position [18].  Thus, it could be  supposed that the selectivity  of th
ligand and the  applicability of the present method  could  be depen
dent on  the features of  the mcDNA molecule.  To further prove  th
robustness of  the methodology described  in this study,  a  compari
son between  mcDNA vectors  with different  sizes and  compositio
was performed. In  Fig.  5A the chromatogram and  respective elec
trophoresis of a  mcDNA molecule with  0.88  Kbp is  presented, whil
in Fig. 5B  the  chromatogram and respective electrophoresis of 
mcDNA molecule with 5 Kbp  is  shown. The same chromatographi
conditions were  used  for 0.88 Kbp and 5  Kbp  mcDNA,  as the
were established for 3.8  Kbp.  In  Fig. 5A, isolation of  the  0.88 Kb
sc mcDNA was  achieved  with some sc  PP contamination, whil
in Fig.  5B the recovery of 5  Kbp sc  mcDNA together with som
sc and  oc PP  content was verified in the  main peak  2. For  bot
assays, the electrophoresis suggests no loss of mcDNA, since all
mcDNA content  is found in  the second step  of the gradient  (peak
2). These  results underline  the applicability of cadaverine as a  lig-
and for mcDNA isolation, but small adjustments may be required
and can  be performed when  working with different  mcDNA sam-
82 Samples corresponding to  the respective chromatographic peaks;  Lane IS  10 g/m
– Initial Sample of  PP lysate supplemented with 10 g/mL;  Lane  7–9 - Samples cor
responding to  the respective chromatographic peaks. C)  Chromatographic run fo
mcDNA lysate sample for  mcDNA  content assessment.
ples  to  maintain the same purity degree. However, the  selectivity o
cadaverine ligand towards mcDNA  isolation is undeniable given it
ability  to  isolate two extremely different mcDNAs (with a 5  time
size  difference) under the  same exact chromatographic conditions
To  the best  of our  knowledge, it is  also the  first time  that it i
reported  a  comparative  study  of  the  behaviour of  mcDNA molecule
with  different  sizes  and composition, through the use of the  sam
purification strategy.4.  Conclusion
In  this work, a  new methodology for  mcDNA quantification
and  analysis  is  proposed, resorting to a chromatographic strategy
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Fig. 5.  Chromatographic profile and electrophoresis of the clarified E. coli lysate  of  differently  sized  mcDNA  molecules injected in the  analytical cadaverine-modified monolith.
Chromatographic runs performed with  1.07 M  NaCl in 10  mM Tris-HCl/EDTA (pH  7.0,  91.01 mS/cm),  followed by 1.16 M NaCl in  10 mM  Tris−HCl/EDTA  (pH 7.0, 96.72  mS/cm)
and 1.3 M  NaCl  in 10 mM  Tris−HCl/EDTA (pH 7.0,  106.2  mS/cm). A)  Chromatographic run for 0.88  Kbp  mcDNA clarified E.  coli  lysate and corresponding electrophoresis. B)























at had been previously established  for mcDNA isolation  with
daverine-modified chromatographic monolith.  Linearity, preci-
on and accuracy were proven  suitable  within  1–25  g/mL mcDNA
ncentration range  and  the  LLOQ  and LOD were established as
g/mL.  Supplementation studies  demonstrated the applicability
 this method for  mcDNA  quantification in a complex mixture.
so, for  the  first  time, different mcDNA –  PP  size  pairs (with mcD-
As presenting  a  size varying from 0.88  to  5  Kbp)  were analysed
der the same  chromatographic conditions to  assess its  elution
ndency, demonstrating the  robustness  of  this  new analytical col-
n.
This study  demonstrates for  the first  time the development of
mcDNA quantification chromatographic methodology employing
M chromatographic monoliths  that  can  be  gently adjusted to  suit
si
V
refferent mcDNA –  PP pairs. Contrarily to expensive  qPCR methods
at  have been currently  used for mcDNA  analysis/quantification,
is  strategy  is  more  economic  and  less  time-consuming, especially
hen  it is  necessary to control  mcDNA production and purification.
ch  achievement might represent  in  the future a useful tool  for
e  biotechnological industry regarding the  preparation of mcDNA
opharmaceuticals.
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The link between the infections caused by Human Papillomaviruses (HPV) and the 
development of cervical cancer has long been established. HPV high risk types such as 
HPV16 and HPV18 express E6 and E7 oncoproteins, which interfere with cell cycle 
regulation and repair mechanisms by downregulating the expression of tumor suppressors 
such as p53 and pRB, respectively. Due to this problematics, researchers have been 
focused on innovative treatment options, and the interest in silencing harmful proteins 
has been rising. Minicircle DNA (mcDNA) is a new vector whose efficacy has been proven 
to be higher than the highly studied plasmid DNA (pDNA). This work describes the 
preparation of a mcDNA encoding the pri-miR-375 gene, aiming to increase the microRNA-
375 (miR-375) expression in cervical cancer cells to silence HPV E6 and E7 oncoproteins. 
E6 and E7 transcript levels were assessed and found to be nearly 80% diminished 24 hours 
after transfection of CaSki cells, a HPV16-infected cervical cancer model. Proliferation 
studies demonstrated growth arrest for CaSki cells throughout 72 hours, while viability of 
these cells was also found gradually decreasing for the same time period. Moreover, a 
comparison between mcDNA and its parental plasmid, the pDNA molecule which 
originates mcDNA, demonstrated that mcDNA displays higher effect on E6 and E7 
transcripts silencing, proving the increased efficacy of this cutting-edge non-viral DNA 
technology. These results suggest that mcDNA-pri-miR-375 has potential to be further 









Cervical cancer is a health problem common to a variety of countries, especially 
underdeveloped ones. Due to lack of health conditions and appropriate vaccine distribution, 
Eastern and Central Africa remain as the regions most affected worldwide [1]. Human 
Papillomavirus (HPV) plays a crucial role in cervical cancer development. In fact, HPV DNA has 
been detected in between 79% to 100% invasive cervical cancer cases worldwide [2,3]. The 
presence of such viral genome leads to the expression of E6 and E7 oncoproteins, which in turn 
are responsible for the impairment of cell regulation and proliferation mechanisms [4,5].  These 
oncoproteins interfere with important tumor suppressor proteins such as p53 and pRB. While 
E6 is responsible for the low p53 levels by inducing its degradation, E7 binds to pRB inactivating 
its function as E2F transcription factor regulator [4,5]. Thus, considering the relevance that E6 
and E7 have in cervical cancer development, current therapeutic strategies are mainly focused 
on targeting these proteins [1].  
 
One approach that has recently been gaining a lot of attention is gene silencing. Many efforts 
have been placed to explore the silencing of these harmful proteins through the use of artificial 
RNA vectors, such as small-interfering RNA (siRNA), or gene editing technologies, such as 
clustered regularly interspaced short palindromic repeats (CRISPR) [1]. However, increasing 
attention has been given to the use of microRNAs (miRNAs) for such goal. MiRNAs are small non-
coding RNA molecules, which have been proved to regulate cellular mechanisms, by regulating 
gene expression at post-transcriptional level. These are first naturally expressed as primary 
miRNA transcripts (pri-miRNA) in the nucleus, followed by processing into precursor miRNA 
(pre-miRNA) before being transported to the cytoplasm to be processed into mature miRNA 
(miR) [1]. In the cytoplasm, miRNAs associated to the RNA-induced silencing complex enable 
the recognition of mRNAs whose nucleotide sequence is complementary to the miRNA [6]. Then, 
accordingly to the complementary level displayed between mRNA and miRNA, the targeted 
mRNA molecule can be inactivated or degraded [6,7]. MiR-375 is a miRNA which has been  found 
down-regulated in cervical cancer [8]. In fact, different studies performed under this context 
have unveiled the potential of miR-375 as a therapeutic tool for cervical cancer: the 
overexpression of this miRNA leads to the decrease of E6 and E7 mRNA and protein levels, 
consequently increasing the p53 and pRB tumor suppressor levels and interfering with the 
proliferation and invasion of HPV-infected cancer cells [8–10]. Thus, the study of such approach 
as a therapeutic treatment for cervical cancer seems very interesting and promising. 
  
Minicircle DNA (mcDNA) is an innovative non-viral DNA vector, which is considered safer and 
more effective than the popular plasmid DNA (pDNA) [11]. This molecule is devoid of bacterial 
sequences, presenting only the eukaryotic genes necessary for therapeutic purposes. Such 
structural feature is accomplished through the production of a parental plasmid (PP) molecule, 
which presents both prokaryotic and eukaryotic sequences required for its production in 
bacteria, and for the therapeutic effect, respectively [11,12]. However, the PP molecule can 
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be recombined into two different molecules, originating the miniplasmid (mP), containing the 
prokaryotic sequences, and the mcDNA molecule, containing the eukaryotic sequences [12]. 
The elimination of the prokaryotic sequences renders mcDNA as a smaller molecule, which 
facilitates its entry into the targeting cells. Moreover, the lack of these bacterial sequences 
increases the expression of the target gene, considering the fact that these sequences have 
been proven to silence the expression of pDNA due to the formation of repressive 
heterochromatin [13]. Consequently, mcDNA displays higher expression levels than the 
conventional pDNA, which can consequently contribute to different therapeutic outcomes [14–
16].  Therefore, this work consisted in the construction of a mcDNA vector able to encode the 
pri-miR-375 for further assessment of its potential in decreasing the expression of E6 and E7 
oncoproteins in a HPV-infected cervical cancer cell model. CaSki cell line was selected as the 
cancer cell model to be used for this study due to its HPV high copy level in comparison to other 
well-known HPV-infected cervical cancer models such as HeLa or SiHa [17]. For that, a 
comparison between the efficacy of PP and mcDNA on oncoproteins silencing effect was 
performed. 2 - Methods 
 
2.1. Construction and production of mcDNA-pri-miR-375 
The pMC.CMV-MCS-EF1-GFP-SV40Poly A empty PP vector was amplified by E. coli ZYCY10P3S2T 
bacterial growth in Terrific Broth medium (20 g/L of tryptone, 24 g/L of yeast extract, 4 mL/L 
of glycerol, 0.017 M KH2PO4, 0.072 M K2HPO4) supplemented with 50 μg/mL of kanamycin at 250 
rpm, 42 ºC. Pri-miR-375-containing pcDNA-3 plasmid was purchased from Genescript Limited 
(Hong Kong) and used as a template for Polymerase Chain Reaction (PCR) for pri-miR-375 
fragment amplification. For PCR, primers pri-miR-375 FW 5’-CGGGACAAGCTCCAAGGCGT and 
pri-miR-375 RV 5’- TTTCCACCTCCAGAAGGGTT were used. PCR was first carried out at 95 ˚C for 
5 min, followed by 30 cycles of 95 ˚C for 40 sec, 60 ˚C for 30 sec and 72 ˚C for 1 min, before 
proceeding 5 minutes at 72 ˚C. For cloning, XbaI and BamHI enzymes were used to digest PP 
empty vector and pri-miR-375 fragment before using T4 DNA Ligase (NZYTech – Genes and 
Enzymes, Portugal), according to the manufacturer’s instructions. Through thermal shock, 
competent E. coli ZYCY10P3S2T bacteria were transformed with the resultant cloning mixture. 
Positive colonies were isolated from LB – agar plates and PP-pri-miR-375 cloning was confirmed 
by pri-miR-375 PCR. To produce mcDNA-pri-miR-375, PP-pri-miR-375 was amplified, as 
aforementioned, until an optic density of 5 was attained, followed by PP recombination 
induction through 0.01% L-Arabinose addition. Induction was carried out for 3 hours at 32 ˚C, 
before bacteria were recovered through centrifugation and stored at -20 ˚C. 
 
2.2. PP and mcDNA extraction and purification 
For PP extraction and purification, NZYMaxiprep commercial kit (NZYTech, Lisbon, Portugal) 
for pDNA isolation was used according to the manufacturer’s instructions. To recover mcDNA 
from bacteria, given the lack of commercial kits available for mcDNA purification, an alkaline 
modified lysis was first performed according to Diogo and co-workers [18]. The resulting sample 
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was desalted with PD-10 desalting columns (GE Healthcare, Buckinghamshire, UK) and the 
supercoiled (sc) mcDNA isoform was purified from host impurities, other mcDNA isoforms or PP 
non-recombined molecules, as described by Almeida and co-workers [19]. Briefly, a 
chromatographic column with a bed height of 60 cm containing 121 mL of Sephacryl SF-1000 
matrix was coupled to an AKTA Püre system (GE Healthcare, Buckinghamshire, UK). A volume 
of 2 mL of clarified mcDNA complex sample was injected to the column and separated by size 
exclusion with a flow of 0.3 mL/min and UV detection at 260 nm. The target peak containing 
sc mcDNA was concentrated and desalted with Vivaspin® 6 Centrifugal Concentrator 
(Vivaproducts, Littleton, MA, USA), for further assays. 
 
2.3. Cell culture and transfection  
HPV-16 infected cervical cancer (CaSki) and fibroblast cell lines were used for in vitro studies. 
Cell growth was carried out at 37 ˚C, 5% CO2 with RPMI (CaSki) and DMEM-F12 (fibroblasts) 
medium supplemented with 10% (v:v) of fetal bovine serum (FBS) and 1% (v:v) of antibiotic 
mixture of penicillin (100 μg/mL) and streptomycin (100 μg/mL). The day before transfection, 
cells were deprived from antibiotic. Cell transfection with PP-pri-miR-375 and mcDNA-pri-miR-
375 was carried out with Torpedo (Ibidi, Martinsried, Germany), according to manufacturer’s 
instructions (ratio 3:1 - reagent:mcDNA) and, 6 hours later, medium containing antibiotic was 
re-established. 
 
2.4. FITC staining and mcDNA uptake 
To assess mcDNA entry, CaSki cells were grown in 8 μ-slide 8 well (Ibidi, Martinsried, Germany) 
before 80-90% confluence was reached. Afterwards, purified mcDNA sample was stained as 
described by Almeida and co-workers [20]. Once the mcDNA was labeled with FITC, 
complexation with Torpedo (Ibidi, Martinsried, Germany) was performed and CaSki cells were 
transfected. After 6 hours, cells were fixed with 4% paraformaldehyde, nuclei were stained 
with Hoescht and the μ-slides were visualized through LSM710 confocal laser scanning 
microscope (Carl Zeiss, Germany) under a 633 magnification and analyzed with the Zeiss LSM 
710 laser scanning confocal microscope (Carl Zeiss SMT, Inc., Oberkochen, Germany). 
 
2.5.RNA extraction, RT-PCR and RT-qPCR 
To assess miR-375, E6 and E7 transcripts, CaSki cells were seeded with a density of 6.86 x 104 
cells/cm2 in 12-well plates, and after 24 h of transfection, the total RNA extraction of 
transfected and non-transfected cells was performed resorting to TripleXractor reagent (Grisp 
Research Solutions, Porto, Portugal), following the manufacturer’s instructions. For E6 and E7 
transcripts, 1 µg of total RNA was reversed transcribed into cDNA with the Xpert cDNA Synthesis 
(GRiSP - Research Solutions, Portugal) according to the manufacturer’s instructions. For miR-
375 transcripts, cDNA was synthetized by using a stem-loop primer specifically designed for 
miR-375, as described by Wang and co-workers [8]. Afterwards, RT-PCR was carried out with 
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NZYTaq2x Green MasTerMix (NZYtech, Lisbon, Portugal) at the following conditions: 95 ˚C for 
5 minutes, 30 cycles at 95 ˚C for 30 seconds, 60 ˚C for 30 seconds and 72 ˚C for 1 minute and 
final extension at 72 ̊ C for 5 minutes. The primers used for this methodology are the following: 
miR-375 stem-loop: 5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCACGC; 
miR-375 FW: 5’ GCCGTTTGTTCGTTCGGCT; miR-375 RV: 5’ GTGCAGGGTCCGAGGT; E6 FW : 5’- 
CAGGAGCGACCCAGAAAGTT; E6 RV: 5- GTCATATACCTCACGTCGCAGT; E7 FW: 5’- 
TCCAGCTGGACAAGCAGAACCGGA; E7 RV: 5’- GCACACAATTCCTAGTGTGCCCAT. On the other 
hand, RT-qPCR was carried out as previously described by Almeida and co-workers [20]. Primers 
for GAPDH housekeeping gene were employed for data normalization and its constitution is the 
following: FW: GAPDH 5’- ATGGGGAAGGTGAAGGTCG; GAPDH RV: 5’- 
GGGGTCATTGATGGCAACAATA. Statistical analysis was performed with one-way ANOVA, with 
an N=3, resorting to GraphPad Prism 7. 
 
2.6. Western Blot 
To assess protein content, CaSki cells were seeded with a density of 6.86 x 104 cells/cm2 in 6-
well plates and western blot was carried out with 40 µg of protein extracted after 24 hours of 
transfected and non-transfected CaSki cells. Briefly, all samples were quantified by Bradford 
micro-assay from BioRad (Hemel Hempstead, UK), before injection in vertical polyacrylamide 
electrophoresis for protein separation. Electroblotting was performed resorting to Trans-Blot 
Turbo system (BioRad, Hemel Hempstead, UK), throughout 15 minutes with standard SD pre-
programmed protocol. Mouse anti-E6 IgG monoclonal antibody or mouse anti-E7 IgG monoclonal 
antibody (Santa Cruz Biotechnology, Heidelberg, Germany) were incubated with resulting 
membranes overnight, with a dilution of 1:200. Then, membranes were incubated with goat 
anti-mouse IgG polyclonal antibody conjugated with alkaline phosphatase (Santa Cruz 
Biotechnology Heidelberg, Germany), before 5 minutes incubation with enhanced 
chemofluorescence, (GE Healthcare, Buckinghamshire, United Kingdom) and were visualized in 
BioRad FX-Pro-plus (Bio-Rad, Hemel Hempstead, UK). 
 
2.7. Proliferation Assays 
To evaluate the mcDNA-pri-miR-375 impact in cell growth, proliferation assays were performed 
throughout 72 hours with CaSki. Briefly, cells were respectively seeded with a density of 6.86 
x 104 cells/cm2 in 12-well plates, to normalize the cell density between wells, transfected as 
aforementioned and trypsinized after 24, 36, 48 and 72 hours. Then, cells were recovered 
through centrifugation and viable cells were counted resorting to trypan blue and Neubauer 
chamber.  As a control for normal cancer cell growth, non-transfected cells were trypsinized in 
each time-point and counted concomitantly. All assays were performed with an N=3 and each 
N was counted 4 times. Statistical analysis was performed with two-way ANOVA, resorting to 




2.8. Viability studies 
To understand the effect of mcDNA-pri-miR-375 in the viability of CaSki and Fibroblasts after 
transfection, viability studies were performed with resazurin compound. Briefly, cells were 
seeded with a density of 6.86 x 104 cells/cm2 and 3.33 x 104 cells/cm2, respectively, in 96 well 
plates and transfections were carried out at 24, 36, 48 and 72 hours. Resazurin was prepared 
at 0.1% (m/v) and added to each well to a concentration of 20%. After 4 hours incubation, the 
resazurin-medium mixture was transferred and fluorescence was read in SpectraMAX Gemini 
EM (Molecular Devices,USA) Microplate Reader at 544 nm excitation and 590 nm emission 
wavelengths.  Non-transfected cells were used as negative control and non-transfected cells 
treated with 70% ethanol were used as positive control. All assays were performed with an N=4 
and statistical analysis was performed with two-way ANOVA test in GraphPad Prism 7.  
 
3. Results and discussion 
Despite all the efforts that have been dedicated to the prevention and treatment of HPV 
infection, the reality is that many countries are still affected by the infection caused by this 
virus and new therapeutic methodologies should be explored [1].  
 
Considering the potential that miR-375 has shown in silencing HPV oncoproteins, pri-miR-375 
gene was synthetized and cloned into PP backbone. After PCR confirmation, bulk production 
was performed, alongside with recombination and purification, for the attainment of sc mcDNA-
pri-miR-375 for further transfection studies, through the use of methodologies previously 
established by our research group [12,19]. For in vitro studies, a commercial transfection agent 
was chosen, given our aim was to understand the therapeutic effect of the newly constructed 
mcDNA-pri-miR-375 vector. At first, to guarantee that the transfection conditions suggested by 
the manufacturer were adequate for mcDNA entry in CaSki cells, fluorescent labeling was 
performed with FITC and cell entry was detected 6 hours after transfection, as suggested by 
the manufacturer and presented in figure 1.  The presence of labeled-mcDNA inside the nucleus 
of CaSki cells confirmed the efficacy of the transfection protocol, suggesting that further 








Figure 1 – McDNA transfection of CaSki cells, 6 hours after. The blue staining represents the cell 
nucleus while the green staining represents FITC-labeled mcDNA. 
 
Therefore, after guaranteeing mcDNA transfection, it was necessary to evaluate the correct 
expression of pri-miR-375 and its processing into mature miR-375. Thus, after 24 hours of 
transfection, CaSki cells were harvested and total RNA was extracted before cDNA was 
synthetized. To correctly synthetize cDNA from miR-375, a protocol described by Wang and 
colleagues was applied, resorting to the use of a stem-loop primer specifically designed for 
miR-375 [8]. In figure 2A is presented the electrophoresis performed for miR-375 RT-PCR. As 
perceivable, band density seems to be less intense in non-transfected cells, comparatively to 
PP and mcDNA transfected cells. This could be indicative that PP and mcDNA are correctly 
overexpressing miR-375, comparatively to the natural miR-375 expression in CaSki cells. 
However, such illation should not be taken right away as a proof of the pri-miR-375 gene 
effectiveness. It is necessary to evaluate the transcripts of E6 and E7 genes to understand if 
they present a decreased level in transfected cells. Therefore, the evaluation of E6 and E7 
mRNA transcripts were performed by PCR for RNA samples of CaSki cells collected 24 hours 
after transfection, as presented in figure 2B. It is possible to verify an intense band for non-
transfected cells, which naturally express HPV oncoproteins due to the presence of HPV 
genome, for both E6 and E7 transcripts. However, a difference is notorious for PP and mcDNA 
samples. For both transcripts, PP presents a very lighter band, comparatively to non-
transfected cells, while mcDNA does not present any band. First of all, these data further 
suggest that pri-miR-375 is correctly being processed into miR-375 and it is acting on E6 and E7 
silencing, due to the lighter/none band displayed by transfected cells. Furthermore, it is 
possible to perceive the different outcome between PP-pri-miR-375 and mcDNA-pri-miR-375 
vectors. This difference suggests that mcDNA has a better performance than PP, in accordance 
with other works performed within this thematic. For instance, Wu and co-workers designed a 
study to compare the therapeutic outcome of mcDNA and pDNA vectors bearing the liver 
regeneration/ growth factor ERV1-like (ALR/GFER) gene [16]. In their preliminary studies, 
higher expression from mcDNA vector, comparatively to pDNA, was detected. This led 
researchers to adjust the final mcDNA dose, which would be administrated to liver fibrosis 
disease rats, to 30% of the pDNA final dose. Even with this adjustment, rats treated with mcDNA 








demonstrated an increased therapeutic effect than rats treated with pDNA. Thus, it is 
noticeable the increased potential of mcDNA as a non-viral vector. To further confirm these 
results, RT-qPCR was performed for analysis of these oncoproteins mRNA expression between 
PP-, mcDNA-transfected and non-transfected cells. In figure 3A and 3B is portrayed the results 
obtained for the expression of E6 and E7 mRNA, respectively. As it is shown, E6 and E7 mRNA 
are found to be significantly decreased, nearly 80%, in cells transfected with PP and mcDNA, 
comparatively to non-transfected cells, further reinforcing the results obtained for PCR. In E6 
mRNA assessment, mcDNA-transfected samples demonstrate to be significantly decreased 
comparatively to PP-transfected samples. This is also in agreement with the findings of Wu and 
co-workers [16]. However, no difference was visualized between these samples for E7 mRNA 
assessment, suggesting more data should be collected. 
 
Figure 2 – Electrophoresis RT-PCR result for miR-375 (A), E6 (B) and E7 transcripts (C) after 24 
hours transfection of CaSki cells. CT – Non-transfected cells, PP – cells transfected with PP-pri-
miR-375, mcDNA – cells transfected with mcDNA-pri-miR-375. 
 
Figure 3 - E6 (A) and E7 (B) mRNA relative expression between PP-, mcDNA-transfected and 







































































































However, it is still necessary to further prove the E6 and E7 decreased expression in the protein 
content of transfected CaSki cells. Thus, western blot for staining of both proteins was 
performed for CaSki cells after 24 hours of transfection. In figure 4 is presented the western 
blot results obtained for E6, E7 and β-actin proteins. The latter is a housekeeping gene that is 
normally expressed within cells and is often used for the normalization of western blot 
techniques. As perceivable, E6 protein content for mcDNA seems to be lower than non-
transfected cells and PP protein content. However, such difference is not as notorious as the 
one observed for E7 protein, where both PP and mcDNA samples demonstrate much lower E7 
content than non-transfected cells. These results are in agreement with the data previously 
obtained by RT-PCR and RT-qPCR. Although this seems very promising, further assays should be 
performed to obtain more data so that protein quantification can be assessed. 
 
Figure 4 – Western blot results for E6, E7 and β-actin proteins for 24 hours after transfection of 
CaSki cells. CT – Non-transfected cells, PP – cells transfected with PP-pri-miR-375, mcDNA – 
cells transfected with mcDNA-pri-miR-375. 
 
Although E6 and E7 silencing is the general aim of this approach, the influence of this DNA 
vector in a potential therapeutic effect should be evaluated. This therapeutic effect should 
rely in the stoppage of cancer cell growth, and perhaps its consequent death. Therefore, 
proliferation studies were performed with CaSki cells. This assay was based on cell transfection 
with mcDNA, followed by cell trypsinization at 24, 36, 48 and 72 hours to assess if this vector 
somehow affected cell growth. In figure 5 is presented the growth curve found for cells 
transfected with mcDNA (purple), alongside the growth curve obtained for non-transfected cells 
(blue). It is perceivable that transfected cells present lower proliferation than non-transfected 
cells. This might be related with the fact that E6 and E7 are being silenced, therefore not being 
able to trigger the cancer cell mechanism to survive. Thus, with E6 and E7 silencing, tumor 
suppressors such as p53 and pRB might be rescued from inactivation/degradation, re-








establishing cell repairing mechanism. This hypothesis has been proven by Jung and co-workers, 
who were able to demonstrate that the increase of miR-375 levels led to the silencing of E6 
and E7 proteins and consequent re-establishment of p53 and pRB content in SiHa and HeLa cell 
lines, cervical cancer models, which are respectively infected by HPV-16 and HPV-18 [9]. Thus, 
the lower exponential growth displayed by mcDNA transfected cells can be a consequence of 
the p53 and pRB levels re-establishment, which might be triggering the cell cycle arrest.  
However, this cannot be proven by proliferation studies, given that other hypothesis could be 
driving cell quiescence, such as vector toxicity.  
Thus, to prove the effect of pri-miR-375 expression in transfected cells is safe for surrounding 
healthy tissues, viability studies were performed by resorting to resazurin technique. These 
were carried out in CaSki and fibroblast cell lines to compare the effect this vector presents in 
malignant and healthy cells, respectively. As perceivable in the results schematized in Figure 
6, both cell lines present a significant viability decrease in the first 36 hours. However, from 
this point on, fibroblasts seem to be able to recover from this viability decrease, being fully 
restored at 72 hours. On the other hand, CaSki cell line viability loss seems to continue gradually 
over time, being more significative at 72 hours. This suggests that such loss of viability in 
fibroblasts might be related with a small influence of the transfection process or some toxicity 
associated to the transfection reagent, which is known to be slightly aggressive towards cell 
integrity. In the case of CaSki cells, the viability loss is more evident probably due to the 
expression of pri-miR-375, which is enabling the silencing of E6 and E7 oncoproteins and re-
establishment of p53 and pRB levels.  
 
 
Figure 5 – Proliferation results for non-transfected CaSki cells (blue line) and mcDNA-pri-miR-
375 transfected CaSki cells, throughout 72 hours. (N=3, ** p < 0.05, **** p <0.0001, compared 
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Figure 6 – Viability studies for CaSki (A) and Fibroblast (B) cell lines. Control + – positive 
control (non-transfected cells incubated with 70% ethanol), Control - – negative control (non-
transfected cells), mcDNA-pri-miR-375 – cells transfected with mcDNA-pri-miR-375. (N=3, * 
p<0.05, ** p< 0.001, **** p<0.0001, compared to negative control) 
 
4. Conclusion and future perspectives 
In this study, it was shown that mcDNA-pri-miR-375 vector presents a stronger effect on HPV 
oncoproteins transcripts silencing, comparatively to PP molecule, highlighting the potential of 
this innovative non-viral DNA vector. Nonetheless, further assays should be performed to gather 
significant statistical results to guarantee such effect. Also, this work demonstrated the 
potential displayed by pri-miR-375 in silencing E6 and E7 proteins, leading to growth arrest in 
HPV-infected cervical cancer cell line model, CaSki. Also, although fibroblast cell line 
demonstrated a small viability loss in the first 36 hours after transfection, such viability is 
recovered and fully re-established by 72 hours. This suggests that the initial loss of viability 
might be related with commercial transfection reagent toxicity or, perhaps, with the 
transfection process itself. More studies should be performed to confirm this possibility, such 
as the administration of the commercial transfection reagent alone. In case this hypothesis is 
indeed confirmed, it might be concluded that mcDNA-pri-miR-375 does not present a toxic 
effect towards healthy cells. Nonetheless, to further prove this vector therapeutic effect, p53 
and pRB levels should be assessed, followed by apoptosis evaluation.  
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This work was designed to explore two different approaches, namely DNA vaccines and gene 
therapy, by establishing suitable biotechnological platforms for the production of each 
bioproduct and understanding its potential impact in the treatment of cervical cancer.  
In what concerns to the first approach, DNA vaccines, a pDNA molecule containing the genetic 
information for the expression of E6 and E7 HPV-16 oncoproteins was used. Through the use of 
a purification strategy previously established by our research group, which resorted to the use 
of affinity chromatography based on the utilization of a monolithic disk bearing arginine ligands, 
it was possible to assess the expression efficiency displayed by this vector in in vitro studies. 
Concomitantly, to further comprehend the effect that sc pDNA purity level may exert in the 
expression of the target proteins, a commercial purification kit was used to obtain the DNA 
vaccine. In vitro studies performed with the DNA vaccine obtained by these two different 
methods demonstrated that sc content influenced the expression levels displayed by 
transfected cells. Thus, the sc homogenous DNA vaccine purified by arginine modified monolith 
exerted a significantly higher expression level than the DNA vaccine obtained by a commercial 
purification kit, due to the presence of other pDNA isoforms in the latter strategy, highlighting 
the importance of choosing adequate purification strategies for the maximization of the 
therapeutic outcome. 
Also, a modification of the strategy previously implemented with arginine monolith was 
explored by preparing an arginine monolith bearing a spacer arm in the purification of this 
vaccine. This modification was performed with the intention of providing more accessibility of 
the arginine ligand to the target molecule. The results obtained demonstrate the purification 
of sc pDNA with binding capacities higher than 1 mg/mL when using a complex lysate sample 
and 2.53 mg/mL with a pre-purified sc pDNA sample. This data was found to be lower than the 
one obtained for the previous arginine monolith strategy, possibly due to the occupation of a 
larger area by the spacer arm, limiting the available arginine ligands. Nonetheless, purity was 
found to increase in loading conditions due to sample displacement phenomena, as the non-
functional isoforms were eluted throughout column loading.  
Since DNA vaccines must be efficiently delivered in order to enhance its therapeutic potential, 
calcium carbonate nano-delivery systems coupled with gelatin were fabricated to encapsulate 
and deliver the DNA vaccine to dendritic cells. After nanocarrier characterization, in vitro 
studies were carried out to access the ability of this system to promptly deliver the DNA 
vaccine. After 24 hours, fluorescently labeled pDNA molecules were found within THP-1 
dendritic cell line, suggesting transfection occurred with success. This result was later 
confirmed by RT-PCR detection of E6 transcripts and detection of E6 protein presence in 
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transfected cells through Western Blot technique, suggesting the DNA vaccine was being 
correctly expressed. These results suggest that calcium carbonate gelatin nanoplexes are able 
to efficiently deliver the DNA vaccine to antigen presenting cells, such as dendritic cells, which 
are cell lines which have been known to be difficult to transfect. This data highlights the 
potential of said nanocarriers when developing new DNA vaccine strategies.  
On the other hand, E6 and E7 protein silencing through gene therapy was also explored for the 
treatment of cervical cancer with the use of a mcDNA containing genetic information for miR-
375 expression. However, before proceeding into the therapeutic evaluation of this vector, it 
was first necessary to establish suitable strategies for its production and purification. 
Considering the lack of adequate mcDNA universal purification strategies, a comparison 
between the utilization of two different monolithic disks was carried out to assess the most 
promising approach for sc mcDNA purification. Thus, two monolithic disks were prepared, one 
containing lysine ligands and the other containing cadaverine ligands. It was found that sc 
mcDNA isolation from a complex sample with cadaverine-modified monolith was the most 
suitable strategy, allowing the recovery of 78.6% of the injected sc mcDNA, with 98.4% purity 
and devoid of host components such as genomic DNA, proteins, endotoxins or RNA. The 
implementation of this strategy without resorting to backbone modification or enzymatic 
digestion stood as a very promising approach to be scaled-up for industrial mcDNA production. 
However, it was found that each chromatographic run allowed the purification of a low mcDNA 
mass (1.97 μg), a feature that could compromise the scale-up of this strategy to a low-cost 
industrial methodology. With the intention of further improving the obtainment of pure sc 
mcDNA, size exclusion chromatography was explored. 
A column containing Sephacryl SF-1000 matrix was prepared to assess its ability to separate sc 
mcDNA from a complex sample. After optimizing the necessary chromatographic conditions, 
the purification of sc mcDNA was successfully achieved with Sephacryl SF-1000, allowing a sc 
mcDNA yield of 66% and a purity of 98.35%. Also, it was found that host contaminants were 
within the levels specified by regulatory agencies. Moreover, the use of a larger mcDNA 
provided insightful information regarding the adjustments that should be performed to obtain 
pure sc mcDNA with higher sizes, mainly the increase of column size and the lowering of flow 
rate. Although this strategy allowed the purification of 24.02 μg pure sc mcDNA in a single run, 
the assays were more time consuming and recovery yield was found to be lower than 
cadaverine-modified monolith, suggesting that each approach should be applied accordingly 
with the final aim.  
In fact, the results obtained with cadaverine-modified monolith suggested that this strategy 
could be explored for the implementation of an analytical methodology for mcDNA quality 
assessment. Currently, few methodologies have been implemented with this finality and are 
usually expensive or inaccurate. Thus, by making use of the chromatographic conditions 
previously established for sc mcDNA isolation, an analytical method was implemented resorting 
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to cadaverine-modified monolith. After thoroughly assessing different parameters necessary for 
the establishment of an analytical method, a chromatographic quantification methodology was 
successfully developed and validated for sc mcDNA assessment in pure and complex samples. 
Moreover, it was possible to verify the robustness of this methodology by assessing its ability in 
separating differently composed sc mcDNA-PP pairs, requiring only small adjustments to the 
chromatographic conditions. For the first time, to the best of our knowledge, an analytical 
chromatographic method was implemented for sc mcDNA assessment, allowing the evaluation 
of a mcDNA sample within 40 minutes.  
Once appropriate conditions were settled for the purification and characterization of sc 
mcDNA, production of sc mcDNA-pri-miR-375 was carried out for further evaluation of its 
therapeutic potential in in vitro studies. Thus, CaSki, the cervical cancer infected with HPV-16 
cell line model, was used to assess the ability of this strategy to suitably silence E6 and E7 
oncoproteins. Concomitantly, PP-pri-miR-375 sample was used to compare the expression 
efficiency of a pDNA-like vector or of a mcDNA. After 24h hours of transfection, cells were 
retrieved and total RNA was extracted to evaluate miR-375, E6 and E7 transcripts through RT-
PCR. It was found that, in comparison to non-transfected cells, both PP and mcDNA samples 
were able to slightly increase miR-375 content. Moreover, the difference in E6 and E7 
transcripts between non-transfected cells and transfected cells was notorious, suggesting miR-
375 was indeed being correctly expressed. While non-transfected cells presented a marked 
band, PP-transfected cells demonstrated a fainter band followed by absence of band for 
mcDNA-transfected cells. These results seem to highlight the potential displayed by mcDNA in 
obtaining higher expression efficiencies than conventional pDNA. Afterwards, protein content 
was assessed to understand if it would corroborate the previously obtained data. Through 
preliminary western blot analysis, transfected cells also demonstrated lower E6 and E7 content 
than non-transfected cells. Once the silencing of HPV viral proteins was proven, the impact in 
cancer cell regulation was evaluated. Proliferation assays were performed to understand if 
cervical cancer cells, upon silencing E6 and E7 oncoproteins, could maintain the fast 
proliferation rate associated with cancer cells. It was found that, throughout 72 hours, 
transfected cells growth would stagnate comparatively to non-transfected cells, suggesting that 
miR-375 could be re-establishing the mechanisms for cell repairment and growth control. On 
the other hand, such stagnation could also be synonym that transfection cytotoxicity could be 
occurring. Thus, viability studies were performed in CaSki and healthy fibroblasts to understand 
if this behavior was characteristic of cancer cells or if transfection would be affecting non-
cancer cells too. It was found that for both cell lines, viability was significantly decreased in 
the first 36 hours, comparatively to non-transfected cells. However, healthy cells would recover 
and proliferate afterwards, suggesting that this could be a consequence from the transfection 
process or toxicity associated to the commercial transfection agent, which is known to be 
slightly aggressive towards cell integrity.  
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Overall, this doctoral thesis allowed the study and exploration of two different approaches in 
the treatment of cervical cancer. In addition, useful and innovative methodologies were 
developed and established for downstream processing of these biotechnological products, 





To complete the work under preparation in this thesis, and to fully understand miR-375 
therapeutic effect in cervical cancer treatment, further in vitro studies should be conducted. 
Besides obtaining more statistical data for E6 and E7 content assessment after transfection, 
other techniques should be performed to understand the entire impact miR-375 might have in 
cell regulation of proliferation and death. The use of a scrambled miR will be useful to 
understand if the obtained results are indeed specific to miR-375 action. Also, the evaluation 
of tumor suppressor proteins levels, such as p53 and pRB, will allow to confirm that E6 and E7 
action has been prevented. Finally, apoptosis evaluation should be performed to assure that 
controlled cell death is occurring. 
On the other hand, different directions can be explored in the future to reach the ultimate 
approach for developing a suitable cervical cancer treatment. For instance, considering that 
the presence of CpG motifs in the bacterial backbone of the DNA vaccine might be useful to 
facilitate the triggering of an immune response, specialized nano-delivery systems should be 
studied and developed through its functionalization with specific ligands that might direct the 
delivery of the pDNA vaccine to the antigen presenting cells. This could allow higher antigen 
expression and, therefore, the elicitation of a stronger immune response with better 
therapeutic outcome. This therapeutic outcome should ultimately be evaluated resorting to in 
vivo studies with C57BL/6 mice models. Upon injection of cancer cells infected with HPV to 
induce tumor nodules, the triggering of the therapeutic immune system pathway might be 
evaluated in these models, followed by tumor regression assessment to comprehend the 
therapeutic effect displayed by the DNA vaccine.  
In what concerns to mcDNA, further methodologies should be expected to rise, given its 
innovative character. Currently, more upstream and downstream methodologies should be 
explored to optimize the industrial production of this biotechnological product, since it is the 
main limitation associated to this vector comparatively to well established pDNA. Moreover, 
the development of suitably functionalized nano-delivery strategies to cervical cancer cells is 
imperative, since the more specific the delivery is, the more efficient it will be in expressing 
the target gene. This will allow to concentrate the therapy used within the tissue area to which 
it was designed to act, without losing its effect to surrounding tissues. In addition, these 
delivery systems will allow the protection of mcDNA from degradation, maximizing its delivery 
and therapeutic action.  
Finally, in vivo studies should be conducted to understand which of strategies described in this 
thesis can be more adequate for the treatment of cervical cancer. Eventually, the combination 
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of both strategies could be performed to assess its potential in maximizing its therapeutic effect 
against cervical cancer.  
 
